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1. INTRODUCTION 
 
 
1.1. Cancer and Immune Intervention 
Cancer represents the second leading cause of death worldwide as indicated by the 
over eight millions of deaths registered in 2012 (NIH/NCI). In the last decades, several 
immunotherapeutic strategies have been investigated in pre-clinical and clinical studies in 
order to develop new platforms for treatment of tumor-bearing patients. The rationale 
supporting the clinical evaluation of different strategies aiming to induce, amplify or skew 
antitumor immunity is based on the potential capacity of the immune system to mediate tumor 
eradication and most importantly, on the necessity to overcome the limited effectiveness of 
current standard anti-cancer treatments. In particular, pioneering studies performed in animal 
models have initially shown the ability of the immune system, and, in particular, of CD8+ T 
cells, to mediate tumor clearance. These encouraging results have been recently confirmed by 
the characterization of local and systemic immune responses in cancer patients. Indeed, 
increased percentages of tumor specific T cells in peripheral blood and high tumor infiltration 
by CD8+ T cells in tumor deposits have been associated with significantly increased overall 
or progression free survival at least in melanoma, renal, ovarian, lung and gastrointestinal 
cancer patients1,2. However, although therapeutic potential of CD8+ T cell has been 
extensively reported, cumulative results obtained in animal models and clinical evidences 
have also indicated that intrinsic alterations as well as active immune resistance of malignant 
cells represent major limitations preventing the generation of protective CD8+ T cell 
responses mediating cancer elimination3,4. 
Tumor cells express antigens potentially recognized by naturally arising CD8+ T cells. 
Currently, two distinct categories of tumor-associated antigens (TAAs) have been defined 
according to their pattern of expression: (i) shared TAAs and (ii) unique TAAs. In particular, 
unique TAAs are represented by viral antigens, derived from infectious agents responsible of 
neoplastic transformation, and antigens that results from mutations, deletions and 
recombination of specific gene sequences (neo-antigens). In contrast, shared TAAs include 
antigens that are overexpressed (overexpressed antigens) or expressed at similar levels by 
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transformed cells and by their normal counterparts (differentiation antigens) or in germline 
cells (cancer-testis antigens)5. 
 
Interestingly, results obtained in pre-clinical and clinical studies, addressing the 
therapeutic potential of vaccination strategies, have indicated that the therapeutic 
 
effectiveness of targeting of CD8+ T cells against major histocompatibility complex 
class I (MHC class I) restricted peptide (pMHC complexes) derived from neo-antigens, may 
be limited by heterogeneous expression among malignant cells. Furthermore tolerance might 
prevent the induction of immune responses against antigens of predominantly self-origin. 
Indeed, with the exception of viral antigens derived from human papilloma virus that have 
shown clinical effectiveness in prevention and treatment of cervical carcinoma, a major 
limitation for cancer immunotherapies strategies targeting differentiation and overexpressed 
TAAs, is represented by the low-affinity nature of the circulating T cell receptors specific for 
self/tumor antigens. In this respect, studies have shown that curative potential of low-affinity 
tumor-reactive CD8+ T cells may be limited either as a consequence of a reduced clonal 
expansion of antigen-specific precursor or by a limited implementation of effector functions 
upon recognition of target cells6. Indeed, among the different factors that synergistically 
contribute to cancer immune evasion, a critical determinant is represented by the ability of 
tumor cells to prevent the formation of a productive immunological synapse with tumor- 
reactive CD8+ T cells. Furthermore it has been extensively reported, in particular for solid 
tumors, that reduced expression of pMHC complexes by tumor cells results in a defective 
activation of low-affinity tumor-specific CD8+ T cells due to a reduced TCR occupancy7-9. 
 
In addition to the intrinsic features of tumor antigens, curative potential of tumor- 
reactive CD8+ T cells, regardless of the affinity of TCR expressed, is also limited by the 
activation in transformed cells of distinct mechanisms that synergistically promote the 
immunological tolerance of cancer. In this respect, it has been extensively reported that anti- 
tumor activity of CD8+ T cells can be limited by the expression, on cellular surfaces of 
transformed cells, of inhibitory ligands10. Furthermore, the infiltration and/or the activity of 
tumor-reactive CD8+ T cells may also be regulated by the activation of genes encoding for 
enzymes and soluble factors directly or through the recruitment of immunosuppressive cells 
including regulatory T cells (Tregs) and myeloid-derived suppressor cells (MSDC)11-14. 
In  this  scenario,  the  harnessing  of  CD8+  T  cells  against  cancer  as  a  successful 
immunotherapy may appear as a difficult challenge. However, the increased overall survival 
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and/or objective cancer regression evaluated according to the RECIST criteria (Response 
Evaluation Criteria in Solid Tumors) reported by several clinical trials where cancer patients 
were administered antibodies mediating immunological checkpoints blockade, adoptive 
cellular therapy (ACT) and different formulations of cancer vaccines clearly demonstrate the 
therapeutic potential of immunotherapies strategies aimed at promoting the generation and the 
antitumor activity of CD8+ T cells. Furthermore, clinical evidence obtained from treated 
cancer patients indicates that strategies aiming at promoting antitumor CD8-mediated immune 
responses may result in more durable clinical benefits as compared to standard chemotherapy 
and radiotherapy treatments. 
 
1.2. Cancer Immunotherapy strategies. 
 
 
Passive cancer immunotherapy strategies are based on the administration of 
therapeutic antibodies or tumor- reactive T lymphocytes. In contrast, active strategies aim at 
promoting the in vivo generation or boosting of the immune system against tumor cells, based 
on the administration of different vaccine formulations. Although with distinct mode of 
actions, both strategies share a common denominator, namely they rely on tumor-specific T 
cell responses. 
 
1.2.1 Passive Immunotherapeutic Approaches. 
 
 
 
Administration of antibodies targeting TAAs or immunological checkpoints blockade 
and adoptive transfer of in vitro expanded tumor-infiltrating lymphocytes (TILs) or 
genetically engineered T cells, represent successful examples of passive immunotherapeutic 
approaches. Several of these strategies have been recently approved by US Food and Drug 
Administration (FDA) as well as European Medicines Agency (EMA) as first line therapy for 
solid tumors and hematological malignancies. 
 
 
 
1.2.1.1	  Antibodies-­‐-­‐-­‐against	  Immune	  Checkpoints	  Blockade.	  	  
	  
	  
	  
Therapeutic potential of monoclonal antibodies (mAbs) for cancer treatment is 
primarily related to their unique capacity to recognize specific cell surface antigens. In 
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addition to this marked specificity, mAbs are also able to promote through their Fragment 
crystallizable region (Fcr), the elimination of target cell by activating innate immune cells. 
According to the definition of “magic bullets” provided by P. Ehrich, mAbs have been 
successfully used in the last two decades as successful treatments for solid tumors and 
hematological malignancies. In particular, initial strategies were based on the direct 
antineoplastic activity of mAbs targeting specific markers expressed by tumor and associated 
stromal and endothelial cells15. In contrast, in the last years a novel target for mAbs have 
been extensively evaluated in clinical setting. In particular mAbs targeting lymphocytes 
inhibitor receptors or their cognate ligands (Immune Checkpoints) has been developed in 
order to bypass the poor cellular immunogenicity as well as the active immune-evasion of 
tumor cells. 
 
Activation of T cells is triggered by T cell receptor (TCR) mediated antigen 
recognition. However effective generation of a protective immune response is tightly 
regulated by the balance of co-stimulatory and inhibitory signals received by antigen specific 
T cells during cellular immune responses. In this regard, Cytotoxic T-lymphocyte Associated 
Antigen 4 (CTLA-4, CD152) and Programmed Death protein 1 (PD-1, CD279) have been 
extensively indicated as the master regulators of T cell responses. Initial studies suggested 
distinct patterns of immunomodulation mediated by these immune-checkpoint receptors. In 
particular, CTLA4 receptor has been traditionally indicated as a critical inhibitor of early 
activation of T cells in secondary lymphoid organs whereas PD1 receptor has been mostly 
associated to maintenance of self-tolerance in peripheral tissues. 
 
This initial dichotomy has been recently revised. Indeed, our current understanding of 
immune regulation mediated by CTLA-4 and PD-1 receptors is in line with a synergistic 
inhibitory activity of these two receptors in secondary lymphoid organs as well as in 
peripheral tissues. 
 
 
 
1.2.1.1.1 CTLA-­‐-­‐-­‐4	  pathway.	  	  
	  
	  
	  
CTLA-4 belongs to the CD28 family. Its inhibitory activity is mostly related to the 
down modulation of CD28 costimulatory receptor activity. CTLA-4 inhibitor receptor is 
characterized by a higher affinity in comparison to CD28, for the co-stimulatory surfaces 
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molecules CD80 (B7.1) and CD86 (B7.2) expressed by professional antigen presenting cells 
(APCs)16. Due to its high affinity for the ligands, CTLA-4 receptor can abrogate early phase 
of T cell activation by preventing CD28-CD80/CD86 interaction. CTLA-4 receptor can 
directly recruit and activate distinct intracellular phosphatases which, in turn, “switch off” the 
activation signals delivered by TCR and CD28. These inhibitory activities synergistically 
abrogate the acquisition of effector functions and proliferative potential by T cell upon 
antigen recognition. In preclinical studies, a pivotal role of CTLA-4 : CD80/CD86 inhibitory 
pathway, in preventing the generation of a stable T cell conjugation with APCs (Schneider, 
2006), has also been documented. Notably, inhibition of T cell responses mediated by CTLA- 
4 receptor is further supported by a direct activity on APCs via the induction of the 
indolamine-2,3-dioxigenase (IDO). The induction of this inhibitory enzyme in APCs, has 
been reported as a consequence of backward signals transduced by CD86 molecules upon 
interaction with CTLA-4-expressing T cells17. 
CTLA-4 receptor is normally stored in the cytoplasm of resting naïve and memory T 
cells and it is rapidly translocated on the cellular surface upon TCR engagement. Due to its 
inhibitory mode of action and further supported by the rapid expression on T cell surface upon 
antigen recognition, CTLA-4 receptor has been extensively indicated as a critical regulator of 
the early phase of T cell activation18,19. In this regard, experimental studies performed in 
animal models confirmed the pivotal role of CTLA-4 receptor. Indeed, the insurgence of 
lethal lymphoproliferative disorders characterized by the massive activation of auto-reactive 
CD8+ and CD4+ T cells in secondary lymphoid tissues was extensively reported in gene 
deficient or anti-CTLA-4 mAbs treated mice20,21. Notably, preclinical models also support a 
critical role for CTLA-4 receptor in modulating T cell activity in peripheral tissues by 
mediating the immunosuppressive function of regulatory T cells (Tregs). Fully humanized 
mAbs targeting CTLA-4 inhibitory receptor have been generated for cancer treatment in view 
of the critical role of this immune checkpoint in tolerance maintenance. Indeed, limited clonal 
expansion of tumor-reactive CD8+ T cells bearing “low affinity” TCRs and high infiltration 
of Tregs within tumor tissues represent two major limitations in the establishment of 
immunological control of several solid tumors6,11. 
In 2011, Ipilimumab a fully humanized (IgG1) monoclonal antibody targeting CTLA- 
4 receptor has been approved by US Food and Drug Adiministration (FDA) as well as 
European Medicine Agency (EMA) as first line of therapy for advanced melanoma patients in 
virtue of the results obtained in two randomized double blind phase III clinical trials. In 
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particular, in 2010 Hody and co-workers22 initially reported an increased overall survival in 
refractory-metastatic melanoma patients receiving Ipilimumab alone (10.1 months; 137 
patients) or in combination with gp100 specific vaccination (10.0 months; 437 patients) in 
comparison to those receiving only gp100 vaccine (6.4 months; 136 patients). Therapeutic 
potential of Ipilimumab was promptly confirmed in 2011 by the results obtained by Robert 
and collaborators on a cohort of 502 patients with previously untreated stage III/IV metastatic 
melanoma23. In particular a higher survival rates at three years, was observed in patients 
receiving Ipilimumab plus dacarbazine (20.8%) as compared to those treated with dacarbazine 
plus placebo (12.2%). Finally, clinical benefits associated to ipilimumab-based therapy have 
been recently restated by the cumulative results obtained from the follow up of more than 
1800 patients enrolled in phase II/III clinical trials. Indeed, durable survival (in some case 
extended to 10 years) has been observed in almost 20% of Ipilimumab-treated patients19,24. 
Despite the objective and durable clinical responses observed in cancer patients upon 
Ipilimumab administration, critical considerations are now emerging regarding CTLA-4 
blockade strategies. In particular, antitumor activity of anti-CTLA-4 mAbs is critically 
affected by their specific isotype. Indeed Tremelimumab, a fully humanized IgG2 anti-CTLA- 
4 antibody, despite encouraging results in early melanoma trials failed to induce a statistical 
significant survival advantage as compare to standard-of-care chemotherapy in first line 
treatment of patients with metastatic melanoma25. In this regard, a possible explanation for 
this negative result can be formulated in view of some preclinical studies. In particular results 
obtained in animal models, clearly underline how the antitumor effect of anti-CTLA-4 
treatment is also dependent by the ability to induce Fc Receptor © (FcR©)-mediated 
intratumoral Tregs depletion possible due to antibody-dependent cell-mediated cytotoxicity 
(ADCC).  According to these results, it is possible to speculate that the reduced antitumor 
activity of Tremelimumab (IgG2) in comparison to Ipilimumab (IgG1), is associated to a 
reduced ability of anti-CTLA-4 IgG2 monoclonal antibody (Tremelimumab) to modulate 
immune system as a consequence of reduced ligation of FcR©. In addition to this 
“technical issue”, anti-CTLA-4-blockade therapy based on the administration of Ipilimumab, 
has shown two major limitations represented by the limited antitumor activity in non-
melanoma cancers and  by  the  insurgence  of  a  new  category  of  potentially  lethal  side  
effects  indicated  as 
immune-related adverse events (irAEs)22,23,25. 
 
In this regard, clinical benefits observed in melanoma patients have not been 
confirmed in patients bearing non-melanoma tumors such as renal (RCC), lung and metastatic 
12 	  
castration-resistant prostate cancer (mCRPC) in response to Ipilimumab-based therapy. The 
observed therapeutic discrepancy of anti-CTLA-4 blockade it is nowadays correlated by the 
relative higher immunogenicity of melanomas as compared to other solid tumors. Indeed, in 
melanoma patients the ability of the immune system to spontaneously generate tumor-reactive 
CD8+ T cells recognizing well-known antigens including MelanA/MART-1, Tyrosinase and 
gp100 has been extensively reported. In addition recent technological advances in whole- 
exomic sequencing clearly indicate that this already high immunogenicity of melanoma cells 
is further increased by high frequency of non-synonymous mutation in transformed 
melanocytes resulting in the expression of a broad range of tumor-specific mutated antigens 
(neo-antigens). In this scenario, as indicated by a detailed characterization of melanoma- 
specific CD8+ T cell repertoire during Ipilimumab-based therapy, antitumor effects 
associated with CTLA-4 blockade appear to be mostly associated to the rapid appearance of 
new  tumor-specific  CD8+  T  cell  reactivities  against  patient  specific  neo-antigens26-28. 
Unfortunately, therapeutic potential of CTLA-4 blockade is also limited in melanoma patients 
by the severe immunotoxicity observed in 15-30% of treated patients. In particular, side 
effects commonly observed mostly affect skin, gut, liver and endocrine system. Notably, the 
insurgence of these immune-related adverse events (irAEs) may be considered as an intrinsic 
effect of CTLA-4 blockade strategy, tightly associated to therapeutic potential of Ipilimumab- 
based therapy. Indeed, abrogation of inhibitory signals in secondary lymphoid organs and in 
peripheral tissue by partial depletion of Tregs, is obviously associated with the activation and 
acquisition of effector functions by auto-reactive CD8+ T cells. Furthermore, the severity of 
collateral damages to normal tissues during anti-CTLA-4 therapy can be further exacerbated 
by direct activity of auto-reactive T cells recognizing self-antigens overexpressed by 
malignant cells. In this scenario, its tempting to speculate that severe side effects observed in 
cancer patients receiving anti-CTLA4 monoclonal antibodies may arise as a consequence of 
cross-reactivity or/and as a consequence of bystander activation of self-reactive CD8+ T cells. 
 
 
 
1.2.1.1.2 PD1	  :	  PD-­‐-­‐-­‐L1/2	  pathway.	  
	  
	  
	  
Programmed cell Death protein 1 (PD-1; CD279) is an inhibitory receptor that belongs 
to CD28/CTLA-4 family of T cell co-receptors and it is critically involved in the modulation 
of T cell activity. Although PD-1 and CTLA-4 receptors display a similar pattern of 
expression,  these  two  immunological  checkpoints  receptors  are  differentlially  regulated. 
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Indeed, similar to CTLA-4, PD-1 receptor is constitutively expressed at high level on cellular 
surface of Tregs and also detectable on naïve and memory T cells following TCR-mediated 
activation. However, PD-1 expression on activated T cells is regulated at transcriptional level, 
thus its expression on cellular surface is delayed (12hours) as compared to that of CTLA-4 
receptor10,18,19.  Interestingly,  engagement  of  PD-1  receptor  on  different  T  cell  subsets 
produces distinct effects. Indeed, PD-1 signaling has a pivotal role in promoting the survival 
and the immunosuppressive function of CD4+ Tregs through the up-regulation of phosphatase 
and tensin homolog (PTEN) molecule and by sustaining the expression of forkhead-box- 
protein p3 (FoxP3) transcription factor29. In contrast, engagement of PD-1 receptor expressed 
by activated T cells results in their progressively reduced proliferative capacity and effector 
cytokines production (T cell exhaustion) and might ultimately lead to clonal deletion of 
specific T cell 30,31. Furthermore, progressive reduction of T cell effector functions by PD-1 
receptor engagement is associated to the recruitment on its intracellular domain of inhibitor 
phosphatases (SHP-2, PP2A), which in turn abrogates kinases signals derived by TCR and 
CD28 co-stimulatory receptor triggering19,32. In contrast, PD-1-mediated induction of T cell 
apoptosis has been correlated to direct inhibitory effects on the expression of anti-apoptotic 
molecules such as BCL-   19,32-34 
So far, two PD-1 ligands, PD1-ligand 1 (PD-L1; CD274, B7-H1) and PD1-ligand 2 
(PD-L2; CD273, B7-DC) have been identified. These two ligands belong to B7 family and 
arise from gene duplication as suggested by their 37% sequence homology. Nevertheless, PD- 
L1 and PD-L2 display a distinct spectrum of expressions and regulation. In particular, PD-L1 
is expressed on cellular surface of hematopoietic, stromal and endothelial cells in response to 
interferon-© (IFN-©) produced by activated T cells. In contrast, PD-L2 is prevalently 
detected on antigen presenting cells (APCs) and its expression is regulated by IFN-© and 
to a much greater extent by interleukin-4 (IL-4). In view of the broad distribution of the 
ligands and to the relatively delayed expression of PD-1 on activated T cell as compared to 
CTLA-4 receptor, PD-1 : PD-L1/PD-L2 pathway has been indicated as the major regulator 
of T cell 
activity in peripheral tissues during inflammatory responses as suggested by the insurgence of 
milder autoimmune disease in PD-1 deficient mice10,35. 
 
Among the different immune suppressive mechanisms promoting tumor escape, dis- 
regulation of PD-1 : PD-L1/PD-L2 inhibitory axis has been extensively indicated as a critical 
determinant promoting cancer progression. In particular, expression of PD-1 receptor on 
cellular surface of a significant fraction of tumor-infiltrating T-lymphocytes (TILs) has been 
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reported in several solid tumors and in particular for melanoma patients7. Expression of PD-1 
receptor on TILs is related  to intrinsic regulation patterns and further promoted by the 
immunosuppressive tumor microenvironment (TME). Indeed, the extent of PD-1 receptor 
expression and thus its immunosuppressive activity is directly associated to the chronic low 
affinity recognition by tumor-reactive T cells of their cognate antigens but also by the marked 
dominance of immunosuppressive factors in the tumor microenvironment (TME) including 
transforming growth-factor ® (TGF-®) and interleukin-10 (IL-10)36-38. In addition, cancer 
progression as a consequence of a dis-regulation of PD1 : PD-L1/PD-L2 pathway, is also 
associated to the extensive expression of PD-1 ligands on cellular surface of malignant and 
tumor infiltrating immune suppressive cells. In particular, up-regulation of PD-L1 and PD-L2 
on tumor cells surface has emerged as an intrinsic as well as adaptive mechanism underlying 
immune resistance to endogenous tumor-specific immune responses. Intrinsic immune 
resistance is referred to the up-regulation of both ligands on cellular surface of malignant cells 
because of genetic instability of cancers. Indeed, the constitutive expression of PD-L1 and/or 
PD-L2 has been reported in different solid tumors and hematological malignancies as a 
consequence of the activation of specific signaling pathways associated to neoplastic 
transformation and/or chromosomal re-arrangement. In contrast, adaptive immune resistance 
is referred to the active expression of PD-1 ligands and particularly PD-L1, on cellular surface 
of tumor cells in response to IFN-© production by infiltrating NK, activated CD4+ T 
helper 
cells and CD8+ T cells38-40. Based on this background and further stimulated by the objective 
clinical responses observed in Ipilimumab-based treatment and by the milder and less 
frequent autoimmune side effects observed in preclinical studies, generation and evaluation of 
therapeutic potential of monoclonal antibodies targeting PD-1 : PD-L1/PD-L2 pathway in 
cancer patients has been recently investigated. 
 
Two fully human IgG4 monoclonal antibodies targeting PD-1 receptor, Nivolumab 
(BMS-936558; Bristol-Myers Squibb, ONO Pharmaceuticals) and Pembrolizumab (MK- 
3475; Merck) have been recently FDA-approved as first-line of therapy for advanced 
unresectable melanoma and non-small-cell lung cancer 41-44. The FDA approval of these two 
anti-PD-1 monoclonal antibodies for cancer treatment is based on the striking results observed 
in randomized phase III clinical trials. In particular, Nivolumab-based therapy resulted in an 
objective response rate of 40% and 20%, respectively, for advanced melanoma and NSCLC 
patients whereas only in 13.9% and 9% of melanoma and lung cancer patients dacarbazine or 
docetaxel based therapies resulted in objective clinical responses41,42. Therapeutic potential of 
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anti PD-1 monoclonal antibodies for unresectable stage III-IV melanoma has been recently 
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confirmed by the results obtained by Robert C. and co-workers44. Notably, PD-1 inhibition 
resulted in a significantly prolonged progression free-survival as compared to CTLA-4 
blockade. Indeed, the estimated 6 months progression free-survival rates were 47.3% and 
46.4% for those patients receiving Pembrelizumab every 2 or 3 weeks respectively, whereas 
Ipilimumab based therapy resulted effective only in 26.5% of treated patients44. 
The marked clinical efficacy of monoclonal antibodies targeting PD-1 inhibitor 
receptor has represented a critical element promoting the further evaluation of antitumor 
activity and immune correlates in different cancer types of drugs interfering with PD1: PD-L1 
inhibitory axis. In this regard, encouraging results have been recently reported from clinical 
trials designed in order to evaluate therapeutic potential in different epithelial cancers such as 
head and neck squamous carcinoma, renal, lung, ovarian, gastric and colorectal cancer of 
monoclonal antibodies targeting PD-L1 42,45,46. 
 
In addition to their antitumor activity and in line with results obtained in animal 
models, monoclonal antibodies targeting PD-1 inhibitory pathway are also characterized by a 
reduced incidence of drug-related adverse events. A parallel clinical evaluation of antitumor 
activity and side effects associated to Ipilimumab and Pembrelizumab (Robert C NEJM 2015) 
treatments in advanced melanoma patients clearly indicates a reduced insurgence of fatigue, 
nausea and pruritus as treatment-related adverse events of grade 3-5 severity in 
Pembrelizumab group (10.1%) as compared to patients receiving Ipilimumab (19.9%). 
Furthermore, safety of Pembrelizumab based therapy was also reinforced by the specific 
evaluation of immune related adverse events (irAe) associated to the distinct treatments. In 
this regard, although intravenous administration of Pembrelizumab or Ipilimumab resulted in 
a different pattern of irAe probably reflecting a different mode of action, both monoclonal 
antibodies resulted in the insurgence of colitis. However, only 2.5% of Pembrelizumab- 
treated patients experienced immune related colitis whereas the insurgence of this side effect 
was   detected   in   about   7%   of   advanced   melanoma   patients   receiving   intravenous 
administration of Ipilimumab44. Insurgence of milder toxicity as a consequence of therapeutic 
targeting of PD-1 inhibitory pathway has been recently confirmed by clinical data obtained in 
anti-PD-L1 monoclonal antibodies based therapy. In particular, cumulative resulted obtained 
in different phase I dose escalating clinical trials showing that adverse events associated to 
intravenous administration of MPDL-3280A, were mostly limited to the first cycle of therapy 
and did not require medical treatment42,45,47. 
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The immune characterization of patients receiving monoclonal antibodies targeting 
PD-1: PD-L1 pathway critically contributes to increase our knowledge on the role of this 
inhibitory axis during cancer progression. In particular, initial studies reported discordant 
observations particularly concerning tumor PD-L1 status and patient prognosis. Indeed, in 
different studies immunohistochemical analysis of PD-L1 expression within tumor masses 
was initially reported as having no impact on the survival of tumor bearing patients. However, 
recently published observational and clinical studies on the prognostic role of PD-L1 in 
cancer patients are in line with the inflammatory tumor model. In this regard, PD-L1 
overexpression on tumor cells appears to be associated to a high infiltration by IFN-
© producing T cells. However, clinical efficacy of anti-PD-L1 based therapy correlates to 
ligand overexpression on recruited immune cells including myeloid derived suppressor 
and canonical dendritic cells. In view of this specific pattern of expression, it is 
tempting to speculate that PD-1 : PD-L1 pathway promotes tumor escape by modulating at 
different levels tumor specific cellular responses. In particular, PD-L1 overexpression by 
tumor cells may represent a first line of defense against initial host protective immune 
response whereas ligand expression   on   immune   cells   may   be   considered   as   an   
additional   layer   of   local 
immunosuppression exploited by solid tumors in order to bypass T cell responses10,38,39,48. 
 
 
 
1.2.1.1.3 Immune	  Checkpoints	  Blockade:	  Conclusions	  
	  
	  
	  
Clinical benefits observed in tumor bearing patients receiving monoclonal antibodies 
(mAbs) targeting immune checkpoint receptors and ligands, have opened a new era for cancer 
immunotherapy and, most importantly, further confirmed how immune system harnessing 
against cancer represent more than an attractive idea. However, critical considerations also 
arise from the recent clinical and preclinical studies. Indeed, the insurgence of considerable 
immune related adverse events (irAEs) particularly in cancer patients receiving CTLA-4 
blocking antibodies and objective therapeutic effects only against solid tumors characterized 
by high mutational load (Restifo and Rosenberg C.Cell 2015) still represent major limitations 
of immune checkpoint blockade based therapies. In this regard, a detailed characterization of 
the immune effects in cancer patients receiving mAbs targeting CTLA-4 receptor and PD-1 
inhibitory axis represents a critical step for a further exploitation of this immunotherapeutic 
strategy. Interesting, recent clinical evidences have clearly pointed out how survival benefits 
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observed in cancer patients responding to CTLA-4 blockade based therapy are related to “de- 
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novo” generation of tumor specific T cell responses whereas clinical benefits as a 
consequence of PD-1 : PD-L1 pathway inhibition are associated to the re-activation of a pre- 
existing antitumor immunity. Based on these observations, the rationale supporting the initial 
clinical evaluation of monoclonal antibodies targeting immune checkpoints has been recently 
revised. In particular, it is now becoming evident that clinical efficacy of cancer therapies 
based on intravenous administration of mAbs targeting CTLA-4 receptor or PD-1 pathway is 
not associated to a general activation of T cell responses but is related to their ability to 
promote respectively the priming of naïve or the restoration of memory activity only of 
tumor-reactive CD8+ T cells. In line with these distinct effects on naïve and memory CTLs, 
in patients receiving anti CTLA-4 mAbs, tumor shrinkage  is usually delayed and often 
preceded by an increase of tumor mass whereas in patients receiving mAbs inhibiting PD-1 : 
PD-L1 pathway tumor regression is commonly rapid and mostly detectable already at the first 
therapy response assessment. These observations confirm, one more time, the ability of the 
immune system to generate potentially protective T cell responses against tumor. 
Furthermore, in view of the durable clinical responses observed in responding patients 
receiving mAbs targeting immune checkpoints and in particular PD-1 receptor, a critical 
determinant dictating the outcome of mAbs based therapies is represented by the generation 
and maintenance of long-lasting (memory) tumor-reactive CD8+ T cells26,28,45,46. 
 
 
 
1.2.1.2	  Adoptive	  cellular	  therapy	  (ACT)	  for	  cancer	  treatement.	  
	  
	  
	  
Identification of interleukin-2 (IL-2) as a T cell growth factor, and its therapeutic 
effect observed upon intravenous administration in tumor bearing mouse can be considered as 
the first indirect proof of T cells capacity to mediate tumor-regression. This initial observation 
was then reinforced by the results obtained in pioneering studies of adoptive cell transfer 
(ACT) performed in animal models. In particular, the effectiveness of in vitro IL-2 expanded 
tumor-infiltrating lymphocytes (TILs) to mediate, upon re-infusion in singenic mice, 
regression of established tumors was formally demonstrated. In the last decades, these 
findings in murine models have been successfully confirmed also in cancer patients. Indeed, 
the clinical efficacy of adoptive cellular therapies based on re-infusion of large numbers of in 
vitro-expanded TILs has been consistently reported 49-51. 
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Initial evidence of therapeutic potential of ACT strategies for cancer treatment has 
been provided in 1994 when the results obtained from 86 metastatic melanoma patients 
enrolled in a clinical trial were reported. In particular, TILs used in this clinical study were 
obtained by enzymatic digestion of tumor specimens and in vitro expanded by sequential 
serial passage in 6000 IU/ml of IL-2 until an average of 1x1011 of lymphocytes was obtained. 
TILs generated with this protocol were then intravenously administered to cancer patients in 
combination with high dose of IL-2 (720.000 IU/kg). A relatively low responses rate (34%), 
comparable to studies in which dacarbazine and IL-2 cytokine were administered alone or in 
combination to metastatic melanoma patients, was observed in this first trial. However, this 
initial study clearly indicates also the clinical effectiveness of immunotherapies strategies 
based on adoptive transfer of tumor-reactive T cells51,52. Furthermore a retrospective analysis, 
comparing responder versus non-responder patients enrolled in this clinical trial, has provided 
crucial informations influencing the design of subsequent anti-cancer adoptive therapies. In 
this regard, objective clinical responses were preferentially observed in those patients 
receiving TILs generated from subcutaneous lesions (49%) as compared to melanoma patients 
receiving TILs obtained from lymph nodes (17%), thereby suggesting that suitable tumor- 
reactive T cells were localized, mostly, within tumor mass. In addition, anti-cancer efficacy of 
TILs was inversely correlated with the time required for their in vitro manufacturing and 
resulting in a reduced survival and expansion of infused cells. Based on these initial findings, 
different protocols aiming to identify suitable target antigens as well as the generation of TILs 
displaying higher persistence and reduced senescence have been extensively evaluated. 
 
An initial attempt performed in order to select effective anti-tumor reactivity within 
the bulk of TILs cultures was represented by the introduction of a selective screening of in 
vitro expanded lymphocytes before re-infusion. In particular, after initial expansion of 21-36 
days in presence of high doses of IL-2, individual TILs cultures, upon enrichment for CD8+ T 
cells, were selected for large-scale production according to their capacity to produce IFN-
© upon co-culture with autologous or HLA-matched established melanoma cell lines. 
Notably, the introduction of an enzyme-linked immunosorbent assay (ELISA) for the 
selection of tumor-specific CD8+ T cells represents the basis of clinical success of “selected 
TILs protocol” as a cancer immunotherapy for metastatic melanoma. Indeed, cumulative 
results 
from different trials indicate how re-infusion of selected TILs resulted in objective and 
durable clinical responses in 50% of metastatic melanoma patients51. A major limitation of 
ACT therapies based on selected TILs protocol is represented by the complexity of the 
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methodology resulting in the generation of sufficient numbers of TILs only in a limited 
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percentage of patients undergoing through surgical excision of melanoma lesions. In addition, 
a limited reproducibility of the in vitro expansion of autologous lymphocyte cultures obtained 
from tumors of different origin still represents a limitation preventing the widespread 
application of ACT for treatment of other cancers. Based on these observations and with the 
aim to expanding clinical efficacy of ACT-therapies to a broaden cohort of melanoma and 
also other cancer patients, different techniques have been developed. In particular, genetic re- 
targeting  of  peripheral  blood  lymphocytes  and  protocols  based  on  a  reduced  in  vitro 
manipulation of TILs (“young TILs”) have been extensively explored35,53. 
 
The introduction, through lenti or retroviral vectors, of genes encoding for tumor- 
reactive conventional alpha-beta TCR or chimeric antigen receptors (CARs) in autologous T 
lymphocytes has extensively been indicated as a powerful resource for cancer treatment based 
on ACT. The first clinical evidence on the effectiveness of adoptive cell therapy based on the 
re-infusion of engineered T cells was obtained from the induction of objective clinical 
responses with manageable toxicity in two out of 17 metastatic melanoma patients receiving 
autologous T lymphocytes expressing a α/β TCR recognizing MelanA/Mart-1 melanoma 
differentiation antigen cloned from a melanoma patients enrolled in a previous trial54. In line 
with this observation, in a subsequent clinical study objective clinical responses were 
observed in 30% (6/20) and 19% (3/16) of metastatic melanoma patients receiving 
respectively engineered T cells targeting with high avidity MelanA/Mart-1 or gp100 HLA- 
A0201-restricted epitopes. However, unwanted and most importantly non-negligible side 
effects related to the infusion of engineered T cells recognizing with high avidity tumor 
shared antigens were also observed in treated patients. In particular, destruction of normal 
melanocytes in the skin, eyes and inner ear was directly correlated with the insurgence of 
vitiligo, eye toxicity and hearing loss on treated patients55. The insurgence of toxicity related 
to the recognition of minimal amount of cognate antigen on cellular surface of normal cells 
(on-target toxicity) has been reported, to different extents, in several clinical trials and is 
widely considered as a formal proof of anti-tumor efficacy of adoptive cellular therapies. 
However, the onset of life-threatening side effects has been also described in patients 
receiving  engineered  T  cells  recognizing  with  high  avidity  non-mutated  self-antigens 
expressed also on normal tissue56-58. In line with this observation, the needs for improved 
methods in the selection of suitable target antigens have been extensively indicated as a 
critical determinant dictating the outcome of adoptive cellular therapies. In line with this 
consideration, autologous T cells have then been re-targeted against cancer-testis antigens 
(CTA) and/or mutated antigens selectively expressed by malignant cells. In this respect, 
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controversial results have been obtained. In particular, adoptive cellular therapies based on 
autologous lymphocytes expressing conventional α/β TCR recognizing with high affinity 
cancer testis antigens (CTA) have shown objective clinical responses in metastatic melanoma 
(5/10 OR) but resulted also in the death of four out 11 treated patients. Remarkably, patient 
death was attributed to neurotoxicity related to the, initially unrevealed, expression in the grey 
matter of genes belonging to MAGE family of cancer-testis antigens. In addition to on-target 
toxicities against normal cells, the insurgence of fatal cardiogenic shock has been also 
reported and associated to an unexpected cross-reactivity of affinity-enhanced TCR against 
HLA-A01-restricted  MAGE-A3  with  an  unrelated  peptide  derived  from  titin  protein 
expressed in cardiac muscle cells (off-target toxicity)56-58. In line with these observations, 
similar results were obtained from cancer patients receiving antitumor re-targeted autologous 
T lymphocytes through the introduction of chimeric antigen receptors (CARs). A CAR 
structure is composed of a single-chain variable fragment (scFv) of a monoclonal antibody 
fused with a spacer domain and intracellular T cell signaling domains derived by CD3-zeta 
chain, CD28 and CD137 (4-1BB). The rationale supporting the development of CARs was 
represented by the attractive idea to simultaneously confer an antibody-like tumor-specificity 
to transduced T cells and to further promote their production of effector and cytotoxic 
molecules. Technological  advantage  of CARs was  based  on their capacity  to  allow the 
recognition of target antigens in an MHC class I unrestricted manner thereby overcoming 
tumor immunoevasion associated mechanisms such as downregulation of peptide-HLA 
complexes and/or to alteration of antigen presenting machinery of tumor cells and, most 
importantly, to the possibility to apply ACT to all cancer types59-61. Clinical effectiveness of 
ACT based on anti-CD19 CAR has been extensively reported and resulted in 2010 in the FDA 
approval for treatment of B-lymphomas53,62,63. Although in vitro studies and pre-clinical 
studies in murine models have indicated a marked antitumor activity for T cells expressing 
chimeric receptors targeting antigen overexpressed by transformed cells, so far, a limited 
clinical effectiveness has been observed in patients bearing solid tumors. In addition, clinical 
application of CARs technology for treatment of solid tumor is further restrained by the 
objective difficulty in the identification of target antigens selectively express on tumor cells or 
alternatively detectable only in nonessential tissues. Indeed, the insurgence of severe side 
effects related to on-target activity of CAR-T cells against normal cells has been described 
particularly in colorectal and renal cell carcinoma patients receiving transduced lymphocytes 
expressing  chimeric  receptor  targeting  tumor  shared  antigens  such  as  carcynoembrionic 
21 	  
antigen (CEA), receptor tyrosine-protein kinase ERBB2 antigen or carbonic anhydrase 9 
antigen57,64. 
 
The insurgence of severe side effects associated either to on-target and/or off-target 
toxicities still represent a major limitation restraining clinical application of engineered T 
cells for treatment of solid tumors. Different strategies have been studied in order to prevent 
the insurgence of ACT-related immunopathology. In particular, selective expression, on/in 
engineered lymphocytes of CD20, truncated EGFR and thymidine kinase derived from herpes 
simplex virus has shown promising results by rendering infused cells sensible to cytotoxic 
effects of clinically approved monoclonal antibodies and anti-viral therapies65. 
 
An alternative strategy that has been extensively explored in order to reduce the high 
dropout rate associated to standard selected TILs protocol for melanoma treatment is 
represented by the “young TILs” methodology35,66,67. Generation of younger lymphocytes has 
been initially prompted by the necessity to simplify the laboratory procedures for the 
generation of selected TILs. In this regard, failure in the generation of autologous tumor cell 
line and limited availability of established melanoma cell lines expressing less frequent HLA 
alleles have been traditionally ascribed as critical limitations of selected TILs protocol. 
Furthermore, initial clinical evidences suggested that extended culture times might potentially 
restrain their antitumor efficacy by reducing their survival upon in vivo re-infusion. In this 
scenario, clinical effectiveness of unscreened, minimally cultured TILs has been extensively 
reported. In particular, cumulative results obtained from different trials indicate that young 
TILs protocol resulted in the eligibility of nearly 90% patients undergoing through surgical 
excision of melanoma lesions and resulted, upon re-infusion, in the induction of objective and 
durable clinical response in almost 50% of treated patients. Furthermore, clinical experience 
based on young TILs protocols has contributed to the identification of critical determinants 
regulating antitumor potential of ACT strategies. In this respect, clinical relevance of neo- 
antigens  and  the  impact  of  differentiation  status  of  re-infused  TILs  have  been  initially 
suggested by the results obtained in different trials in which melanoma patients received 
younger lymphocytes35,66,67. 
 
The suggestion that tumor specific mutations might be suitable targets for cancer 
therapies has initially been provided by the inherent genetic instability of transformed cells 
and further restated by the increased immunogenicity of tumor cells displaying a higher 
mutation rate. In this respect, an increased interest for nonsynonymous mutations has been 
recently  registered  among  cancer  immunologists.  Indeed,  emerging  data  from  exomic 
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sequencing of different tumor types have indicated either a high frequency of nonsynonymus 
mutations in epithelial cancers and, most importantly, that these exomic alteration might 
results in the creation of new epitopes recognized with high avidity by naturally arising T 
lymphocytes. Initial evidences suggesting a correlation between recognition of neo-antigens 
and induction of cancer regression have been provided by some trials in which tumor 
reactivity of in vitro expanded autologous T lymphocytes was evaluated in response to the 
recognition of autologous melanoma cell lines and/or HLA-matched cell lines expressing 
defined differentiation antigens and/or cancer-testis antigens CTA. In particular, the selective 
production of IFN-© in response to autologous tumor cells and not against established 
cell lines observed in a consistent fraction of TILs, obtained from responder patients, 
suggested that cancer regression can be driven by the recognition of patients specific 
tumor mutated antigens. The formal proof that nonsynonymous mutations, more than 
epigenetic changes triggering the expression of CTA, might be targets of T recognition of 
tumor cells, resulting in the induction of objective and durable clinical responses has recently 
been provided. Indeed, it has been shown that clinical efficacy of TILs re-infused in 
melanoma patients is mostly 
associated  to  the  recognition  of  random  somatic  mutations  in  the  cancer27,67,68.  Despite 
identification of nonsynonymous mutation has restated the therapeutic potential of tumor- 
reactive T cells and might potentially overcome the insurgence of side effects commonly 
observed by targeting shared antigens, critical theoretic and pratical considerations still 
prevent the widespread application of ACT strategies against neo-antigens for cancer 
treatment. Indeed, high frequency of mutations has been identified only in specific cancer 
types including melanomas, renal and lung cancer. Furthermore, whole-exomic sequencing of 
melanoma tumor has revealed that, only a limited number of nonsynonymous mutations can 
efficiently result in the generation of immunogenic peptides presented in the contest of MHC 
class I and class II molecules. In addition, despite considerable efforts by the scientific 
community, the identification of clinically relevant mutations to target during ACT therapies 
is still complicated. Indeed, algorithms predicting peptide binding to patient specific MHC 
molecules are not yet reliable in particular for less frequent MHC alleles. In contrast, 
generation of strings of minigenes encoding each mutated amino acid flanked by 10-12 amino 
acids has been indicated as an efficient approach allowing the precise screening of patient 
specific TILs reactivity regardless of their HLA restriction. However, generation of these 
DNA constructs still appear far  from routine application and has  so far been clinically 
evaluated only in melanoma patients27,50,69. 
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In addition to critical information concerning tumor-reactivity, clinical experience 
with “young TILs protocol” has further contributed to underline the relevance of intrinsic 
properties of infused CD8+ T cells in dictating the clinical success of ACT-based strategies. 
Adoptive cell therapies have been extensively defined as “living” treatment based on the 
capacity of infused TILs to expand and, most importantly, to long-term survival. Objective 
clinical responses have been extensively correlated to TILs persistence one month after 
transfer and durable clinical benefits associated to their persistence at later timepoints. In this 
respect, clinical effectiveness of current ACT protocols has been significantly associated to 
patient pre-conditioning through administration of lymphodepleting nonmyeloablative 
chemotherapy (NMC) and total-body irradiation. The rationale supporting the pre- 
conditioning of the host is represented by the necessity to overcome the global 
immunosuppression of late stages cancer patients. However, immunodepleting chemotherapy 
with cycloposhamide (60mg/kg) and fludarabine (25 mg/m2) alone or in combination with 
200 or 1200 centigray total-body irradiation before the adoptive transfer of highly selected 
tumor reactive CD8+ T cells resulted in an increased, but not significant, overall response 
rate51,70. These clinical evidences indicate that although lymphodepleting preparative 
regimens may enhance antitumor efficacy by promoting the depletion of immunosuppressive 
cells (Tregs, MDSCs), augmenting the availability of specific homeostatic cytokine (IL-15), 
induction of durable responses is also affected by functional properties of infused T cells. In 
line with this consideration, it has been reported in different trials in which patients received 
TILs in vitro expanded either with the standard or young protocols, that objective and, most 
importantly, durable clinical responses were observed in patients receiving less differentiated 
tumor-reactive lymphocytes. Indeed, durable clinical benefits were correlated with the 
percentages of CD8+CD27+ and length of telomeres of infused TILs and associated with their 
long-term persistence49,51,70,71. 
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1.2.2 Active Immunotherapeutic strategies: Cancer Vaccines 
 
 
 
Active immunotherapies strategies rely on different vaccine formulations designed to 
amplify pre-existing, or, alternatively, prime tumor-reactive CD8+ T cells mediating 
elimination of transformed cells, and CD4+ T cells sustaining, through the production of 
cytokines, expansion and acquisition of effector functions by cytotoxic T lymphocytes. 
 
Anti-cancer vaccines have traditionally been classified as therapeutic and preventive. 
Therapeutic vaccines are administered in order to promote regression of existing cancer 
whereas the clinical relevance of preventive vaccines is related to their capacity to prevent 
tumor occurrence 72-75. 
 
 
 
1.2.2.1 Preventive	  cancer	  vaccines	  
	  
	  
In line with the clinical effectiveness against infectious agents, prophylactic vaccines 
preventing cancers of viral origin such as liver, hepatocellular carcinoma (hepatitis B virus; 
HBV) and cervical cancer (human papilloma virus; HPV) have entered routine clinical 
practice. In particular, therapeutic potential of all the licensed preventive cancer vaccines 
targeting oncoviruses relies on their unique capacity to promote the generation of virus- 
specific humoral and cellular responses preventing HPV and HBV infections73. 
 
 
 
1.2.2.2 Therapeutic	  cancer	  vaccines	  
	  
	  
In addition to protective potential in preventive regimens, vaccines targeting human 
papilloma virus have also shown a marked clinical efficacy as therapeutic approach for cancer 
treatment. In particular, sub-cutaneous immunization with a mix of synthetic long-peptide 
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encompassing different MHC-class I and class II restricted epitopes derived from early HPV- 
E6 and -E7 antigens, may result in objective and long-lasting cancer regression76. Since 
viruses represents the underlying cause in approximately only 10% of all cases of cancer73, 
the latter observation has critically contributed to generate a renewed interest for the design of 
cancer vaccines aiming to instruct CD8+ T cells to specifically target non-viral tumor 
associated and/or specific antigens. In particular, different strategies based on (i) peptides, (ii) 
proteins, (iii) whole cells and (iiii) viral vectors have been developed with the aim of 
promoting antitumor immunity by modulating the antigen presenting capacity of dendritic 
cells74,75. In the last decade encouraging and objective clinical responses have been observed 
in cancer patients, leading in 2010 to FDA approval of Sipuleucel-T (Provenge) for treatment 
of metastatic castration-resistant prostate cancer (mCRPC)77. 
Initial attempts to promote the in vivo generation of a specific immune response 
against cancer were based on the administration of MHC-class I restricted peptides derived 
from identified tumor antigens. In this respect, initial results obtained upon clinical 
application of epitope-based cancer vaccines indicated limited therapeutic benefits in treated 
patients and infrequent expansion of CD8+ T cells recognizing the selected tumor antigens. 
The limited effectiveness of these initial trials has been related to our poor understanding of 
the biology of dendritic cells. Indeed, administration of peptide-based cancer vaccines in these 
pioneering studies was often performed without an effective dendritic cell-activating adjuvant 
and therefore immunization with peptides was mostly associated to the induction of tolerance 
more  than  cellular  immunity  against  selected  epitopes74,78,79.  Based  on  these  initial 
observations, considerable efforts have been done to overcome this initial limitation of 
immunization protocols and different adjuvants increasing either the half-life of administered 
free-peptides as well as the activation of dendritic cells have been identified for clinical 
application. Therapeutic potential of peptide-based cancer vaccines has been recently restated 
by the results obtained in a multicenter phase III clinical trial involving 185 patients with 
stage IV or locally advanced stage III cutaneous melanoma. In this study melanoma patients 
were randomly assigned to receive standard IL-2 therapy alone or in combination with a 
therapeutic vaccine composed of gp100209-217 short peptide plus incomplete Freund’s 
adjuvant. Notably, co-administration of vaccine plus IL-2 resulted, as compared to IL-2 
monotherapy, in an increased overall response rate (16% vs 6%) as well as an increased 
overall survival (17.8 months vs 11 months)80. Although initial limitations, associated to poor 
immunization induced by single epitope, were overcome by the introduction of adjuvants as 
core element of these therapeutic vaccines, critical determinants prevents the widespread 
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application of these methodology for cancer treatment. In particular, the application of 
epitope-based vaccines is mostly limited to subsets of patients expressing frequent HLA- 
alleles and further restrained among these groups by the ability of transformed cells to prevent 
CD8+ mediated immune recognition through antigen mutation and loss. In addition, single 
short-peptide based vaccines are unable to promote the activation of CD4+ T cells, required 
for the establishment of anticancer long-lasting immunity. Therefore, different immunization 
protocols, based on the administration of proteins, tumor cells (or their lysat), in vitro pulsed 
dendritic cells and viral vector, have been extensively evaluated for cancer treatment. The use 
of full-length proteins as targets for cancer vaccines has initially been promoted by the 
necessity to provide, in a HLA-independent manner, a broad panel of epitopes that might be 
presented, in the contest of MHC class I and class II molecules, on cellular surface of 
dendritic cells. However, only a limited clinical effectiveness has been traditionally observed 
in treated patients. Indeed, different phase III clinical trials involving non-small cell lung 
cancer or B-lymphoma bearing patients receiving respectively full MAGE-3 and individual 
idiotype protein have failed to reveal a clinical benefit associated to the vaccination74. 
 
An alternative strategy of similar immunotherapy is represented by the use of cell- 
based vaccines. In this regard, immunization protocols based on the sub-cutaneous injection 
of autologous or allogeneic tumor cells or alternatively in vitro antigen loaded dendritic cells 
have shown opposite results. Therapeutic potential of whole tumor cells as a cancer vaccine 
was initially associated to the possibility to simultaneously elicit the immune response CD4+ 
and CD8+ mediated against undetermined but patient’s specific antigens. In this respect, 
pioneering studies have shown a significant immune response in pancreatic and colorectal 
cancer patients receiving respectively GM-CSF-transduced or irradiated autologous tumor 
cells. In particular, in two small trials, administration of whole cell based vaccines has been 
associated  to  the  induction  of  tumor-reactive  CD8+  T  cells  in  3  out  of  14  pancreatic 
cancer74,81. In addition to crucial information concerning the immune-related effects of tumor- 
cell based vaccines, their clinical relevance has been stated in a phase III trial (ONCOVAX) 
involving 254 colorectal cancer patients receiving, following cancer resection, irradiated 
autologous tumor cells demonstrating a 61% risk reduction for recurrence and a significantly 
longer recurrence free period82. Based on these promising results and the difficulty to obtain 
autologous tumor cells for immunization protocols, allogeneic tumor cell lines have been 
clinically evaluated as therapeutic cancer vaccines. However, evaluation of this therapeutic 
approach has not revealed, so far, the induction of clinical benefits in treated patients. In 
particular initial phase I/II trials enrolling almost 200 prostate cancer patients indicate an 
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encouraging therapeutic potential for an allogeneic vaccine composed by a mixture of 
irradiated and GM-CSF expressing LNCap and PC3 established cancer cell lines 
(GVAX).Based on this background, two subsequent phase III trials were initiated but were 
interrupted respectively as a consequence of discouraging predictive analysis and for safety 
reasons74,83. 
 
In sharp contrast, a significantly increased overall survival has been reported for 
metastatic castration-resistant prostate cancer (mCRPC) patients receiving cell-based 
therapeutic vaccine termed Sipuleucel T (Provenge). Sipuleucel T vaccine is composed by 
autologous antigen presenting cells (APCs) cultured with a chimeric protein resulting from 
the fusion of GM-CSF with differentiation antigen prostatic acid phosphatase (PAP; GM- 
CSF-PAP). Currently, Sipuleucel T represents the first, and so far the only, FDA approved 
active immunotherapeutic approach for advanced prostate cancer patients. In particular, the 
license for Sipuleucel T as treatment of cancer derives from the results obtained in a double 
blind, multicenter phase III clinical trial involving 512 mCRPC patients. These patients were 
randomly assigned in a 2:1 ratio to receive either Sipuleucel T or placebo intravenously every 
two weeks for a total of three infusions and resulting in significant reduction of risk of death 
and increased median overall survival of treated patients. Indeed, for Sipuleucel T group were 
reported a 22% relative reduction of risk of death and a median survival of 25.8 months 
versus 21.7 months in the placebo group77. However, cancer immunologists have extensively 
questioned the FDA approval of Sipuleucel-T vaccine. In particular, the lack of a precise 
definition of infused vaccine, the use of an inadequate placebo control, limited immunological 
characterization of treated patients and the failure of the trial to report evidence of tumor 
regression or delay in disease progression have been criticized. To this respect, it must be 
underlined that majority of clinical trials performed are, to different extent, affected by 
limiting factors influencing the production of standardize products. Furthermore, the lack of 
tumor shrinkage is not an unusual result for immunotherapeutic approaches for cancer and it 
has extensively related to delayed antitumor activity of induced immune responses or 
alternatively to their capacity to keep malignant cells under constant restrain. These 
observations have promoted the recent reformulation of criteria adopted in defining 
effectiveness of immunotherapies strategies and have led to the restatement of overall survival 
as the unique arbiter of clinical success for therapeutic approaches. 
 
Finally, an alternative strategy that has been heavily exploited for the generation of 
efficient therapeutic cancer vaccines is represented by the generation of recombinant viral 
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vectors expressing tumor-associated antigens alone or in combination with 
immunomodulatory molecules. In addition to logistic considerations such as reduced cost for 
a relative easy production, several evidences obtained in pre-clinical studies have initially 
prompted the use of viral vector for cancer treatment. A high immunogenicity has been 
traditionally ascribed for viruses and related to their recognition through toll-like receptors 
(TLRs) expressed by host-immune cells and resulting in the generation of a pro-inflammatory 
environment. In addition, in different studies it has been reported how infection of dendritic 
cell with recombinant viral vectors expressing a transgene encoding a tumor associated 
antigen resulted in an increased expansion of cognate CD8+ T cells leading to the elimination 
of malignant cells expressing the tumor antigen encoded by the viral vector79,84 . In line with 
these pre-clinical evidences, it has been extensively indicated that transgenes expressed by a 
viral vector are more immunogenic than protein administered with adjuvant79,84. Nevertheless, 
the production of neutralizing antibodies and the expansion of vector-reactive CD8+ T cell 
have initially limited the clinical effectiveness of virus-based vaccines. Indeed, it has been 
initially reported how the suitable induction of tumor-reactive CD8+ T cells upon vaccination 
in murine models and cancer patients with recombinant vaccinia virus expressing the cognate 
tumor associated antigen was significantly reduced. These evidences have led to the design of 
the heterologous prime-boost approach for clinical application of viral vector-based cancer 
vaccines. In the prime boost approach, tumor- specific CD8+ T cells are initially primed with 
a recombinant viral vector expressing the cognate antigen whereas their further expansion is 
guaranteed by multiple booster vaccinations induced by a different recombinant viral vector 
expressing the same tumor antigen or alternatively peptides and DNA constructs thereby 
limiting the host-neutralizing and virus-specific cellular immunity79. 
Among different viral vectors, therapeutic cancer vaccines composed by recombinant 
modified vaccinia virus Ankara (MAV) has shown a remarkable clinical effectiveness for 
treatment of advanced prostate cancer patients. In particular, in a multicenter phase II clinical 
trials in which patients were randomly assigned in a 2:1 ratio to receive either a recombinant 
vaccinia virus carrying different transgenes encoding for prostate specific antigen (PSA) 
along with three immunostimulatory molecules (B7.1, ICAM-1 and LFA-3; TRICOM ; PSA- 
PROSTVAC V) in combination with GM-CSF or an empty vector plus saline injection. After 
priming with PSA-PROSTVAC V patients, tumor-reactive immune responses were further 
stimulated with six fowlpox-based vector boosts (PSA-PROSTVAC). Despite the absence of 
significant differences between the two groups in terms of progression free survival, 
PROSTVAC VF vaccine resulted in a better overall survival (30% vs 17%) and a longer 
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median survival by 8.5 months (25.1 vs 16.6). Therefore, and to a larger extent than 
Sipuleucel T, a viral vector has been significantly associated with objective clinical benefits 
for treated patients. Indeed, PROSTVAC VF vaccine, as compared to cell-based vaccine, has 
produced in concurrent studies involving 32 mCRPC patients and in a pilot study enrolling 25 
metastatic carcinoma patients, clinical evidences of post-vaccination increased T cell 
responses targeting respectively PSA antigen, carcynoembrionic antigen (CEA) and mucin-1 
(MUC-1) and clinical benefits85-87. 
 
 
1.2.2.3 ncer	  vaccines;	  where	  do	  we	  stand.	  
	  
	  
	  
In the last 60 years, the attractive idea to immunize patients against cancer has been 
heavily exploited and resulted in the establishment of different platforms of cancer vaccines. 
Despite extensive efforts by cancer immunologists and encouraging results in animal models, 
clinical applications of different active immunotherapies strategies including peptides, 
proteins, whole cells and viral-vectors based vaccines have shown, so far, a limited antitumor 
effectiveness. A major limitation affecting the impact of different active immunotherapeutic 
strategies is represented by the late time of intervention. Indeed, late-stages cancer patients 
have been mostly involved in clinical trials. In these patients, a global immunosuppression 
characterized by the exhaustion of tumor-reactive T cells and further exacerbate by the 
establishment of a corrupted tumor microenvironment have been associated to the failure of 
therapeutic vaccines in clinical settings. In this scenario, despite hundreds of vaccine 
strategies evaluated, only few have shown clinical efficacy in phase II/III trials. The 
better/increased overall survival observed in cancer patients receiving respectively Sipuleucel- 
T and PROSTAVAC VF vaccines represent an objective achievement and underline the 
clinical effectiveness of active immunotherapeutic strategies. 
 
In this regard, further studies are urgently required to elucidate the induction and the 
infiltration of tumor reactive CD8+ T cells within tumor mass in vaccinated patients in order 
to formally correlate therapeutic potential of cancer vaccines with their capacity to instruct the 
immune system to eliminate malignant cells. Beside practical advantages and reduced 
invasiveness/morbidity in comparison to passive strategies, cancer vaccines can potentially 
results in the generation of effective and long-lasting protection against cancer by promoting 
the generation of effector and memory-tumor reactive CD8+ T cells. 
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1.3. Primary and Memory CD8+ T cell responses 
 
 
Generation of antigen specific CD8+ T cells is crucial for the control of a variety of 
bacterial and/or viral infections and mostly for the eradication of malignancies. As a 
consequence of an infection or upon vaccination, the immune system responds by generating 
a primary immune response with the aim to control the infectious agent. Classically, CD8- 
mediated primary immune response consist of three distinguishable phases: a) expansion 
phase b) contraction phase c) memory maintenance phase (Fig.1)88. 
 
 
 
 
 
be in the range of 1 in 100.000. However, upon appropriate antigen recognition, these antigen 
reactive CD8+  T cells undergo a massive clonal expansion resulting in the generation of 
50.000 daughter cells. Remarkably, during expansion, naïve CD8+  T cells differentiate into 
effector cytotoxic T-lymphocytes (CTLs) able to migrate to infected sites where, through the 
production of cytotoxic molecules (perforin and granzymes) and cytokines (IFN-γ and TNF- 
α), they can mediate the elimination of infected cells. Once the elimination of the 
pathogen/antigen source is completed, the population of antigen specific CTLs undergo a 
rapid contraction phase and the large majority of effector cells (90-95%) die by apoptosis. 
Only a small fraction of CTLs (5-10%) survive to this contraction phase and further mature 
Figure 1. Kinetic of CD8-mediated primary immune response. Upon antigen recognition, antigen specific naïve CD8+ T cells 
originate a burst of effector cells. After pathogen clearance, only a minor fraction of effector CD8+ T cells (5-10%) survive and 
differentiate into memory cells conferring a long lasting protection to the host upon re-exposure to the same pathogen. 
 
(modified from Effector and Memory CTL differentiation. Williams M.A. and Bevan M.J. Annu.Rev.Immunol.2007. 25: 171-92. 
The frequency of naïve CD8+ T cell specific for a given antigen has been reported to 
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into memory CD8+ T cells. This memory CD8+ T cells are then maintained in antigen- 
independent but cytokines dependent manner. To this respect, a pivotal role for the common- 
γ-chain cytokines such as IL-7 and IL-15 in promoting memory CD8+ T cells survival and 
proliferation, has been extensively reported88-90. 
 
The generation of immunological memory during a primary immune response is the 
hallmark of the adaptative immune system and leads, over many decades, to the host 
protection in case of re-exposure to the same infectious agent. Indeed, memory CD8+ T cells 
in comparison to naïve T cells display a higher efficacy to control the secondary exposure to a 
pathogen. Notably, the superior host protection mediated by memory CD8+ T cells is related 
to their higher frequency, increased capacity to proliferate and to their enhanced capacity to 
rapidly acquire effector functions and to generate a secondary burst of effector CD8+ T cells 
upon antigen recognition 88,91,92. 
 
 
 
1.3.1 Heterogeneity of memory CD8+ T cell compartment. 
 
 
Identification of memory CD8+ T cells was initially based on the selective expression 
of specific surface molecules including CD27, LFA-1 (CD11a), LFA-3 (CD58) and the low 
molecular weight protein product of splice variants of CD45 gene, CD45RO 93-95. 
 
Today, it is widely accepted that memory pool is composed by different subsets of 
CD8+ T cells that can be distinguished according to the expression of unique combination of 
surface and intracellular markers associated to distinct cellular functions as well as distinct 
anatomic localizations 96-98. 
 
The initial evidences on the heterogeneity of CD8 memory compartment were 
provided by Sallusto et al.99 and unequivocally revealed the existence of two distinct subsets. 
These two subsets were identified according to the selective expression of homing and 
chemokine receptors by CD8+CD45RO+ T cells99. Notably, one subset of memory CD8+ T 
cells similar to naïve T cells, express both the lymph-node homing receptor CD62L (L- 
Selectin; SELL) and the T-cell zone homing CC-chemokine receptor 7 (CCR7; CD197)100 
This CD45RO+CD62L+CCR7+ subset was subsequently defined as central memory T cells 
(TCM) to indicate their potential to home to secondary lymphoid organs. On the other hand, 
the memory subset lacking on cellular surface either CCR7 or/and CD62L was instead termed 
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as effector memory T cells (TEM) because of their preferential localization in non-lymphoid 
tissues99,101. 
 
A more detailed analysis of TCM and TEM further revealed how the different 
phenotypic profile and anatomic location of these two subsets of memory CD8+ T cells also 
reflected distinct cellular functions. Indeed, upon in vitro stimulation and/or in vivo re- 
challenge, CD8+ TCM displays are characterized by a marked proliferative response supported 
also by the production of IL-2 but not to the release of substantial amount of effector 
cytokines (e.g. TNF-α and IFN-γ) and/or cytotoxic molecules (Perforin and Granzymes). In 
contrast,  CD8+  TEM  display  a  reduced  proliferative  response  but  can  promptly  mediates 
inflammatory reaction and cytotoxicity as indicated by their rapid and robust secretion of 
IFN-γ, TNF-α and granules containing perforin and granzymes99,102,103. 
This initial classification of memory CD8+ T cells, as initially suggested by Sallusto et 
al., was then further divided using new surface markers, leading to the characterization of 
additional subsets of memory CD8+ T cells endowed with specific phenotypic and functional 
properties. 
 
In particular, in combination with CD45RO and lymph-node homing receptors 
CD62L/CCR7, the selective expression of the member of tumor necrosis factor (TNF) 
superfamily of receptors CD95 (APO-1/Fas)104 and CD28105 allows the identification of three 
further discrete subsets of memory CD8+  T cells named as stem cell-like memory cells 
(TSCM), transitional memory  (TTM) and terminal  effector memory CD8+   T cells (TTE   or 
TEMRA+) 94,106,107 (Fig.2). Interestingly, the observation of a progressive reduction in 
telomerase length, the content of T cell receptor (TCR) excision circles (TRECs) and a 
parallel increased in the effector-associated genes (Granzymes, Perforin and IFN-γ) from 
TSCM  > TCM  > TTM  > TTE  , a precursor-product relationship   has been proposed for these 
different subsets of memory CD8+ T cells 103,108-110. 
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espan protection: Maintenance of Memory Pool 
 
 
 
 
 
 
 
1.3.2. Lifespan protection: maintenance of memory CD8+ T cells. 
 
 
 
Long-term maintenance of antigen-experienced T cells has been traditionally 
associated to the homeostatic signals induced by common- γ-chain cytokines. Indeed, 
different model of acute infection showed how survival of memory CD8+ T cells does not 
require a continue exposure to the cognate antigen but is mostly associated to the presence of 
IL-7 whereas exposure to IL-15 has been associated to the homeostatic turnover of memory T 
cells. Interestingly, this initial though has been recently extended in virtue of the identification 
of memory CD8+ T cells with stem cell-like qualities (TSCM). In this scenario, it has been 
suggested the TSCM  cells can be consider like the conventional hematopoietic stem cells 
(HSCs), as quiescent and undifferentiated progenitors. In this regard, it has been proposed 
how this small subset of memory CD8+ T cells, characterized by the unique capacity to self- 
renew, can also generate a differentiated progeny (TCM, TEM and TTE) in response to 
homeostatic stimuli (IL-7, IL-15) and TCR stimulation108,109,111. 
Despite the remarkable attractiveness, the existence of a subset of memory CD8+ T 
cells with stem-like attributes is still debated and mostly complicated by the absence of a clear 
anatomical relationship among memory T cell subsets109. The initial identification of stem 
cell-like memory CD8+ T cells was based on the overexpression of ATP-binding cassette 
(ABC)-superfamily multidrug efflux protein (ABC-B1). The interest for ABC-B1 transporter 
was related to its ability to confer protection from toxic xenobiotics (e.g. chemotherapeutic 
agents) and endogenous metabolites, to canonical hematopoietic stem cells. The analysis of 
Figure 2. Heterogeneity of memory CD8 compartment. Polychromatic flow cytometry characterization of CD8+ T cells isolated 
from peripheral blood of healthy donor. Identification of multiple subsets of memory CD8+ T cells according to the selective 
expression of CD45RO, CCR7, CD95 and CD28. 
 
(modified from The who’s who of T cell differentiation: Human Memory T-cell subsets. Mahnke YD1, Brodie TM, Sallusto F, 
Roederer M, Lugli E. Eur J Immunol. 2013, 43(11):2797-809. 
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ABC-B1 in memory CD8+ T cells from acute myeloid leukemia (AML) patients after 
repeated cycles of chemotherapy, allowed the identification of a small subpopulation of TCM 
and TEM further characterized by the selective expression of CD161 (KLRB1; NKRP1A), the 
α-chain of IL-18 receptor (IL-18Rα) and high levels of c-kit. Interestingly, a fraction of these 
subpopulations of stem cell-like memory cells, specific for immunodominant epitopes derived 
from Cytomegalovirus (CMV), Epstein Barr Virus (EBV) and Influenza virus, were readily 
detectable in peripheral blood of AML patients after chemotherapy. The latter observation 
clearly suggested how these subsets of stem cell-like memory CD8+ T cells are able to 
mediate host-protection against re-activation of CMV and EBV and, most importantly, their 
ability to mediate immune reconstitution of the memory T cell pool 112,113. However, the 
stemness of this chemotherapy-resistant population of CD8+ T cells has been then questioned 
as a consequence of their further characterization. Indeed, it was then reported that these 
CD161+ IL-18Rα+ memory cells also express characteristic features of terminally 
differentiated CD8+ T cells such as KLRG1, Blimp-1, shorter telomeres and reduced 
telomerase  activity  114.  In  addition,  the  analysis  of  TCR  repertoire  revealed  a  marked 
abundance of the T cell receptor chain Vα 7.2+ indicating that these cells are mostly mucosal 
associated invariant T cells (MAITs) rather than canonical T cells with stem cell-like 
properties108. 
 
This initial failure in the identification of TSCM has been apparently overcome by the 
work of Gattinoni et al.108 describing, in the peripheral blood of healthy donors, the existence 
of discrete population of memory T cells that, in vitro, was shown to be self-renewing and 
multipotent. In particular, this discrete subset of memory CD8+ T cells was defined by a 
specific phenotypic profile (CD45RA, CD62L, CCR7, CXCR3, CD122, CD127, CD95), 
which also reflected a distinct gene expression profile characterized by low levels of 
transcripts associated with T cell senescence (T-bet, KLRG1, Granzyme A and Perforin). 
Interestingly, Gattinoni et al. also reported how the generation of this stem cell-like 
population of memory T cells is a consequence of the triggering of Wnt-pathway during the in 
vitro priming of sorted naïve CD4+  and CD8+  T cells whereas studies performed in non- 
human primates (NHPs) indicate that antigen-specific TSCM naturally arise upon infection with 
simian immunodeficiency virus (SIV) and persist for long-term in an antigen-independent 
manner 115. 
 
Despite a plethora of studies, performed in human and animal models, confirmed the 
existence of a subset of TSCM, their stemness (self-renew and multipotency) has been always 
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demonstrated by in vitro assays and never at single cell level. In this regard, the development 
of cellular barcoding technologies 116,117 and the adoptive transfer of a single CD8+ T cell 
have recently questioned the existence of TSCM. Indeed, it was reported in mouse model, 500 
days post-infection (500 p.i.) with Listeria Monocytogenes (LM), the long-term persistent 
memory pool was composed only by canonical TCM (CD44hi CD62L+ CXCR3+ CD122+) and 
TEM (CD44hi CD62L- CXCR3+ CD122+) subsets. No antigen-specific CD8+ T cells, with a 
stem-cell like phenotype, were detected. In addition, using an elegant serial transfer of single 
CD8+ TCM, the authors unequivocally demonstrated the stemness capacity of central memory 
CD8+ T cells. Indeed, a single primary TCM upon adoptive transfer and subsequent LM- 
challenge, was able to confer protection to the host by generating an entire heterogeneous 
progeny of antigen specific CD8+  T cells including secondary TCM. Moreover, similarly to 
primary TCM, a single secondary TCM was equally efficient in conferring protection to 
immunocompetent or immunocompromised host upon LM infection118. 
 
In view of the latter observation the characterization of adult stem cells in the immune 
system remain to be clarified. Nevertheless, analysis of the clonogenic potential of individual 
T cell reinforces the therapeutic potential of TCM according to their self-renewal and 
multilineage differentiation capacity. 
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1.4. The origin of long-lived memory CD8+ T cells. 
 
 
Generation of long-lived antigen specific CD8+ T cells has always represented the aim 
of the different immunization protocols for infectious disease and malignancies. However, the 
underlying mechanisms regulating the formation of immunological memory and the lineage 
relationship between memory and effector CD8+ T cells are still poorly defined 96,119-121. 
 
 
1.4.1. Identification of effector and memory CD8+ T cells. 
 
 
 
In view of the natural history of CD8-mediated immune response, the initial key 
question was about the selection of the effector cells able to survive to the contraction phase, 
and to further mature in memory CD8+ T cells. This process of selection of memory cells 
among the effector CD8+  T cells was originally proposed to be completely random. In this 
scenario, all effector cells are equipotent and their further maturation into memory CD8+ T 
cells is related to the encounter, during and after the peak of primary immune response, with 
survival factors and/or, depending on their high TCR avidity6,103,109,122-124. 
 
This initial interpretation on the formation of immunological memory referred as the 
ON-OFF-ON model, also imply that the effector cells can be consider the progenitors of long- 
lasting memory CD8+  T cells. In support of this model, the use of genetic tagging systems, 
controlled by effector-associated genes, clearly indicate how also memory CD8+  T cells 
precursors, during primary immune response, are highly activated and transiently display 
effector functions but do not lose the ability to home to secondary lymphoid organs and to 
persist in an antigen independent fashion and to self-renew 125,126. 
In sharp contrast with the ON-OFF-ON model, the “Developmental Model” can 
alternatively explain the origin of memory CD8+ T cells. In the latter model, memory cells do 
not arise from effector cells but directly from activated naïve T cells, furthermore these 
memory precursor cells does not experience a proper effector state during the primary 
immune response109. This model is based on the observations that following stimulation, 
memory CD8+ T cells proliferated less as compared to effector cells, as indicated by the 
increased telomerase activity and telomeres length, and that upon  in vitro restimulation 
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memory CD8+ T cells can arise from memory cells but not from effector cells 94,107,120,127,128 
(Fig.3). 
 
 
 
 
 
 
 
 
 
 
 
 
The Developmental model is further supported by the ex-vivo characterization of 
antigen specific CD8+ T cells at the peak of primary immune response. In this regard, several 
evidences clearly pointed out how, like the memory compartment, the pool of effector cells is 
quite heterogeneous and different subsets of CD8+ T cells can be identified according to 
selective expression of genes and surface molecules, proliferative capacity and long-term 
survival. In this scenario, a population of short-lived effector cells (SLEC) mediates pathogen 
removal, during the primary immune response, by the production of cytotoxic molecules 
(perforin and granzymes) and effector cytokines (IFN-γ and TNF-α) and then rapidly undergo 
apoptosis. 
 
In sharp contrast with SLECs, a subset of memory precursor effector cells (MPEC) 
was also identified. In particular, MPECs are characterized by a reduced effector functions, a 
marked production of IL-2 upon antigen recognition and are able to further mature in long- 
lasting memory CD8+ T cells. Identification of SLECs and MPECs is based on the selective 
expression  of  killer  lectin-like  receptor  1  (KLRG1)  and  α-chain  of  the  IL-7R  (IL-7Rα; 
Figure 3. Heterogeneity of memory CD8 compartment. Two different model have been proposed to explain the acquisition of memory 
qualities by antigen-specific CD8+ T cells. The on-off-on model postulates that effector CD8+ T cells can acquire memory qualities after 
resolution of infection. In contrast, according to the developmental model, memory CD8+ T cells precursors are originated during primary 
immune response from antigen specific naïve precursor that does not acquire enhanced effector functions and do not undergo through 
several rounds of divisions. 
 
(modified from Lineage relationship of effector and memory T cells. Gattinoni L. and Restifo N.P. Current Opinion in Immunology (2013) 
25 (556-563) . 
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CD127) respectively 129,130. As expected, these phenotypic differences are associated with 
different gene expression programs orchestrated by dedicated transcription factors. In this 
regard, the commitment of naïve CD8+ T cells toward SLEC lineage is tightly regulated by 
high levels of T-bet (T-box transcription factor TBX21) and the transcriptional repressor 
Blimp-1 (B-lymphocyte-induced-maturation protein 1). These two transcriptional factors 
promote, in a synergistic manner, the generation of SLECs by activating the expression of 
effector molecules (IFN-γ, perforin and granzymes) and inhibiting the expression of factors 
associated with generation of MPECs. 
 
On the contrary, differentiation of activated naïve CD8+ T cells toward MPEC lineage 
is initially promoted by the transcription factor eomesodermin (EOMES; T-box brain protein 
2) and then maintained by Id3 (inhibitor of DNA binding 3) and TCF-1 (T cell Factor-1). In 
addition, according to their marked memory potential and long-term survival, MPECs are also 
characterized by the expression of anti-apoptotic members of the Bcl-2 (B-cell lymphoma 2) 
family such as Bcl-2, Bcl-XL and Bcl-6 128-132. 
The identification and characterization of MPECs and SLECs as distinct and stable 
populations of effector CD8+ T cells, do not exclude the existence of transitional subsets of 
effector cells  with  intermediate  phenotypes  and  functional  attributes.  In  this  regard,  the 
differentiation state of intermediate subsets of effector CD8+ T cells has been reported to be 
associated with the selective expression of several surface markers. In particular, in 
combination with KLRG1 and IL-7Rα, the selective expression of CD62L, CXC-chemokine 
receptor 3 (CXCR3; CD183) and CD27 allow the identification of effector cells with marked 
memory potential 128,133. 
 
 
 
1.4.2. Mechanisms of memory CD8+ T cell formation. 
 
 
 
Despite the development of widely applicable technologies allowing the identification 
of memory CD8+ T precursors cells within the effector pool, there is still a debate about the 
origin of these memory precursors. In this regard, four different models have been proposed 
to explain the simultaneous generation of effector and memory CD8+ T cells during a primary 
immune response (Fig.4) 116,128,129. 
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The initial thought regarding the origin of immunological memory, was consistent 
with the one naïve cell, one fate model. According to this model, before the recognition of the 
cognate antigen, a naïve CD8+ T cell is already committed to differentiate either into an 
effector cell or alternatively into a memory CD8+ T cell, but not both 116,128. In support of this 
pre-established commitment of a naïve CD8+  T cell, it was initially reported how TCM  and 
TEM, isolated from peripheral blood of healthy donors, were composed by distinct and stable 
clonotypes 116,128,134. However, the recent development DNA barcode-based lineage tracing 
technology, that allows the characterization of the progeny arising from individual clonal 
precursor, clearly indicate that individual naïve CD8+ T cell, with the same antigen 
specificity, can generate either a short-lived progeny or a long-lived effector cells (Fig.4A) 
135. 
 
Notably, this initial model disproved, at single cell level, the plasticity of naïve CD8+ 
T cells as indicated by their capacity to generate all the different subsets of effector and 
memory CD8+ T cells 116,117,128. In sharp contrast with the one naïve cell, one fate model, the 
current understanding of memory cells origin is consistent with one naïve cell, multiple fates 
which postulated that effector cells and all the different subsets of memory T cells can arise 
from the same naïve CD8+ T cell precursor 116,128. In this scenario, three different mechanisms 
have been proposed and distinguished depending on the fact that the fate decision is either 
taken before the first cell division of primed naïve CD8+ T cell, or at later stages of the 
primary immune response as a consequence of multiple rounds of interaction with antigen- 
bearing dendritic cells and in response to pro-inflammatory cytokines. 
 
The first model proposed is the signal-strength model. According to this model, 
differentiation of a naïve CD8+ T cell toward TSCM, TCM, TTM, TEM and effector T cells 
appears to be tightly regulated by the overall strength of the signals derived from the antigen 
(signal-1), co-stimulation (signal-2) and inflammatory cytokines (signal-3) during the priming 
of naïve CD8+ T cells. In view of the signal-strength model, the fate of naïve CD8+ T cell is 
programmed before the first cell division.  According to this model, “minimally  strong” 
signals are required to promote differentiation of naïve cells into memory cells. However, if 
these signals are stronger excess, they induce the generation of effector CD8+ T cells destined 
to die during the contraction phase of primary immune response (Fig.4B)116,128,136-138. 
Similar to the signal strength model, the “decreasing-potential model” describes that 
the fate of primed naïve CD8+ T cells is defined by the overall strength of the signal received 
during the priming. However, in this model, differentiation of naïve CD8+  T cells is not 
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regulated by the intensity of the signals received before their first division but is rather 
modulated by the cumulative effect of successive round of stimulation during the primary 
immune response. In animal models, it has been shown how a decreased inflammation, 
consequence of antibiotic treatment or delayed transfer of naive specific T-cells, is associated 
with  an  increased  differentiation  of  naïve  cells  into  memory  CD8+   T  cells  (Fig.4C) 
116,128,136,139-141. 
 
Finally, the cell fate specification was also proposed to be defined through the 
asymmetric segregation of critical determinants in the daughter cells of a primed naïve CD8+ 
T cell 142. Interestingly, in the asymmetric cell fate model, the unequal inheritance of specific 
factors is realized before the first cell division of the clonal precursor and is orchestrated by 
the protein kinase C-ζ (PKC-ζ). Indeed, this ancestral regulator of asymmetric division allows 
the early identification of daughter cell committed to memory differentiation143. In this regard, 
it has been reported how, in pre-mitotic activated naïve CD8+ T cells, PKC-ζ is preferentially 
accumulated at the opposite side of immunological synapse (distal pole) and identifies the 
distal daughter cell further characterized by preferential accumulation of TCF-1, IL-7Rα and 
CD62L. In sharp contrast, the pole where T cell-APC occurs (proximal pole; proximal 
daughter cell), was described as the segregation location of several determinants such as LFA- 
1, CD8, α-chain of the IL-2 receptor (IL-2Rα; CD25), IFN-γ receptor (IFNγR) and granzyme 
B. This asymmetric partitioning of distinct factors into the daughter cells as a critical 
determinant for fate specification, was reported to formally promote the differentiation of 
proximal cell and distal cell into short-lived and memory precursor effector cells respectively 
(Fig.4D) 127,128,142,143. 
All these different models, proposed for the generation of a heterogeneous pool of 
effector CD8+ T cells, including subsets with a marked memory cell potential and longevity, 
are not mutually exclusive. In addition, for all the suggested models, initial(s) stimulation of 
antigen-specific CD8+ T cells represents a critical step in the definition of memory potential 
of naïve T cells. 
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Figure 4. Heterogeneity of memory CD8 compartment. Different model have been proposed in order to explain origin and 
heterogeneity of memory CD8+ T cells. The separate precursor model postulates that commitment of naïve CD8+ T cells to effector or 
memory lineage is defined during thimic selection. In contrast, signal strenght model, decreasing potential model and asymmetric cell fate 
model postulate that lineage commitment of antigen specific naïve CD8+ T cell is defined during initial stimulation. 
43 	  
1.5. Priming of CD8+ T cell responses: The first step on the path to memory. 
 
 
Generation of CD8+ T cell responses is a regulated process and several factors have been 
reported to affect both clonal expansion and, most importantly, the differentiation of antigen- 
specific naïve precursors into effector and memory T lymphocytes. In this respect, it has been 
extensively shown how antigen dose and its persistence might affect activation of CD8+ T 
cells and acquisition effector functions. In particular, low amount of antigen may impair the 
ability of the immune system to generate CD8+ T cells responses (antigen ignorance)144. In 
contrast, as indicated in several preclinical and clinical studies of chronically infected and 
cancer patients, antigen persistence is normally associated to the acquisition by reactive CD8+ 
T cells of an exhausted phenotype characterized by an impaired proliferative capacity and 
reduced production of effector cytokines upon stimulation7,30,31. Furthermore, the molecular 
structure of the antigen has been also shown to regulate the activation of reactive T 
lymphocytes. Indeed, several studies aiming to elucidate crucial aspects of antigen recognition 
by T cell receptor (TCR) have shown that activation, differentiation and survival of reactive 
CD8+ T is primarily regulated by the capacity of antigen derived peptide to be loaded in the 
groove of MHC class I molecules (pMHC) and by the capacity of reactive T cells to recognize 
with high avidity cognate pMHC complexes express on target cells6. 
Although the primary stimulus promoting CD8+ T cell activation is associated to 
engagement of TCR, different studies underlined that differentiation of antigen specific naïve 
precursors into effector and memory T cells is also critically regulated by other signals 
integrated by responding T cells. Our current understanding is consistent with the “three 
signals model” postulating how activation and differentiation of naïve CD8+ T cells are 
regulated by the composition and the strength of signals associated to antigen recognition 
(signal-1), co-stimulatory receptors (signal-2) and pro-inflammatory cytokines (signal-3)145.It 
has been extensively shown that clonal expansion of antigen specific naïve CD8+ T cells is 
initiated upon T cell receptor (TCR) mediated recognition of antigen-MHC class I complexes. 
However, in particular in situations of low TCR occupancy and/or affinity, activation of naïve 
CD8+ T cells is decisively sustained by signals derived by co-stimulatory receptors, 
predominantly CD28, interacting with their cognate ligands. Indeed, in naïve CD8+ T cells, 
CD28 signaling results in the activation of different transcription factors, including nuclear 
factor  kB  (NF-kB)  and  nuclear  factor  of  activated  T  cells  (NFAT),  regulating  cell 
proliferation and differentiation of responding T lymphocytes6,32,146. Furthermore, execution 
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of cellular programs leading to the acquisition of effector functions and most importantly to 
the differentiation of antigen-specific naïve precursors into long-lasting memory cells has also 
been extensively associated to the cytokine milieu experienced by responding CD8+ T cells 
during the priming.  Studies have shown that specific pro-inflammatory cytokines such as IL- 
12 and IFNs-type I, are critical determinants defining the memory potential of CD8+ T 
cells147-151. 
 
In view of this model and according to their ability to provide all the signals required 
for activation of antigen-specific naïve precursors, a pivotal role for antigen presenting cells 
(APCs) has been repeatedly demonstrated in the generation of protective and long-lasting 
CD8+ T cells responses. 
 
 
 
1.5.1 Role of Antigen Presenting cells and cytokines 
 
 
 
Antigen Presenting Cells (APCs) are a heterogeneous group of immune cells able to 
initiate and/or sustain cellular immune responses by processing and presenting antigens for 
recognition by T lymphocytes. In this regard, it has been extensively reported that  the 
capacity of APCs to mediate the activation of CD8+ T cells is related to the specific subset 
interacting with T-lymphocytes and further regulated by their activation status. Among the 
different cells endowed with antigen presenting capacity, dendritic cells (DC) have been 
traditionally described as the main inducers of CD8+ T cell responses: the “professional” 
APC152,153. 
 
The pivotal role of DCs, in orchestrating cellular immune responses, has been shown to 
correlate with their ability to migrate from periphery to secondary lymphoid organs, upon 
antigen capture, where they mediate initiation of CD8+ T cell responses. Most importantly, 
together with other factors, activation/ maturation status of DCs represent a critical 
determinant dictating the outcome of CD8+ T cell responses towards tolerance or protective 
immunity. In particular, in a number of studies, activated (mature) DCs have been shown to 
more effectively promote, clonal expansion and acquisition of effector functions by naïve 
CD8+ T cells as compared to resting (immature) DC. Remarkably, the effectiveness of 
activated (mature) DCs has been associated to the high expression on cellular surfaces, along 
to antigen/MHC-class I complexes, of a panel of co-stimulatory ligands including CD80 
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(B7.1) and CD86 molecules (B7.2) that amplify, upon engagement of CD28 co-receptor, the 
strength of the signal-1 in responding T lymphocytes146. Furthermore, it has been recently 
showed that activated DCs can also shape the memory potential of responding CD8+ T cells 
due to their capacity to secrete, upon activation, high levels of a broad array of different 
cytokines. In this respect, it has been repeatedly shown that specific pro-inflammatory 
cytokines such as IL-12, IFN-α and IFN-β (IFNs-type I) promote the expansion and the 
acquisition of effector functions by activated CD8+ T cells150,154. 
Interestingly, in the last years, a crucial role for these pro-inflammatory cytokines has also 
been revealed in the effective generation of memory CD8+ T cells. In particular, in different 
studies performed in animal models, it has been observed that abrogation of IL-12 and IFN-α 
signaling on naïve CD8+ T cells affects their differentiation into memory cells, long-term 
survival   and   their   ability   to   mount   strong   proliferative   response   upon   secondary 
stimulation155,156. Interestingly, the ability of IL-12 and IFN-α to shape the memory potential 
of naïve CD8+ T cells has been associated to their capacity to sustain chromatin remodeling 
initiated by TCR and CD28 associated signals. In fact, direct signaling of IL-12 and IFNs- 
type I prevents the decline, over the time, of mRNA levels of genes regulating effector 
functions (IFN-γ, granzymes, perforin) but also survival and differentiation (Bcl-3; Bcl-6; IL- 
7Rα; T-bet and Eomesodermin) of responding CD8+ T cells155,156. A critical relevance of IL- 
12 and, to a lesser extent, IFN-α, in promoting survival and acquisition of memory qualities 
by antigen-specific naïve precursors cells, has been shown in a set of experimental studies 
based on the adoptive transfer of CD8+ T cells lacking expression of functional receptors for 
IL-12 and/or IFNs-type I155,156. However in some other reports, a dispensable role or 
detrimental effect of these pro-inflammatory cytokines in defining the memory potential of 
CD8+ T cells has also been suggested. In particular, in distinct infectious models, it has been 
underlined a potential role for IL-12 and/or IFNs-type I in promoting the generation of 
KLRG1+ IL-7Rα- short-lived effector cells (SLECs). In these studies, commitment to SLEC 
lineage is associated with the induction of transcription repressor Blimp-1 and, most 
importantly, T-bet transcription factor157-159. Indeed, differentiation of naïve CD8+ T cells 
into SLECs has been associated to the capacity of T-bet and Blimp-1 to regulate the 
expression of genes mediating the acquisition of effector functions (IFN-γ, Granzymes, 
Perforin and CD178 (FAS-L)) and to further avoid the generation of memory-precursors 
effector cells (MPECs) by abolishing the expression of different genes encoding factors, 
including Bcl-6 and IL-7Rα, promoting long-term survival124,160. 
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Remarkably, different hypothesis have been formulated in order to explain these 
contradictory observations. In particular, differences in the experimental settings such as the 
use of specific infectious agents, different doses and transgenic mice may partially account for 
the opposite results reported. In addition to these technical considerations, several evidences 
suggest that mostly the timing and the intensity of pro-inflammatory cytokines signaling on 
naïve CD8+ T cells are critical determinants, dictating their differentiation toward SLECs or 
MPECs lineage141. In this regard, IL-12 and, to a lesser extent, IFN-α signaling on CD8+ T 
cells is crucial during the priming for the definition of memory potential and does not result in 
the up-regulation of KLRG1 senescent marker on their cellular surfaces156. In line with this 
observation, it has been recently shown that during clonal expansion, before the acquisition of 
phenotypic signature of SLEC or MPEC lineage, the majority of antigen-specific naïve CD8+ 
T cells acquire a phenotype, termed of early effector cells (EEC), characterized by the lack of 
KLRG1 as well as IL-7Rα. Interestingly, hierarchical characterization of antigen-specific 
EEC CD8+ T cells has revealed that although this population is programmed to differentiate 
into SLECs or MPECs based on the intensity of early inflammatory signals received during 
the priming, it is also susceptible to additional inflammatory signals that can alter the lineage 
commitment161. Hence, it is reasonable to assume that paracrine production of pro- 
inflammatory cytokines, mostly IL-12 and IFNs-type I, by antigen-bearing DCs during 
priming is crucially involved in the definition of memory potential of CD8+ T cells whereas 
inflammatory signals derived by other cells may potentially drive the differentiation  of 
antigen specific precursor toward SLEC lineage. In addition, although animal models have 
shown that strong and persistent inflammatory signals favor the generation of SLECs in a T- 
bet dependent manner157, clinical evidences observed from acute or chronic infected 
individuals indicates that, more than the expression of T-bet, it is the ratio T- 
bet/Eomesodermin which defines the capacity of CD8+ T cells to mediate long-term viral 
control. Indeed, in HIV chronic infected individuals and in patients experiencing CMV 
opportunistic infection upon solid organ transplantation a reduced T-bet/Eomesodermin ratio 
have been correlated respectively with an in vivo exhausted phenotype and an impaired 
proliferative response of virus-specific CD8+ T cells161-163. 
In this scenario, the pivotal role of dendritic cells in shaping the magnitude and also the 
memory potential of CD8+ T cell responses has induced considerable efforts by the scientific 
community in order to modulate the immunostimulatory potential of dendritic cells. In this 
respect, it has been demonstrated that the activation of dendritic cells can be mediated by (i) 
innate immune system derived inflammatory cytokines, (ii) upon recognition, via pathogen 
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recognition receptors (PRRs), of pathogen associated or damage associated molecular patterns 
(PAMPs and DAMPs respectively) and, most importantly, (iii) by CD4+ T cells. 
 
 
 
1.5.2 CD4+ T helper cells. 
 
 
 
CD4+ T lymphocytes can be considered as critical regulators of the immune system. 
In particular, the pivotal role of CD4+ T cells in different processes of innate and adaptive 
immune responses has been traditionally ascribed to the heterogeneity and the marked 
plasticity of the members of this T lymphocytes lineage. So far, different subsets of CD4+ T 
cells with specialized functions, reflecting the selective expression of cellular surface 
antigens, transcription factors and cytokines production profile, have been identified164. 
Among the different subsets, CD4+ T helper 1 (Th1) have been repeatedly shown to support 
generation of effective memory CD8+ T cells against intracellular pathogens and solid 
tumors. However, despite considerable research efforts, several aspects regarding the helper 
activity of Th1 are not completely defined yet. In particular, definition of the time window for 
CD4+ T cell requirement as well as the molecular mechanism(s) supporting the generation of 
protective and long-lasting CD8+ T cell responses are still debated165. 
 
Initial results obtained in different immunization models suggested a critical role for 
Th1 cells during the priming of antigen specific CD8+ T cell responses (Programming 
model)165,166. Interestingly, this initial interpretation has been later extended. Indeed, it has 
been reported that CD4+ T helper cells may also promote survival and proliferative response, 
upon re-challenge, of memory CD8+ T cells (Maintenance Model)165,167. Notably, the 
existence of two different models concerning the intervention of CD4+ T helper cells can be 
explained in virtue of the distinct mechanisms by which help can be delivered during CD8+ T 
cell responses. 
 
Th1 cells have been repeatedly shown to provide help basically through the paracrine 
production of high amounts of cytokines, most importantly, interleukin-2 (IL-2) and by 
“licensing” antigen-presenting cells (APCs Licensing) to optimally stimulate naïve CD8+ T 
cells. In view of the pivotal role of DCs in shaping the memory potential of antigen-specific 
naïve precursor, collective results obtained by different studies suggested that cytokines 
production, including IL-2, by bystander CD4+ Th1 cells is mostly associated to survival of 
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memory CD8+ T cells after resolution of primary infection and/or in promoting their 
proliferative response upon re-challenge. Indeed, it has been shown that IL-2 can act as a 
surrogate of CD4+ T helper cells during maintenance phase or recall but not during the 
priming  of  naïve  CD8+  T  cells.  Furthermore,  it  has  also  been  shown  that  in  vivo 
administration of IL-2 during initial stimulation of CD8+ T cells could potentially lead to the 
generation of SLECs160,165,168. 
 
 
 
1.5.3. Shaping memory potential of naïve CD8+ T cells: CD4+ T cells and APC 
Licensing. 
 
 
The initial evidence on the pivotal role of CD4+ T helper 1 cells in modulating antigen 
presenting capacity of dendritic cells was provided by pioneering studies aiming at 
elucidating T cell help dependence of CD8-mediated immune responses in different 
vaccination/infectious models. In particular, these initial studies clearly underlined a 
differential requirement for Th1 cells, mostly dictated by the biology of the immunization 
setting, in promoting clonal expansion and acquisition of effector functions by CD8+ T cells 
(Primary Response). Indeed, strong CD8+ T cell responses, in absence of CD4+ Th1 cells, 
were extensively described in animal models upon infection with lymphocytic 
choriomeningitis virus (LCMV) vesicular stomatitis virus (VSV), vaccinia virus (VV) and 
listeria monocytogenes (LM). In sharp contrast, presence of CD4+ T cells was critically 
required in order to promote CD8-mediated primary immune responses against non-infectious 
antigens such as minor histocompatibility antigens, protein antigens and tumor-associated 
antigens165,168. Initial interpretation of these results was based on the exclusive capacity of 
different viral and bacterial pathogens, as compared to cellular antigens, to activate antigen- 
presenting cells (APCs) indirectly by inducing innate immune system-derived inflammatory 
cytokines and directly by recognition via pathogen recognition receptors (PRRs), expressed 
by APCs, of pathogen associated molecular patterns (PAMPs). Interestingly, these stimuli 
have been associated to different phenotypic and gene expression profiles. Indeed, it has been 
shown that up-regulation of maturation markers (MHC class II; CD80; CD86) on cellular 
surfaces can be observed as a consequence of the exposure of DCs to inflammatory cytokines, 
including IFNs type I and TNF-α, produced by other cell types. However, the capacity of DCs 
to prime naïve T cells and to promote their differentiation in effector cells was critically 
dependent on the direct recognition of infectious agents. In this respect, different categories of 
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PRRs, most importantly Toll-like receptors (TLRs), have shown to initiate an intracellular 
signaling in DCs, leading to the de-novo transcription of genes encoding pro-inflammatory 
cytokines including IFN-α/β and IL-12 169,170. 
Remarkably, this initial model on CD4+ T cell helper dependence of CD8-mediated 
immune responses has then been revised by different studies in which functionality of 
resulting memory CD8+ T cells generated in absence (“helpless”) or presence (“helped”) of 
CD4+ T cells was evaluated. Collectively, these studies have shown that, although primary 
CD8+ T responses generated in response to different viral or bacterial infections can in fact be 
also CD4+T helper 1 cells independent, memory CD8+ T cells generated in helpless 
conditions were unable to mount productive recall responses. Indeed, in sharp contrast with 
helped, helpless memory CD8+ T cells have been reported to be functional impaired, thus 
conferring a limited protection upon re-challenge166,171,172. In particular, memory CD8+ T 
cells generated under these conditions were reported to be characterized by reduced survival, 
production of a limited array of effector cytokines and defective proliferative response due to 
up-regulation of inhibitory receptor programmed cell death-1 (PD1)173, impaired IL-2174 
production and/or TNF-related apoptosis-inducing ligand (TRAIL) mediated apoptosis upon 
secondary stimulation166. However, these observations have been challenged by different 
studies. Indeed, some reports have described the capacity of the immune system, in different 
model of CD4+ deficient mice, to generate protective and long-lasting CD8+ T cells in 
particular against viral and bacterial pathogens. Indeed, memory CD8+ T cells generated in 
helpless condition were able to confer host protection, upon secondary exposure to the 
pathogen based, on their marked proliferative response and acquisition of effector function 
upon antigen recognition. Intriguingly, this apparent discrepancy has been potentially 
resolved by the observation, in specific experimental settings, of the capacity of some 
pathogens to induce “per se” a high production of IL-12 and IFNs-type I during host 
infection, thereby potentially bypassing the requirement of CD4+ T helper cells during the 
priming of antigen-specific naïve precursors175. 
Based on this background, our current understanding of the interplay between dendritic 
cells (DCs), CD4+ and CD8+ T cell in the generation of immunological memory is still 
consistent with the “APC-Licensing” model postulating that CD4+ T cells orchestrate the 
generation of memory CD8+ T cells predominantly by promoting the activation of dendritic 
cells through CD40 ligand (CD40L; CD154)/CD40 receptor pathway176,177. 
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1.6. CD40 ligand-CD40 receptor pathway. 
 
 
CD40 receptor is a 48 kDa type I transmembrane protein that belongs to Tumor 
Necrosis Factor receptors (TNFR) superfamily. Remarkably, engagement of CD40 receptor 
by its cognate ligand results in the formation of homotrimeric complexes promoting the 
recruitment, on different cytoplasmic domains, of adapter proteins termed TNFR-associated 
factors (TRAFs). The TRAFs family included six different members (TRAF-1,2,3,4,5 and 6), 
and all of them have been shown to mediate the intracellular signaling of the members of 
TNFR family upon interaction with the cognate ligands. Interestingly, CD40 ligation has been 
associated to the activation of a wide spectrum of molecular processes. In particular, CD40 
receptor initiated signals are associated to the activation, through TRAFs family members, of 
distinct intracellular signaling pathways associated to nuclear factor-kB (NF-kB), mitogen 
activated protein kinase (MAPKs), phoshoinositide 3-kinase (PI3K) and pospholipase Cγ 
(PLCγ). In addition to the capacity to promote the activation of distinct signaling pathways, 
engagement of CD40 receptor resulted in the modulation of different cellular functions also as 
a consequence of its broad pattern of expression. Indeed, CD40 receptor is found on different 
cell types including epithelial, endothelial, stromal cells and, most importantly on cellular 
surface of cells endowed with antigen presenting capacity such as B cells, dendritic cells, 
macrophages, monocytes and possibly on T cells178-182. 
 
CD40 ligand (CD40L; CD154; gp39) is a 32-33 kDa type II transmembrane 
glycoprotein that belongs to TNF superfamily expressed on cellular surface of natural killer 
cells (NK), natural killer T cells (NKT), CD8+ and, most importantly, CD4+ T cells. In 
addition to the transmembrane form, two shorter version (31 and 18kDa) of CD40L protein 
have been described. These shorter CD40L forms are generated after proteolytic cleavage and 
are mostly secreted by activated platelets and T cells178-182. 
 
Although soluble and membrane bound CD40L possess an equal ability to form 
trimers, the presence of these two different isoforms is associated with different biological 
effects. Indeed, elevated serum levels of s40L has been described in cancer and chronic 
inflammation and associated to survival, expansion and enhanced immunosuppressive activity 
of myeloid derived suppressor cells (MSDC)14 and Tregs183. In contrast, membrane-bound 
CD40L expressed, mostly, by activated CD4+ T cells is clearly associated with the activation 
of humoral and cellular immune responses. The different effects induced by membrane bound 
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and soluble CD40L isoforms might reflect the different environment and molecular 
characteristic of the ligation of CD40 receptor ligation on different cell types, thereby 
resulting in the modulation of different cellular functions. To this respect, it has been also 
shown that biological responses induced by the ligation of CD40 receptor are correlated to the 
extent as well as the strenght of stimulation on target cells. To this respect, different cellular 
consequences initiated by CD40 receptor triggering have been associated to the selective 
recruitment of different TRAFs molecules and/or to the activation of distinct intracellular 
signaling pathways184,185 
 
 
 
 
 
 
Figure 5. Multiple effects of CD40:CD40L pathway. Ligation of CD40 receptror has been associated to the modulation of different 
cellular responses. The multiple effects associated to CD40: CD40L pathway are related to the broad pattern of expression of CD40 
receptor and to several intracellular signaling cascades initiated in response upon CD40L engagement. In particular, different TNF-receptor 
associated factors (TRAFs) have been identified as critical mediators of CD40 receptor initiated signals. TRAF proteins are recruited on 
different cytoplasmic domains of CD40 receptor and can mediate the activation of NF-kB, JNK and p38/MAPK pathway resulting, 
according to the cell type as well the strength and the extent of the stimulus, in apoptotic or prosurvival effects. Furthermore, ligation of 
CD40 receptor on immune cells such as dendritic cella and B-lymphocytes has been associated to the up-regulation of costimulatory ligand 
on their cellular surface and secretion of pro-inflammatory cytokines. 
 
(adapted from: Molecular mechanisms and funcrion of CD40/CD40L engagement in the immune system. Elgueta R., Benson M.J.,deVries 
VC et al. Immunol Rev.2009 May ; 229 (1) :152-172.) 
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1.6.1 CD40 ligand-CD40 receptor and Immune System. 
 
 
 
CD40/CD40L pathway has been initially described as a critical regulator of humoral 
immune responses. Studies with mutation of the CD40 receptor and/or CD40L genes resulted 
in impaired germinal centre (GC) formation, immunoglobulin (Ig) isotype switching, 
generation of long-lived plasma cells and memory B-cells differentiation. In addition, 
CD40/CD40L pathway is also associated with the induction of T cell response. Indeed, CD4+ 
T cells, activated by TCR mediated recognition of cognate antigen-MHC class II complexes, 
rapidly express membrane bound CD40L on their cellular surface. Hence, activated CD4+ 
CD40L+ T cell can promote the activation of CD40-expressing dendritic cells. Indeed, CD40 
receptor activity on DCs resulted in the delivery of prosurvival signals (Bcl-2), resistence to 
FAS-L induced apotosis, up-regulation of a broad panel of surfaces molecules involved in the 
generation of immunolgical synapse. Indeed, the engagement of CD40 receptor resulted in the 
an increased expression of MHC class I/II molecules and in the up-regulation of adhesion and 
costimulatory molecules including CD80 (B7.1), CD86 (B7.2), CD58 (LFA-3), CD54 
(ICAM-1). Furthermore, CD40-stimulated dendritic cells acquire the capability to secrete pro- 
inflammatory and effector cytokines including TNF-α, MIP-1α, GM-CSF, IFNs-type I, IL-6, 
IL-1β and IL-12. Interestingly, in response to paracrine production of IL-12, responding T- 
cell  can  further  increase  the  expression  on  cellular  surfaces  of  CD40L,  thereby  further 
sustaining activation of dendritic cells179,181. 
 
Different studies have also underlined how stimulation by microbial stimuli and 
selective TLR-agonists (CpG, poly I:C and LPS) can potentially overcome blockade of 
CD40/CD40L pathway186,187. However, experiments in animal models have demonstrated that 
microbial products cannot replace the signals initiated by CD40 receptor. Indeed, in a set of 
studies performed to evaluate CD8+ T cells priming capability of CD40-stimulated or TLRs- 
stimulated dendritic cells, abrogation of CD40 signaling resulted in a marked reduction in 
expansion, cytokines production and acquisition of memory qualities by transgenic and 
antigen-specific endogenous CD8+ T cells188,189. Notably, the relative reduced 
immunostimulatory potential of TLR-stimulated dendritic cells appears to be associated to 
different capacity of TLR-agonists to induce up-regulation of co-stimulatory ligands and of 
selective pro-inflammatory cytokines. Interestingly, TLR-initiated signals, most importantly 
through the nuclear factor kB (NF-kB), resulted in the up-regulation of co-stimulatory CD40 
receptor on cellular surfaces of dendritic cells  recognizing microbial products. Thereby, 
	  despite a marked stimulatory potential of TLR-agonists, only CD40 induction appears 
associated to the full activation of dendritic cells170,189. In support of this hypothesis, it has 
been observed how, in response to autocrine or paracrine production of pro-inflammatory 
cytokines, TLR-stimulated DCs may acquire the capacity to optimally prime naïve CD8+ T 
cells. Interestingly, the increased antigen presentation capacity of dendritic cells, observed 
under these conditions, is correlated to the ability of IFN-α receptor-initiated signals to sustain 
nuclear translocation of NF-kB, resulting in increased cytokines productions by stimulated 
DCs. Furthermore, exposure to IFN-α resulted in up-regulation and/or maintenance of high 
expression of CD40 co-stimulatory receptor on cellular surfaces of DCs. Based on these 
findings, it is reasonable to assume that T-cell help-independence, described in the generation 
of effective memory CD8+ T cells against specific infectious agents, might be related to the 
synergistic effects associated to the recognition of certain pathogen associated molecular 
patterns (PAMP) further sustained by the autocrine and/or paracrine production of pro- 
inflammatory cytokines. Nevertheless, also in these experimental settings, a crucial role for 
CD40L-expressing activated CD4+ T cells is indirectly suggested by the up-regulation of 
CD40 receptor associated to IFNα receptor initiated signals alone or in combination with TLR 
agonists stimulation169,170,190. In particular, it is tempting to speculate that engagement of 
CD40 receptor might result in the modulation of the quantity and quality of signal 2 and 3 
delivered by dendritic cells to responding CD8+ T cells. In addition, though some TLR 
agonists have shown a potential capacity to promote DCs-mediated cross-presentation of 
exogenous antigens to CD8+ T cells, it must be underlined how this latter functional capacity 
has been extensively associated to the ligation of CD40 receptor. In this scenario, stimulation 
of CD40 receptor on cellular surface of antigen presenting cells, most importantly DCs, by 
CD40L-expressing CD4+ T cells represents a critical step in regulating the induction of 
protective CD8+ T cell responses177,191,192. 
The identification of CD40/CD40L pathway has also contributed to reconcile critical 
considerations on the capacity of CD4+ T cells to promote activation as well as differentiation 
of naïve CD8+ T cells. Initial interpretation of “helper activity” was based on the 
simultaneous recognition, on the same DC, of cognate antigens by CD4+ and CD8+ T cells. 
In particular, the CD4+ T help dependence of CD8-mediated immune responses was related 
to the CD4+ paracrine production of high amounts of IL-2, supporting the clonal expansion 
and acquisition of effector functions by antigen specific naïve precursors. A major limitation 
of this model is the low probability that two rare antigen-specific T-cells were simultaneously 
engaged on the same DCs176. 
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  T-cell help dependence of CD8+ T cell responses has been then revised by the 
pionering studies of P. Matzinger177 and collaborator leading to the definition of Antigen 
Presenting cells Licensing model (APCs licensing) suggesting a sequential interaction of 
CD4+ and CD8+ T cells with antigen-bearing dendritic cells. In particular, interaction of 
CD4+ T cells with an antigen presenting cells, via CD40/CD40L pathway, induces a 
sustained activation of the second resulting in an efficient priming of CD8+ T cells even after 
dissociation of CD4+-APC interaction176,177. 
Interestingly, based on recent technological advance, the generation of a “three cell 
cluster” involving DC, CD4+ and CD8+ T cell was shown to occur in vivo. Indeed, in vivo 
imaging studies have shown that antigen-driven interaction of T cells and DC in lymph-nodes 
can last for hours193. Based on these findings, it was proposed that a responding CD8+ T cell 
might encounter, in T cell areas, a pre-existing two cell cluster composed by CD4+ T cells 
and antigen-bearing DC. Noteworthy, it has been also shown how both CD4+ T cells and 
activated DCs can actively recruit responding CD8+ T cells through the production of 
different chemokines. In particular, CCL3 and CCL4 chemokines which play a pivotal role in 
recruiting antigen-specific naïve CD8+ T cell expressing CCR5 receptor, thereby potentially 
orchestrating  the  simultaneous  engagement  of  dendritic  cells  by  both  T  subsets  during 
priming194,195. 
 
In view of the latter observation and according to studies showing the capacity of 
murine CD8+ T cells to express, upon antigen recognition, detectable levels of CD40 
receptor, different studies have been performed to further dissect the molecular basis of 
CD40/CD40L pathway in promoting the generation of CD8+ T cell responses196,197. The data 
showed that the formation of a three cell cluster could potentially also promote the direct 
interaction of CD4+ T cells and naïve CD8+ T cells and the deliver, through CD40/CD40L 
pathway, of signals promoting the differentiation of the latter into memory cells. These 
reports 196,197 also showed that, activation of CD40 receptor-deficient naïve CD8+ T cells did 
not resulted in significative defects in their capacity to mount a protective primary immune 
response. Nevertheless inhibition of CD40-initiated signals clearly affected the capacity of 
responding CD8+ T cells to re-express IL-7R〈 and, most importantly, resulted in the 
generation of “lethargic” memory cells. Indeed, mouse CD40 deficient CD8+ T cells were 
characterized by reduced proliferative capacity and cytokines production, particularly IFN-γ 
and IL-2, upon in vivo antigenic re-challenge or in vitro stimulation196-198. The critical 
relevance  of  CD40  receptor  associated  signals  in  defining  memory  potential  of  antigen 
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specific naïve precursors was further consolidated by several evidences. In particular, studies 
showing the inhability of CD4+ T cells to restore the functionality of memory CD40- 
deficient CD8+ T cells during maintenance phase and/or upon antigenic re-challenge196. 
Based on these findings, it was then proposed that CD40 signaling on dendritic cells and 
CD8+ T cells has different effects on the generation of CD8+ T cell responses. In this regard, 
stimulation of CD40 receptor on dendritic cells has been associated to the clonal expansion 
and acquisition of effector functions by antigen-specific naïve precursors. On the other hand, 
CD40 expression on CD8+ T cells appeared as a crucial element mediating the execution of 
cellular programs leading to their differentiation into memory cells. Indeed, in mouse model, 
ligation of CD40 receptor expressed by activated CD8+ T cells has been associated, through 
the activation of different intracellular signalling pathway to the acquisition of effector 
functions (FAS-L; Perforin and Granzymes) and the expression of homeostatic cytokines 
receptor genes such as IL-7Rα, IL-15Rα, and IL-21Rα thereby resulting in a fine modulation 
either of CD8+ primary and memory responses196-198. 
 
Identification of CD40 receptor on CD8+ T cells, as a crucial and non-reduntant 
element supporting their differentiation into memory cells, has been extensively reported, in 
mouse model, in response to cellular antigens 196-198. In contrast, the putative impact of this 
co-stimulatory receptor in mediating the generation of effective memory CD8+ T cells against 
infectious agents has not yet fully elucidated199. Indeed, discrepant results have been reported. 
Some studies indicate that T-helper activity during priming of antigen specific may be 
dispensable in view of the capacity of some pathogens to promote the direct activation of 
dendritic cells and also to induce on their cellular surfaces CD40L expression thereby 
potentially capable to activate either neighbor antigen presenting cells and responding CD8+ 
T cells200. However, other studies reported the generation of fully functional memory CD8+ T 
cells in response to infectious agents even in the absence of CD40 receptor expression on their 
cellular sufaces199. Interestingly, these latter results might be associated to the ability of 
different pathogens, to induce a massive production of IFN-α. To this respect, it must be 
underlined that molecular characterization of CD40 and IFN-α receptor associated signals 
resulted in convergent transcriptional outcomes in dendritic cells, thereby it is tempting to 
speculate that these two pathways can be potentially redundant in CD8+ T cells201,202. In this 
regard, further studies, especially in human system, are urgently required in order to 
characterize the gene expression profile and functional consequence of CD40 activity on 
CD8+ T cells activation and differentiation. Nevertheless, the latter observation represents 
also indirect evidence confirming either the role of certain pro-inflammatory cytokines and 
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most importantly the critical relevance of APC-licensing in shaping memory potential of 
primed CD8+ T cells201-203. 
 
 
 
1.6.2 CD40 ligand-CD40 receptor; a pathway to enhance anti-tumor CD8+ T cells. 
 
 
 
It is nowadays widely accepted that memory potential of naïve CD8+ T cells is 
defined alongside the induction of protective primary immune response. A plethora of studies 
have shown how the initial stimulation of antigen-specific naive precursors can affect either 
their clonal expansion and acquisition of effector functions but also the size, phenotypic and 
functional attributes of the resulting pool of antigen-specific memory CD8+ T cells166,172,174. 
 
Among different factors regulating the generation of effective anti-tumor CD8+ T cell 
responses, CD4+ T cells have been consistently shown to play a pivotal role166,172,174. 
Although different mechanisms have been proposed, similar results obtained in studies 
performed in CD40L- and CD4-deficient mice receiving agonistic monoclonal or recombinant 
protein targeting CD40 receptor, provided the direct correlation between the requirement of 
CD4+ T cells and CD40 receptor/CD40 ligand pathway in the generation of CD8-mediated 
anti-tumor immune responses191,192. In particular, helper activity of CD4+ T cells is 
extensively associated to the ligation of CD40 receptor expressed on cellular surfaces of 
dendritic cells203. In addition, studies also showed a direct help of CD40L+ CD4+ T cells to 
naïve CD8+ T cells expressing, upon antigen recognition, detectable levels of CD40 receptor 
on their cellular surfaces196. One must underlined that, although the actual presence/role of 
CD40 receptor activity on CD8+ T cells is still controversial, CD40L-mediated activation of 
antigen presenting cells, has been consistently reported as a fundamental step promoting 
antitumor immunity177,191,192,203. In this regard, therapeutic potential of CD40-stimulated 
dendritic cells has been associated to their potential capacity to promote activation and 
differentiation of tumor-reactive CD8+ T cells expressing low-affinity T cell receptor (TCR) 
recognizing the cognate antigen in non-inflammatory conditions6,204. 
In line with these observations, initial studies performed in animal models to evaluate 
the therapeutic potential of different strategies targeting tumor-reactive CD8+ T cells 
expressing low-affinity TCR have been extensively criticized. In particular, immunization 
protocols based on MHC-class I epitope vaccines resulted in a limited expansion of tumor- 
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reactive CD8+ T cells characterized by a marked impairment in cytotoxic activity and 
proliferative response upon, antigenic re-challenge. Interestingly, according to the results 
obtained in different studies, the limited effectiveness of this vaccine formulation in the 
generation of effective anti-tumor CD8+ T cell responses has been consistently associated to 
the inefficient priming of antigen-specific naïve precursors. Indeed, different observations 
obtained in murine models have shown that reduced TCR initiated signals might potentially 
results in the generation of effector and memory CD8+ T cells. In this regard, studies 
performed by using altered peptide ligands (APLs) and transgenic lymphocytes displaying 
mutation in the TCR, have indicated that also a weak stimulation of naïve CD8+ T cells is 
sufficient to promote their differentiation into functional effector and memory cells. Although 
major differences were not observed between CD8+ T cells expressing low and high affinity 
TCRs in the acquisition of effector functions and in the capacity to mount memory responses, 
a weak TCR signaling has been associated to a significant reduction in the accumulation of 
stimulated cells6,205. In particular, upon antigen recognition, a limited clonal expansion and 
reduced survival have been described for CD8+ cells bearing a low-affinity TCR6,205. In view 
of the latter observation and further reinforced by different studies in which the role of 
accessory signals, during the priming of tumor-specific naïve precursors, underlined the 
potential role of CD40/CD40L for cancer immunotherapy. Indeed, enhanced co-stimulation 
and production of pro-inflammatory cytokines by CD40-stimulated dendritic cells might 
instruct tumor-reactive CD8+ T cells for effective short and long-term immune responses. 
Up-regulation of co-stimulatory CD80 (B7.1) and CD86 (B7.2) ligands has been shown to 
promote the effective activation of antigen-specific naïve precursor upon interaction with co- 
stimulatory CD28 receptor expressed on their cellular surfaces. Indeed, CD28 receptor 
initiated signals resulted in a clonal expansion of responding CD8+ T cells through the 
amplification of TCR-signaling and also by directly inducing the secretion of IL-2. In 
addition, the marked efficacy of CD40-stimulated dendritic cells to promote the generation of 
effective antitumor CD8+ T cells responses has been further reinforced based on their ability 
to produce high levels of inflammatory cytokines. Inflammation is known to promote the 
generation of high numbers of functional effector CD8+ T cells regardless of the strength of 
TCR stimulus. In this regard, studies performed in animal models and clinical evidences have 
indicated a crucial role for IL-12 and IFNs-type I in cancer immunotherapy. In particular, 
direct signaling of IL-12, produced by CD40L-activated dendritic cells, has been associated to 
efficient priming and survival of self/tumor-reactive CD8+ T cells. In particular, an increased 
expression of the high-affinity IL-2 receptor α-chain (CD25) on cellular surfaces of IL-12 
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conditioned CD8+ T cells was indicated as a critical determinant promoting their clonal 
expansion of primed T cells206. Furthermore, IL-12 initiated signals on tumor-reactive CD8+ 
T cells is also associated to the execution of an effector program, as indicated by the increased 
expression of genes encoding for products mediating cytotoxic effector functions155,156,206,207. 
 
In addition to a pivotal role in promoting the generation of high numbers of functional 
effector cells, CD40-stimulated dendritic cells have shown a marked efficacy in preventing 
cancer recurrence. In particular, generation of long-lasting tumor-reactive immune responses 
has been extensively associated to helper activity, CD40L-mediated, of CD4+ T cells to 
license antigen presenting cells to optimally stimulate tumor-reactive CD8+ T cells. To this 
respect, the acquisition of memory qualities by naïve precursor is also associated to the high 
production of IL-12 and IFNs-type I cytokines produced by CD40-stimulated dendritic cells. 
In particular, IL-12, signaling on CD8+ T cells resulted in the up-regulation, in a STAT-4 
dependent manner, of anti-apoptotic factor such as Bcl-2 as well as Bcl-3 while restraining the 
protein  level  of  pro-apoptotic  protein  BIM208.  In  addition,  studies  in  which  the  relative 
contribution of inflammation in the generation of memory CD8+ T cells pool has been 
evaluated, described a critical role for IL-12 in promoting the differentiation of stimulated 
naïve CD8+ lymphocytes into memory precursor effector cells (MPECs), their ability to long- 
term persist in response to homeostatic cytokines such as IL-7 and IL-15 and further 
differentiate in different memory CD8+ T cell subsets. The impact of the level and quality of 
inflammatory signals, integrated during priming, by tumor-reactive CD8+ T cells appears key 
to regulate their differentiation toward effector or central memory subsets175. 
 
Taken together, these results underline how activation of antigen bearing dendritic 
cells through CD40/CD40L pathway might results in the generation of anti-cancer primary 
and memory response mediated by CD8+ T cells recognizing self/tumor antigens. However, 
anti-tumor activity and potential clinical effectiveness of these CD8+ T cells has been 
questioned mostly for their limited execution of effector function as a consequence of low 
avidity interaction with limited epitope-MHC class I complexes express by tumor cells. Pre- 
clinical and clinical studies, performed in order to evaluate therapeutic potential of agonist- 
anti CD40 receptor antibodies and CD40L-expressing viral vectors, have suggested that anti- 
tumor activity of low-affinity CD8+ T cells might potentially be sustained through indirect 
effects on infiltrating myeloid cells and CD40+ tumor cells. Indeed, ligation of CD40 receptor 
resulted either in the rescue of exhausted dendritic cells, thereby in a potential provision of 
inflammatory signals, and also in an increased immunogenicity of target cells. In particular, 
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stimulation of CD40 receptor expressed by tumor cells resulted in an increased expression of 
peptide-MHC complexes on their cellular surface thus potentially overcoming limitation 
associated to low-affinity with an increased TCRs occupancy84,209. 
 
 
 
1.7. Memory CD8+ T cells and Cancer. 
 
 
CD8+  T  cells  have  been  extensively  indicated  as  critical  mediator  of  protective 
immunity against cancer. Initial immunotherapy strategies were aimed at promoting the in 
vitro expansion or in vivo generation of tumor reactive CD8+ T cells with effector (Teff) or 
effector  memory  (TEM)  phenotype.  Indeed,  therapeutic  potential  of  Teff  and/or  TEM  was 
attributed to their preferential trafficking to peripheral tissues where they might mediate 
tumor eradication through their marked cytotoxic activity and antigen-driven IFN-γ secretion. 
 
In the last years, this interpretation regarding the antitumor activity of CD8+ T cells 
has been revised. Indeed, several studies have underlined how therapeutic potential of tumor- 
reactive CD8+ T cells is also critically regulated by other functional attributes including the 
ability of long-term survival and, most importantly, their capacity to self-renew upon antigen 
recognition. In particular, tumor-reactive CD8+ T cells with stem cell-like (TSCM) and/or 
central memory (TCM) phenotypic profile has been extensively reported as superior mediators 
of therapeutic antitumor immunity against established cancer49,51,111,210-212. 
 
TSCM and TCM are identified according to the expression of CCR7 and CD62L homing 
receptors. These surface molecules have been indicated as critical markers promoting the 
migration of immune cells from peripheral blood to secondary lymphoid tissues such as 
spleen, lymph nodes (LNs) and mucosal Peyer’s patches. In this respect, among other 
integrins and chemokine receptors, a pivotal role for CD62L has been reported. Indeed, 
CD62L engagement of its ligands (glycosaminoglycans; GAGs) expressed on luminal 
surfaces of high endothelial venules (HEV) represents a critical interaction defining the ability 
of TSCM and TCM to continuously re-circulate through lymph nodes. In addition to this 
preferential trafficking, it has been shown that TSCM and TCM can be properly activated as a 
consequence of the recognition of cognate antigens on cellular surfaces of  professional 
antigen presenting cells. Activation of tumor-reactive CD8+ T cells with stem cell-like/central 
memory phenotype induces an enhanced proliferative response resulting in a progeny of cells 
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retaining TSCM/TCM attributes and also of daughter cells with TEM and Teff phenotypic and 
functional properties. Hence, generation of protective anti-tumor immune responses appears 
to be correlated not only to the ability of CD8+ T cells to differentiate into effective cytotoxic 
T-lymphocytes targeting tumor cells but also in the maintenance of a pool of antigen specific 
long-living memory cells representing a reservoir of tumor-reactive effector CD8+ T 
cells108,210. 
Identification of TSCM/TCM as superior mediator of antitumor immunity has critically 
challenged our initial understanding of the protective potential of different subsets of memory 
CD8+ T cells. In particular, according to the initial division model proposed in order to 
explain the heterogeneity of memory compartment, CD8+ TCM have been described as 
mediators of host-protection against systemic challenge whereas TEM function as sentinels for 
immediate protection from peripheral challenge such as solid tumors and some infectious 
agents. However, superior host-protection has been extensively reported for CD8+ TSCM/TCM 
against virus, bacteria and most importantly tumors, irrespective of immunization or 
infectious model and the route of antigenic challenge. This observation has obviously 
influenced the design of passive as well as active immunotherapy strategies. In this respect, in 
order to prevent terminal differentiation of in vitro expanded autologous tumor infiltrating T 
lymphocytes (TILs) before re-infusion in cancer patients, different culture conditions are 
currently under investigation. In this regard, exposure to compounds promoting the activation 
or inhibition of different pathways, such as homeostatic cytokines (IL-7, IL-15 and IL-21), 
have been shown to promote the expansion tumor-reactive CD8+T cells with stem cell-like 
and central memory phenotypic and functional attributes108,111,210-212. Although the rationale 
supporting passive and active CD8+ T cells strategies for cancer treatment is different, 
therapeutic potential of TCM has been unequivocally demonstrated in either case. Indeed, 
antitumor  efficacy  of  adoptively  transferred  tumor-reactive  CD8+  TSCM/TCM   has  been 
observed even at limiting numbers of infused cells211. Furthermore in a recently published 
study, therapeutic potential of CD8+ TCM cells has been further confirmed at single cell level 
in response to bacterial infection118. In view of the latter observation, antitumor efficacy of 
TCM lymphocytes is not only related to the number of cells adoptively transferred but also to 
their intrinsic antitumor activity. Based on this background and prompted by the complex 
logistics of adoptive treatments, the development of immunotherapy strategies aiming at 
promoting the rapid in vitro or in vivo generation of tumor-reactive CD8+ lymphocytes 
displaying phenotypic and functional attributes of central memory T cells is urgently required. 
61 	  
1.8. Targeting CD40 receptor to harness the immune system against cancer. 
 
 
Generation of functional memory CD8+ T has been repeatedly shown to be critically 
affected by the strength and the quality of signals integrated by naïve precursors204,213. In this 
regard, a critical determinant is represented by the maturation status of dendritic cells152,181. 
Indeed, it has been shown that engagement of CD40 receptor expressed on their cellular 
surface by CD40L-expressing activated CD4+ T cells results in the up-regulation of antigen 
presenting molecules (MHC class I/II), co-stimulatory ligands and cytokines production 
leading to optimal prime of naïve CD8+ T cells191,192. Based on these observations and further 
prompted by the necessity to overcome limitations associated to the activation of CD4+ T 
cells in the generation of CD8-mediated antitumor immunity, agonistic anti-CD40 receptor 
and recombinant viral vectors expressing the transgene  encoding for CD40L have been 
extensively exploited in animal models and in early phase clinical trials 84,209. 
Initial evidences underlying the enhanced efficacy of agonist CD40 monoclonal 
antibodies to promote the expansion of tumor reactive CD8+ T cells, were obtained in 
pioneering studies performed in animal models. Indeed, administration of anti-CD40 
monoclonal antibodies has been shown to represent an efficient substitute of CD4+ T cells 
and resulted in the rapid generation of anti-tumor CD8+ T cell responses in response to both 
singenic lymphoma tumor cells and cancer vaccines targeting oncoproteins191,192,214. Based on 
these results, therapeutic potential of agonistic anti-CD40 monoclonal antibodies has been 
recently evaluated209,215. Interestingly cumulative results obtained from different phase I trials 
involving patients bearing lymphoma and solid tumors have reported the induction of a stable 
disease in treated patients (20%-50%) with a variable extent regarding the progression free- 
survival209. In addition to the evaluation of clinical responses according to the RECIST 
criteria, these studies have further restated the rationale supporting the exploitation of 
immunotherapies targeting CD40 receptor. Indeed, targeting of CD40 receptor with the 
administration of chimeric agonist IgG1 mAb (ChiLob 7/4) or with a fully-humanized IgG2 
mAb (CP-870,893) resulted respectively in the maturation of dendritic cells, as indicated by 
the up-regulation of CD83 surface antigen, and in the activation of B-cells as antigen 
presenting cells215,216. Indeed, it was reported a significant up-regulation of CD86 co- 
stimulatory ligand along with a trend of increased expression of antigen presenting (MHC- 
class II) and CD54 (ICAM-1) adhesion molecule on peripheral B cells of patients receiving 
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CP-870,893 monoclonal antibodies and resulting, in a minor fraction of melanoma patients, in 
the transient expansion of MelanA/Mart-1 specific CD8+ T cells 216. 
 
In addition to its pivotal role in promoting maturation of dendritic cells leading to the 
induction of effective cellular responses, the development of cancer immunotherapies 
strategies targeting CD40 receptor has been further prompted by the opportunity to potentially 
overcome several barriers promoting the establishment of immune tolerance of malignant 
cells84,209,215,216. In this regard, it has been reported how triggering of CD40 receptor expressed 
on endothelial cells might results in the production of pro-inflammatory cytokines and in the 
up-regulation, on their cellular surface, of adhesion molecules promoting T cell arrest and 
subsequent infiltration within inflamed tissues 217. In addition to this enhanced recruitment of 
effector cells within tumor mass, targeting of CD40 receptor expressed by tumor cells and 
infiltrating immune cells has been also associated to a significant reduction of 
immunosuppressive mechanisms preventing the elimination, CD8-mediated, of transformed 
cells84,209,215,216. Indeed, CD40 receptor expression has been identified in nearly all B-cell 
malignancies and in almost 70% of solid tumors including melanoma, breast, lung, bladder, 
prostate, colorectal and pancreatic carcinomas209. Interesting, engagement of CD40 receptor 
expressed on cellular surface of transformed cells has been associated to an indirect effect 
supporting the activity of tumor-reactive CD8+ T cells. Indeed, a marked up-regulation of 
molecules promoting antigen presentation (MHC-class I/II) and promoting the formation of a 
functional immunological synapse between target cells and tumor-reactive CD8+ T cells. 
Indeed, increased expression level of CD54 adhesion molecules, co-stimulatory ligands 
(CD86) and production of recruiting (IL-8) and inflammatory cytokines (IL-6) supporting T 
cell activity has been described for in vitro CD40-stimulated tumor cells of different 
origin178,209,215. In addition to a significant effect on the immunogenicity of transformed cells, 
triggering of CD40 receptor has been also indicated as a critical event regulating the survival 
and apoptosis of transformed cells209,218. Indeed, an increased tumor cell survival has been 
associated to the in vitro stimulation of B cells derived from malignancies including NHL and 
CLL209,215. In contrast, stimulation of CD40 receptor express on cellular surface of tumor cells 
derived from melanomas, bladder and ovarian cancer has been associated to the inhibition of 
tumor growth and also potentially associated to the induction of apoptosis of malignant 
cells84,209,215,218. Interestingly, these opposite effects on CD40 receptor expressing transformed 
cells has been correlated to the intensity of CD40 receptor initiated signals leading to a 
selective recruitment of TRAFs molecules and activation of peculiar intracellular signaling 
pathway resulting in the expression of genes encoding for pro-apoptotic factors   and the 
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activation of caspase 3 and 9178,209,215,218,219. Based on these initial evidences, different 
monoclonal antibodies have been engineered with the aim to mediate elimination of 
transformed cells as a consequence of direct signaling on target cells and by promoting, 
through fragment crystallizable region (Fc region), the elimination of tumor cells by 
activating myeloid cells (ADCC) and the complement cascade (CDC). In this regard, 
encouraging results have been recently obtained in pre-clinical studies and early phase trials 
involving patients with multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL) and 
chronic lymphocytic leukemia (CLL) receiving either a humanized agonist anti-CD40 IgG1 
mAbs (Dacetuzumab; SGN-40) or a fully human agonist antibody preventing the ligation of 
CD40 by CD40L (Lucatumumab; HCD122) and resulting in the achievement of stable disease 
in a percentage between 20-65% of treated patients 215. In line with this results underlining the 
critical relevance also of myeloid cells such as macrophages for tumor eradication, critical 
results have been also obtained in pre-clinical and clinical studies performed in pancreatic 
ductal adenocarcinoma (PDA) patients receiving systemic administration CP-870, 893 
monoclonal antibodies. In particular the cohort of patients with surgical incurable PDA 
received intravenous administration of standard-care treatment gemcitabine in combination 
with the agonist anti-CD40 IgG2 monoclonal antibody. Remarkably, therapeutic treatment 
resulted in in the induction, in a significant fraction of treated patients, of objective clinical 
responses. Indeed, the achievement in 4/21 of partial response and 11/21 disease stabilization 
whit a median progression free-survival of 5.6 months on a total of 21 treated patients have 
been observed. Interestingly, analysis of surgically excised tumor lesions obtained from 
patients with partial response indicate an immune infiltrate mostly composed of macrophages 
and not, as expected, of T cells. Cancer regression in a T-cell independent manner has been 
then confirmed in murine model of PDA and a critical relevance for direct CD40 signaling on 
macrophages has been revealed. Indeed, systemic administration of agonist anti-CD40 mAbs 
(FGK45) following gemcitabine treatment resulted in murine model in the rapid activation of 
macrophages, as indicated by the elevated surface levels of MHC class II and CD86 molecule, 
and their rapid infiltration within tumors. Once in the mass of transformed cells, these CD40- 
stimulated macrophages were able to mediate cancer regression according to their capacity to 
secrete high levels of effector cytokines such as IL-12 and TNF-α and most importantly to 
mediate the disruption of tumor matrix by the degradation of collagen I fibers 220. In line with 
the latter observation and further supported by cumulative results obtained in preclinical and 
clinical studies, in the last years a growing consensus has been registered concerning the 
multiple effects of cancer immunotherapies targeting CD40 receptor through antagonist and, 
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most importantly, agonist monoclonal antibodies. In particular, triggering of CD40 receptor 
expressed on cellular surfaces of dendritic cells has been extensively associated to the 
activation and programming of tumor-reactive naïve CD8+ T cells to acquire effector 
functions and potentially differentiate into long-lasting memory cells191,192. Furthermore, anti- 
CD40 monoclonal antibodies can efficiently sustain the anti-tumor activity of reactive CD8+ 
T cells either as a consequence of a direct effect on tumor cells and by modulating the activity 
of tumor-infiltrating myeloid cells therefore overcoming the corrupted tumor 
microenvironment. Unfortunately, a major limitation associated to the administration of 
agonist monoclonal antibodies targeting CD40 receptor is represented by the concerning 
regarding their potential toxicity. In particular, the insurgence of cytokine release syndrome 
(increased serum levels of TNF-α, IL-6, IL-1β and IL-10) and liver stress have been reported 
in a consistent fraction (almost 50%) of cancer patients involved in different trials and often 
requirement of steroids administration. The insurgence of these side effect is directly 
associated to the systemic administration of monoclonal antibodies resulting in the activation 
of immunocompetent and normal cells215. 
Recombinant viral vectors expressing a transgene encoding CD40L protein represent 
an alternative strategy that has been further exploited in order to target CD40 receptor for 
cancer treatment. In particular, CD40L-expressing recombinant adenovirus (AdCD40L) and 
vaccinia virus (rVV40L) have been evaluated in different studies performed in animal models 
and also in few early phase clinical trials. Interestingly, the initial rational supporting the 
generation of engineered viral vectors expressing CD40L was represented by the synergistic 
effects between TLRs engagement and CD40L protein encoded by the transgene in activating 
CD40 dendritic cells. In line with this initial observation several evidences has been reported 
in vitro studies and in animal models regarding the ability of infected dendritic cells to 
promote the expansion of tumor-reactive CD8+ T cells. In addition, clinical evaluation of 
cancer vaccines based on subcutaneous administration of tumor cells transduced with 
AdCD40L have been associated in CLL patients to a count reduction of malignant B-cells 
correlated to the induction of T cells responses targeting leukemic cells 218 221. 
 
In addition to adenovirus based viral vectors, recombinant vaccinia virus encoding 
tumor-associated antigens along with transgene (s) encoding for different co-stimulatory 
ligand (s) have been extensively evaluated in pre-clinical and clinical studies. Vaccinia virus 
is an enveloped double-strand DNA vector that belongs to poxviridae family. Its genome 
length  is  of  approximately  of  190  Kbp  and  contain  250  genes  encoding  for  products 
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regulating both cell-cycle and structural proteins. Remarkably, vaccinia virus has been 
extensively used in the last two centuries as a worldwide vaccine against variola virus and 
resulted in its official eradication in 1979222,223. Furthermore, specific features of vaccinia 
virus have prompted the use of this viral vector as a cancer vaccine. First, in sharp contrast 
with adenoviruses, vaccinia virus can efficiently infect mammalian cells as a consequence of 
a membrane fusion process and not upon engagement of specific cell surface receptors 
expressed by target cells. In addition, vaccinia virus replication in the host cell is also “safe 
and rapid”. Indeed, viral replication does not require the integration in the host genome but 
takes place in cytoplasmic structures termed viral factories and the first viral particle is 
normally secreted 8 hours after infection of target cells. Finally, vaccinia virus can be easily 
engineered and multiple transgenes can be accommodated in the viral backbone making this 
viral   vector   as   a   successful   toll   for   antigen   specific   cancer   immunotherapeutic 
approaches84,222-224. Based on this background, in the last 15 years, we extensively evaluated 
the ability of recombinant vaccinia virus (rVV) to efficiently promote the generation of 
tumor-reactive CD8+ T cells. In particular, we have previously shown in preclinical studies 
how recombinant vaccinia virus (Copenaghen Strain) expressing transgenes encoding tumor- 
associated antigens along with co-stimulatory ligands can efficiently promote the expansion 
of reactive CD8+ T cells from peripheral blood of healthy donors and, most importantly, from 
surgically excised tumor lesions 225-228. The enhanced efficacy of our recombinant vaccinia 
virus in promoting the generation antitumor CD8-mediated immune response has been then 
confirmed in clinical studies. Indeed, a phase I/II trial involving twenty metastatic melanoma 
patients has been recently conducted on metastatic melanoma patients. In particular, 
therapeutic treatment of cancer patients was based on the initial intradermal administration of 
a replication incompetent (UV-inactivated) recombinant vaccinia virus accommodating 
transgenes encoding for HLA-A0201-restricted epitope derived from tumor associated 
antigens (MelanA/MART-127-35, gp100280-288 and Tyrosinase1-9) along with co-stimulatory 
ligands such as CD80 and CD86 proteins (rVVmelB7). Furthermore, boost of vaccination 
represented by the administration of corresponding free-peptide along with GM-CSF were 
further provided to the enrolled patients. Notably, this vaccination protocol resulted in the 
regression of individual metastasis in three out of 11 patients whereas disease stabilization 
was observed in 7/11 melanoma patients. Furthermore, clinical observations indicated how 
clinical benefits induced in treated patients were related to the high immunogenicity of 
rVVmelB7. Indeed induction of CD8+ T cells targeting all the three HLA-A0210 restricted 
epitopes derived from tumor-associated antigens were detected in 43% of patients upon 
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intradermal administration of rVVmelB7. However, tumor-reactive CD8+ T cells induced 
resulted limited in time and critically dependent from further rVVmelB7 boost of stimulation 
229. In order to improve the magnitude and the duration of CD8-mediated cellular responses 
against tumor antigens we have then generated a CD40L-expressing recombinant vaccinia 
virus (rVV40L) that has shown in a previous in vitro study, an enhanced efficacy in 
promoting the maturation of dendritic cells that in turn efficiently activate peptide specific 
CD8+ T cells. However, phenotypic profile and functional properties of stimulated CD8+ T 
cells were not evaluated 230. 
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1.9 STUDY AIM 
 
 
The aim of the current work is to evaluate the capacity of a CD40L-expressing 
recombinant vaccinia virus to mimic molecular basis of CD4+ T cell helper activity in the 
generation of antigen-specific CD8+ T cells with phenotypic and functional attributes of 
central memory lymphocytes. 
 
In addition to the modulation of tumor-specific CD8+ T cell responses, we further 
investigated the ability of rVV40L to inhibit proliferative capacity of established tumor-cell 
lines upon infection or through the activation of myeloid cells. 
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2. MATERIALS AND METHODS. 
 
 
2.1 CD40 Ligand-expressing recombinant Vaccinia Virus construction (rVV40L) 
 
 
 
CD40L Ligand-expressing recombinant Vaccinia Virus (rVV40L) was generated as 
previously described230. Briefly, human CD40L cDNA was PCR amplified from PHA 
stimulated human PBMCs, cloned in a shuttle plasmid under the control of a virus early 
promoter and inserted into the Copenhagen Vaccinia Virus Wild-Type strain (VV WT). 
 
In order to avoid the strong cytopathic/lytic effect of the replicating virus in in-vitro 
studies, viral replication was inactivated by DNA cross-linking by using psoralen (1ug/ml) 
and long-wave UV (365nm) irradiation. The inhibition of replication and cytopathic effect of 
UV-treated viruses was evaluated on infected monolayers of sensitive CV-1 cells (ATCC 
CCL70) and CD14+ monocytes at 24 hours post infection230. 
 
 
2.2 Cell Cultures 
 
 
 
Peripheral blood mononuclear cells (PBMCs) from healthy donors were obtained by 
gradient centrifugation. CD14+ monocytes and CD8+ T cells were isolated by using antibody- 
coated magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany). Cells were then 
cultured in RPMI-1640 supplemented with 1% GlutaMAX-I, 1% non-essential amino acids 
(NEAA), 1% sodium pyruvate, HEPES, 1% Kanamycin Sulfate (Gibco-Life Technologies, 
Lucerne, Switzerland), thereafter referred to as complete medium (CM) and 10%  Fetal 
Bovine Serum (FBS, Gibco-Life technologies, Lucerne, Switzerland) for monocyte activation 
studies or 5% pooled human AB serum (Blutspendezentrum, University Hospital Basel, 
Switzerland) for T-cell stimulation assays. (To add also the information relatives to cell lines). 
Established, verified cell lines were obtained from ATCC (Manassas, VA) and cultured in 
CM supplemented with 10% FBS. 
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2.3 Gene Expression Analysis. 
 
 
Total cellular RNA was extracted from CD14+ monocytes, CD8+ T cells and 
established tumor cell lines using the RNeasyVR Mini Kit (Qiagen, Hombrechtikon, 
Switzerland) according to the manufacturer’s protocol. RNA was reverse transcribed using 
M-MLV reverse transcriptase following manufacturer’s instructions (Invitrogen-Life 
Technologies, Lucerne, Switzerland). Human IL-12p40, IFN-γ, IFN-α, IFN-β, TNF-α, IL-10, 
indoleamine-2,3-Dioxygenase (IDO), TNF receptor associated factor 1 (TRAF1) and CD40 
receptor gene expression was evaluated by quantitative RT-PCR (qRT-PCR) using specific 
primer sets (TaqMan® Assays, Applied Biosystems-Life Technologies, Lucerne, 
Switzerland) and normalized to human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
housekeeping gene expression. 
 
 
 
2.4. Flow Cytometry 
 
 
 
Fluorochrome-labeled monoclonal antibodies (mAbs) recognizing CD1a, CD3, CD8, 
CD14, CD16, CD45RA, CD28, CD54 (ICAM-1), CD62L, CD95, CD69, CD40L (CD154), 
IL-7R〈  (CD127),  CXCR3  (CD183),  PD-L1  (CD274)  HLA-ABC  and  HLA-A0201  were 
obtained from Becton Dickinson (Allschwil, Switzerland). In addition, mAbs recognizing 
CCR7 (CD197) and CD45RO (Clone UCHL1) were obtained from BioLegend (Lucerne, 
Switzerland) whereas mAbs recognizing CD40 receptor (Clone 5C3) were obtained from 
eBioscience (San Diego, CA). In order to identify cells bearing antigen-specific T-cell 
receptors (TCR), CD8+ T cells were stained with soluble HLA-A0201-peptide, streptavidin R- 
PE conjugated multimers containing L27Melan-A/MART-126–35, Vaccinia Virus H3L184–192, 
HCMVpp65495-504 and influenza A MP58-66 (ProImmune, Oxford, UK). 
 
Cells were stained with appropriate mAbs dilutions for 30 minutes at 4°C in the dark. 
Following gentle washing, specific labeling was evaluated by flow cytometry (FACScalibur; 
Becton Dickinson Allschwil, Switzerland). Data were analyzed by FlowJo software (Tree 
Star, Ashland, OR). 
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2.5 ELISA assay 
 
 
 
Presence of interleukin-2 (IL-2) in supernatants of cell culture from was measured three days 
after stimulation of memory CD8+ T cells by using an ELISA kit (Becton Dickinson, 
Allschwil, Switzerland), according to the manufacturer’s instructions. This system uses 2 
different IL-2 antibodies allowing its capture on solid surface followed by the labelling with 
an enzyme coupling secondary antibody. 
 
 
 
2.6 Peptides. 	  	  	   HLA-­‐-­‐-­‐A0201-­‐-­‐-­‐restricted	   L27Melan-­‐-­‐-­‐A/MART-­‐-­‐-­‐126-­‐-­‐-­‐35,	   Vaccinia	   Virus	   H3L184-­‐-­‐-­‐192,	   HCMV	  pp65495-­‐-­‐-­‐504	   and	   Influenza	   A	   MP58-­‐-­‐-­‐66	   peptides	   used	   in	   this	   study	   were	   provided	   by	  NeoMPS	  Laboratories	  (Strasbourg,	  France).	  	  	  	   Purified	   CD14+	   cells	   were	   incubated	   for	   4h	   at	   37° with	   individual	   or	   pooled	  peptides	  at	  1∝g/ml	  final	  concentration	  in	  culture	  medium.	  	  	  	  	  
2.7 Cell sorting. 
 
 
 
Magnetically isolated CD8+ T cells were then stained (as described above) with the 
following mAbs: CD45RO-FITC, CD8-PE CD3-APC or CD62L-APC.  CD3+CD8+  T cells 
and Naïve T cells (CD8+CD45RO-CD62L+) were sorted using FACSAria or Influx Cell 
sorters (Becton-Dickinson Allschwil, Switzerland). Preparations used in this study showed a 
purity of at least 99%. 
 
 
 
2.8 CD14+ cells activation following rVV40L infection or s40L treatment. 
 
Magnetically sorted CD14+ cells were infected in 500ul 10% FCS RPMI 1640 CM for 
1h at 37°C with Vaccinia Virus Wild Type (VV WT) or CD40L-expressing recombinant 
Vaccinia Virus (rVV40L) at a MOI of 5.   CD14+  cells were also activated with soluble 
	  CD40L recombinant protein (s40L; 0.5∝g/ml Enzo Lifescience, Farmingdale, NY) alone or 
upon infection with VV WT (VV-WT+s40L). Following overnight incubation at 37° in FCS 
10% CM supplemented with GM-CSF (10ng/ml, Laboratorio Pablo Cassarà, Buenos Aires, 
Argentina). The expression of surface markers and cytokine gene expression and production 
were evaluated by flow cytometry, qRT-PCR analysis and ELISA assays. 
 
 
 
2.9 In vitro CD8+ T cells priming. 
 
 
Naive CD8+ T cells (CD8+ CD45RO- CD62L+) were co-cultured in RPMI 1640 CM 
supplemented with 5% HS with either allogeneic or autologous peptides-pulsed CD14+ 
monocytes at a 5:1 ratio. On day 8, primed CD8+ T cells were harvested and flow cytometric 
analysis was performed as described above. 
 
 
 
2.10 Activation of CD8+ T cells. 
 
 
 
In order to evaluate the potential CD40 expression upon activation, sorted CD3+ 
CD8+ T cells were stimulated by plastic bound anti-CD3 (10µg/ml, eBiosciences, San Diego 
CA) and soluble anti-CD28 (αCD28; 0.5∝g/ml; Becton Dickinson, Allschwil, Switzerland). 
Alternatively, CD8+  T cells were stimulated with anti-human CD3/CD28 coated beads (TC 
expander, Invitrogen, Basel, Switzerland) a 1:3 CD8+ T cells:beads ratio. In indicated 
experiments activation of CD8+ T cells was performed in presence of soluble CD40L 
recombinant protein (0.5∝g per ml; s40L). Proliferation was assessed by 3H-thymidine 
incorporation according to standard procedures. 
 
 
 
2.11 CD8+ TCM proliferation assays. 
 
 
Proliferative capacity of CD8+ TCM cells was assessed, 72h after antigen specific or 
polyclonal re-stimulation, by carboxyfluorescein-succinimidyl-ester (CFSE, Invitrogen, 
Basel,  Switzerland)   staining  dilution.   Briefly,  CD8+    T  cells   were  washed   in  PBS 
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supplemented  with  0.1%  BSA  (Sigma–Aldrich,  Postfach,  Switzerland).  Cells  were  then 
incubated with 0.5 mM CFSE for 10 min at 37°. After washing with “cold” 5% HS RPMI 
1640 CM, CD8+ T cells were cultured with autologous CD14+ monocytes previously pulsed 
with indicated peptides at a 1:1 ratio of for 72h. Alternatively, proliferation was induced by 
using plastic bound anti CD3 (10µg/ml, eBiosciences, San Diego CA) and soluble anti CD28 
mAbs (1µg/ml) (Becton Dickinson, Allschwil, Switzerland). 
 
 
 
2.12 rVV40L infection of tumor cells. 
 
 
 
Na8, HCT116 and Colo205 cancer cell lines were left untreated or infected with VV 
WT or rVV40L at MOI of 10. Furthermore, tumor cells were treated with s40L (0.5∝g/ml) 
alone or upon infection infection with VV WT. Proliferative capacity of Na8, HCT116 and 
Colo205 was evaluated at day 4 by evaluating 3H-thymidine incorporation in the last 18 hours 
of culture. In addition, percentage of apoptotic cells in cultures under investigation was 
assessed by  using Annexin  V/  Dead cell  apoptosis Kit  according  to the  manufacturer’s 
intructions. 
 
Alternatively, H358 and HepG2 cell lines were left untreated or infected with VV WT 
or rVV40L at MOI of 10. After 24 hours cells were left alone or cultured with isolated CD14+ 
monocytes at the ratio of 1:1. At day 4, cell cultures were harvested and proliferative capacity 
of tumor cells and TNF-α gene expression in CD14+ cells were respectively evaluated by 
3H-thymidine incorporation and qRT-PCR. 
 
 
 
2.13 Statistical Analysis. 
 
 
 
Statistical analysis software SPSS (Version 14.0, SPSS Inc., Chicago, IL) was used 
throughout the study. Skewness, Kurtosis distribution parameters and respective standard 
errors were used to test normality of the concerned populations. Mann-Whitney non- 
parametric test, (non-Gaussian distribution of the population) was used to compare mean of 
gene expression in different samples. Outliers were defined using Grubbs’ test. All reported 
P-values were considered to be statistically significant at P ≤ 0.05. 
73 	  
3. RESULTS 
 
 
In order to evaluate the role of CD40 ligand (CD40L; CD154)/CD40 receptor pathway 
in the generation of immunological memory, initial experiments were performed to assess the 
expression and, most importantly, functional consequences of CD40 receptor triggering on 
isolated antigen presenting cells (APCs) and CD8+ T cells obtained from peripheral blood of 
healthy donors. 
 
 
 
3.1. Characterization of CD40 on human CD8+ T cells. 
 
 
 
In order to evaluate the role of CD40 ligand (CD40L; CD154)/CD40 receptor pathway 
in the generation of immunological memory (CD8+ Tcm), initial experiments were performed 
to assess expression and, most importantly, functional consequences of CD40 receptor 
triggering on isolated antigen presenting cells (APCs) and CD8+ T cells obtained from 
peripheral blood of healthy donors. 
Generation of fully functional memory CD8+ T-cells in experimental mouse models 
was previously reported, in a limited numbers of studies, to be critically dependent on the 
engagement of CD40 receptor expressed on activated CD8+ T-cells. Indeed, selective 
deficiency of CD40 receptor in CD8+ T cells prevented the direct delivery of help by CD40L 
expressing CD4+ T helper cells during the priming of cellular response and resulted in the 
generation of memory CD8+ T cells characterized by a reduced proliferative capacity and 
impaired acquisition of effector functions upon secondary stimulation. Interesting, ligation of 
CD40 receptor on CD8+ T cells has been shown of proven relevance in the response against 
cellular antigens, and, therefore, of remarkable interest for our purposes196,197. 
 
 
 
3.1.1 CD40 on resting or activated human CD8+ Tcells 
 
 
 
In order to evaluate, the potential role of this mouse model mechanism in humans, 
CD40 receptor expression on human CD8+ T-cells was assessed in resting condition or upon 
activation. 
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Similarly to murine T-cells, CD40 receptor expression was undetectable on the surface 
(Fig. 1A) or in the intra-cellular compartment (Fig.1B) of resting human CD8+ T-cells. 
 
  
In order to investigate the expression of CD40 receptor on activated CD8+ T cells, 
magnetically isolated CD8+ T-cells were stimulated with plastic-bound anti-CD3 and soluble 
CD28 monoclonal antibodies or, alternatively, with anti CD3/CD28 coated beads. A clear up- 
regulation in the expression of CD69 and CD40L surface antigens, confirming successful 
activation  and  the  potential  capacity  of  CD8+  T  cells  to  license  APCs  was  observed. 
However, surface expression of CD40 receptor remained undetectable at any of the time 
points tested on stimulated T cells. (Figs. 2A, B). Furthermore, Real Time-PCR (RT-PCR) on 
sorted and activated CD3+CD8+ T-cells (purity>99%) also confirmed that, while IFN-γ gene 
expression was clearly up-regulated, mRNA level CD40 receptor was not (Fig. 2C). 
 
To further assess the possible functional relevance of residual CD40 expression, 
escaping flow-cytometry and RT-PCR detection, CD3+ CD8+ T cells were activated by 
CD3/CD28 triggering in the presence of soluble CD40L recombinant protein (s40L) and 
proliferative capacity of activated CD8+ T cells was assessed at different time points. 
Notably, also in this experimental setting, the expression of CD40 receptor on activated CD3+ 
CD8+ T cells remained elusive. Indeed, activation of CD8+ Tcells in presence of s40L did not 
result in an increased proliferative capacity of stimulated T cells at any of the time points 
tested (Fig. 2D). 
Figure 1. Resting human  CD8+ T 
cells do not express CD40 receptor. 
Expression of CD40 receptor and 
granzymes A-B on the surface (a) or 
in the intra-cellular compartment (b) 
of human peripheral blood CD8+ T- 
cells from healthy donors was 
analyzed by flow-cytometry. Data 
refer to one representative experiment 
out of five performed with similar 
results. 
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Figure 2. Activated human CD8+ T cells do not express CD40 receptor in antigen presenting cells free-system. Magnetically sorted 
CD8+ T-cells were activated (A) with different doses of plastic bound anti-CD3 (10 or 1 ∝g/ml) and soluble anti-CD28 (0.5 ∝g/ml) or anti 
CD3/CD28 coated beads (ratio beads : CD8+  T-cells = 3 : 1) (B) respectively. At the indicated time points, cells were collected and stained 
with anti-CD3 mAbs, anti-CD8 mAbs and (A) anti-CD69 mAbs or (B) anti-CD40L (CD154) mAbs. The results shown here refer to one 
representative experiment out of five performed with identical results. (C) Kinetics of CD40 receptor and IFN-© gene expression analysed by 
RT-PCR from anti-CD3 (10ug/ml) and anti-CD28 (0.5µg/ml) stimulated CD3+CD8+  T-cells. (D) Sorted human CD3+CD8+  T-cells were 
activated with anti-CD3 (10 ∝g/ml) and anti-CD28 (0.5 ∝g/ml) in the presence (black bars) or absence (white bars) of soluble CD40L 
recombinant protein (s40L; 0.5µg/ml). Proliferation of CD3+CD8+ T cells was assessed at the indicated time points by 3H-thymidine 
incorporation during the last 18h of culture. 
 
 
 
 
 
It has been extensively reported that activation of CD8+ T cells is critically affected by 
the cytokine milieu experienced by responding cells during antigen recognition. Based on this 
background, we hypothesized that expression of CD40 receptor on cell surfaces of anti- 
CD3/anti-CD28  stimulated  CD8+  T  cells  could  be  promoted  by  specific  inflammatory 
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cytokines including IL-12 and IFNs-type I. Thus, we evaluated the expression of CD40 
receptor on CD8+ T cells activated in presence of “conditioned medium” derived from 
CD14+ monocytes activated by viral infection and/or by s40L stimulation. Interestingly, 
levels of activation markers of CD8+ T cells in presence of culture medium derived from 
activated CD14+ cells, and, in particular, of infected monocytes, were clearly increased as 
compared to CD8+ T cells stimulated in presence of medium derived from resting CD14+ 
monocytes. However, despite an enhanced up-regulation of CD69 activation marker, CD40 
receptor expression on activated CD8+ T cells remained undetectable in any tested condition 
(Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Human CD8+ T cells activated in presence of stimulated CD14+ derived medium do not express CD40 receptor. Isolated 
peripheral blood CD14+ monocytes were left untreated, infected with rVV40L or with VV WT. Furthermore, CD14+ monocytes were 
also treated with s40L alone or upon infection with VV WT (VV WT+s40L). After treatment, 3x106 CD14+ monocytes were cultured for 
3 days in 1 ml of RPMI-1640 CM supplemented with FCS 10%. Human CD8+ T-cells were activated with plastic-bound anti-CD3 (10 
µg/ml) and soluble anti-CD28 (0.5 µg/ml) in the presence of supernatants from different CD14+ monocytes cultures. At the indicated 
time points, CD8+ T cells were collected and stained with anti-CD40 mAbs and anti-CD69 mAbs. Data refer to one representative 
experiment out of three performed with similar results. 
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Taken together these data indicate that CD40 receptor is not expressed on cell surfaces 
or in the intra-cellular compartment of human CD8+ T cells. Furthermore, in contrast with 
murine counterparts, expression of CD40 receptor remains negative also on activated human 
CD8+ T cells. Indeed, analysis of the gene expression profile of in vitro activated CD8+ T 
cells did not reveal an up-regulation of CD40 receptor mRNA levels. 
 
 
 
3.1.2 Acquisition of CD40 receptor as a consequence of intercellular trogocytosis.	  
	  
	  
	  
Generation of adaptive immune responses is a tightly regulated process in which 
several cell types, endowed with different functions, are involved. Functional attributes 
defining the role of distinct immune cells during immune responses are frequently related to 
the peculiar expression of specific molecules on their cellular surfaces. Interestingly, in the 
last years, this scenario has been partially revised. Indeed, in several in vitro and in vivo 
studies, it has been reported that immune cells can overcome the limits of their transcriptome 
by extracting specific proteins from other cells231-233. This phenomenon has been named 
trogocytosis and different mechanisms promoting the intercellular exchange of surface 
molecules between immune cells have been reported. In this respect, several studies 
performed in animal models have revealed the capacity of T cells to acquire MHC class I/ II 
and co-stimulatory molecules from APC following immunological synapse formation. 
Interestingly, acquisition by T cells of APCs-derived proteins has been shown to be initiated 
by the engagement of T cell receptor (TCR) and to affect the biology of the immune system 
during the generation of adaptive cellular responses231-233. 
 
Based on this background and aiming at investigating the possible role of trogocytosis 
in the acquisition by human T cells of CD40 receptor expressed by APCs, we initially 
evaluated membrane exchange between CD14+ monocytes and CD8+ T lymphocytes in 
autologous and allogeneic settings. Interestingly, in accord with studies in experimental 
animals, we detected a limited presence of CD40 receptor on CD8+ T cells cultured with 
allogeneic but not with autologous CD14+ monocytes (Fig. 4A). In order to formally prove 
that detection of CD40 receptor on T lymphocytes was due to membrane exchange, we co- 
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cultured in a mixed leukocyte reaction (MLR) HLA-A0201- CD8+ T cells with HLA-A0201+ 
CD14+ monocytes and we then performed a detailed polychromatic flow cytometry analysis. 
 
Remarkably, as shown in Fig. 4B, in this experimental setting, we could detect CD40 
receptor expression on cellular surfaces of CD8+ T cells as a consequence of the membrane 
exchange with allogeneic CD14+ monocytes as confirmed by the transfer of the heterologous 
HLA type on CD8+. Indeed, detection of CD40 receptor on cellular surface of activated 
CD8+ T cells resulted in the extraction from allogeneic CD14+ monocytes also of HLA-0201 
class I molecules, restricting antigen presentation. Hence, these data indicate a possible 
involvement of trogocytosis phenomena in the acquisition by CD8+ T cells of CD40 receptor 
from cellular surfaces of APCs. However, evaluation of the magnitude of membrane 
exchange between CD14+ monocytes and CD8+ T cells revealed that only a very limited 
percentage of T lymphocytes was able to acquire, over the time, CD40 receptor (Figs 4A, B). 
Moreover, as stated previously, this positivity only appeared in allogenic setting. 
 
 
 
 
 
Figure 4. Activated human CD8+ T cells acquire CD40 receptor as a consequence of membrane exchange phenomenon. Isolated 
human CD8+ T cells were co-cultured with autologous or allogeneic CD14+ monocytes at 1:1 ratio. CD69 and CD40 receptor 
expression was evaluate at indicated time points on CD3+ CD8+ T cells. Stimulation with allogeneic monocytes resulted in the 
expression of CD40 receptor on activated (CD69+) CD8+ T cells (A). Mixed leukocyte reaction involving HLA-A2- CD8+ T cells 
and HLA-A2+ CD14+ monocytes revealed that CD40 receptor expression on cellular surface of T-lymphocytes is associated to 
membrane exchange, trogocytosis, phenomenon. Indeed CD40+ CD8+ T cells also express HLA-A2 molecules derived from allogeneic 
CD14+ monocytes (B). Data refer to one representative experiment out of three performed with similar results. 
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In this respect, although further investigation would enable the evaluation of the 
putative benefits related to the acquisition of CD40 receptor for CD8+ T cells, it is reasonable 
to assume that in a human setting effects of CD40L/CD40 receptor triggering in the 
generation of effective memory CD8+ T cells are only related, to the activation of antigen 
presenting cells. 
 
 
 
3.2. CD40 receptor on human CD14+ monocytes. 
 
 
 
Activation of cells endowed with antigen presenting capacity like dendritic cells, B 
cells and monocytes may be achieved following engagement of CD40 receptor expressed on 
their surfaces by CD40L expressed by activated T cells176. In this regard, we previously 
showed that APC infection by rVV40L promotes their activation. Indeed, rVV40L infection 
of in vitro generated DCs resulted in a marked up-regulation of co-stimulatory molecules’ 
expression and IL-12 secretion230. Based on this background, we investigated the activation of 
CD14+ monocytes following treatment with rVV40L or s40L alone or in combination with 
vaccinia virus wild- type (VV-WT+s40L) infection. In particular, we assessed the expression 
of a panel of co-stimulatory and inhibitory ligands on cell surfaces of treated CD14+ 
monocytes and we further evaluated their cytokine gene expression profiles. 
 
IL-12 and IFNs type I have been shown to play important roles in memory T cell 
generation. In particular, T cell help independence observed in the generation of effective 
memory cells has been attributed to the ability of some infectious pathogens to promote 
secretion of high amounts of IL-12 and IFN-α/β156,207. Furthermore the critical relevance of 
these pro-inflammatory cytokines, in promoting anti-tumor CD8+ T cells responses, has been 
extensively reported in preclinical and clinical studies (see above). Interestingly, we observed 
a marked and sustained up-regulation of IL-12p40, IFN-α and -β gene expression in CD14+ 
monocytes upon rVV40L infection whereas activation of CD14+ cells by s40L, alone or in 
combination with VV-WT, was significantly less efficient (Fig.5). 
 
Remarkably, in sharp contrast to rVV40L, s40L, and, to a lower extent, VV-WT, 
appeared to promote the expression of interleukin 10 (IL-10) and indoleamine-2,3- 
dyoxigenase (IDO) genes in treated CD14+ cells (Fig. 5). Interestingly, IL-10 has been 
indicated as a critical immunoregulatory cytokine abrogating the activity of innate immune 
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system and preventing the generation of adaptive immune responses. In particular, IL-10 
production by myeloid-derived suppressor cells (MDSCs) has been indicated as a critical 
mediator promoting tumor tolerance. Furthermore, IL-10 cytokine has been reported, among 
other soluble factors, as critical mediator involved in Treg-mediated suppression in particular 
by promoting, through phosphorylation of STAT-3, IDO enzyme production by tumor- 
infiltrating MDSC13,84. Interestingly, expression of high levels of IDO enzyme have been also 
correlated in different solid cancer, with the ability of tumor cells to evade antitumor immune 
responses. In particular, immunosuppressive effects on CD8+ T cells activity have been 
associated to the ability IDO enzyme to promote local depletion of tryptophan as well as 
accumulation of kinurenyn 234. 
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Figure 5. CD40L-expressing recombinant Vaccinia Virus (rVV40L) efficiently induces pro-inflammatory cytokines in 
infected CD14+ monocytes. Purified peripheral blood CD14+ cells from healthy donors were left untreated, infected with 
rVV40L (rVV40L) or with VV-WT (VV WT) at MOI 5. Moreover, CD14+ cells were also treated with soluble CD40L 
recombinant protein alone (s40L) or following VV WT infection (VV WT+s40L). After 24 hours of culture, CD14+ cells were 
harvested and total cellular RNA was then extracted, reverse transcribed and (A) expression of IL-12p40 (n=5), IFN-α (n=4), 
IFN-β (n=4), Indoleamine 2,3-dioxygenase (IDO; n=3) and IL-10 (n=4) genes was analyzed by qRT-PCR, using GAPDH gene 
expression as reference. Values are reported as mean+/-standard error to the mean (SEM). 
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CD8+ T cell activation requires sustained T cell receptor (TCR) interaction with 
MHC-peptide complexes in the immunological synapse (IS) between T cells and antigen- 
presenting cells (APCs). In this regard, we assessed the expression the expression in CD14+ 
cells of a panel of molecules involved in the generation of the immunological synapse with T 
cells. Interestingly, culture of CD14+ monocytes in the presence of VV-WT, rVV40L, s40L 
or both, resulted in a similar increase of MHC class I molecules expression (HLA-ABC), as 
compared to  untreated cells  whereas  expression of  CD54  (ICAM-1) adhesion  molecule, 
promoting the stabilization of APC-T cell interaction, was only marginally affected (Fig. 6). 
Activation of APCs promotes the expression of a variety of markers involved in co- 
stimulation or inhibition of CD8+ T cell responses. Indeed, s40L induced a significant 
increase of the expression of CD80 co-stimulatory but also PD-L1 T-cell inhibitoryligand, as 
compared to untreated controls (P<0.001). In contrast, infection with VV-WT or rVV40L, 
resulted in a non-significant increases of CD80 and PD-L1 expression levels on infected 
monocytes (Fig. 6). 
 
 
 
 
 
 
¨ 
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CD14+ monocytes are highly plastic myeloid cells. In this respect, it has been 
extensively reported that activated CD14+ cells could progressively differentiate towards 
dendritic cell (DC) and/or macrophages (Mo). In order to evaluate the differentiation potential 
of viral infection and s40L treatment, we evaluated the cell surface expression of CD1a and 
CD16 on untreated and differentially activated CD14+ monocytes. Notably,  CD16 
expression, suggestive of a macrophages differentiation was not significantly affected by 
Figure 6. rVV40L-infected CD14+ monocytes do not express PD-L1 (CD274).CD14+ activation was analyzed by evaluating 
increases in mean fluorescence intensity (MFI) of HLA-ABC and CD54 (ICAM-1) expression on differently treated monocytes (shaded 
histograms), as compared to untreated controls (open histograms) whereas CD80 and PD-L1 (CD274) expression was evaluated as 
percentage of positive cells. Data in the left panel summarize the results from three independent assays performed with cells from 
different donors. Similar results were obtained by flow cytometric analysis of differentially treated CD14+ monocytes. Remarkably, in 
contrast with s40L stimulated cells, rVV40L-infected CD14+ monocytes did not significantly up-regulate PD-L1 (CD274) expression. *: 
P<0.05, **: P<0.01. 
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activation of  CD14+  monocytes. Furthermore, CD1a  expression was undetectable  in  all 
culture conditions. Hence, up-regulation on cell surfaces of co-stimulatory molecules and 
enhanced IL-12p40, IFN-α and -β gene expression on/in rVV40L-infected CD14+ monocytes 
is consistent with the ability of our recombinant viral vector to promote antigen presenting 
capacity of CD14+ monocytes without promoting their differentiation into more specialized 
APCs (Fig.7). 
 
 
 
 
 
 
 
 
Figure 7. rVV40L-infected CD14+ monocytes do not differentiate into professional antigen presenting cells (CD1a+). 
Magnetically isolated CD14+ peripheral blood monocytes were left untreated or treated as indicated. After 24h of culture, CD14+ 
monocytes were harvested and stained with anti-CD16 mAbs and anti-CD1a mAbs in order to evaluate their differentiation toward 
specialized antigen presenting cells such as macrophages and dendritic cells. A representative experiment (upper panel) and cumulative 
results from four independent experiments are shown (bottom panel). 
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These data may also underline the different biological properties of membrane-bound 
CD40L, as provided by rVV40L-controlled infection, as compared to its soluble form. In this 
regard, it is tempting to speculate that differential pro-inflammatory cytokine gene expression 
observed in rVV40L- infected as compared to s40L-activated CD14+ cells possibly reflect a 
differential cross-linking of CD40 receptor expressed on the cellular surfaces of monocytes. 
Indeed, rVV40L infection, as compared to recombinant s40L protein, resulted also in a 
sustained expression of genes encoding for pro-inflammatory cytokines. In particular, high 
expression of IL-12p40, IFNs-type I genes was observed in rVV40L infected CD14+ cells but 
not in s40L-treated monocytes (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
Figure 8. CD40L expressing recombinant vaccinia virus infection of CD14+ monocytes induces a sustained gene-expression of 
pro-inflammatory cytokines. Isolated CD14+ monocytes were left untreated or treated as previously described. At indicated time 
points, culture were harvested and total cellular RNA from CD14+ monocytes was then extracted, reverse transcribed and (A) IL-12p40 
(n=3), IFN-α (n=2) and IFN-β (n=2), gene expression was analyzed by qRT-PCR. Values are reported as mean+/-standard error to the 
mean (SEM). 
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3.4 rVV40L infected CD14+ monocytes promote “in vitro” generation of alloreactive 
central memory-like CD8+ T cells. 
 
 
Induction of CD8+ memory cells and effective immune response against infectious 
agents and, most importantly, solid tumors have been shown to require IL-12 and /or IFN 
Type I156,204,207. Therefore, gene expression and phenotypic profiles suggested that rVV40L- 
infected CD14+ monocytes might be highly effective APC in these regards, as indicated by 
the increased IL-12 and IFN-type I gene expression in the absence of IL-10 and IDO gene 
expression and by the fact that they minimally expressed PD-L1. Based on these observations, 
we evaluated the ability of rVV40L-CD14+ monocytes to promote the differentiation of naïve 
CD8+ T-cells into memory cells in different antigenic settings. 
Initial experiments were performed by using allogenic CD14+ cells as stimulators, to 
bypass the issue of the low frequency of antigen specific CD8+ T cell precursors in the naïve 
lymphocyte compartment. In particular, sorted naive CD8+ T-cells (CD8+ CD45RO- CD62L+) 
were co-cultured with allogeneic CD14+ cells, previously treated as described above. 
Phenotypic characterization of primed CD8+ T-cells performed on day 8, revealed the 
enhanced ability of rVV40L-infected CD14+ cells to promote the differentiation of a 
significant fraction of alloreactive naïve CD8+ T-cells into central memory-like cells as 
indicated by the co-expression of CD45RO and CD62L. Of note, s40L-activated CD14+ cells 
were also able to promote the generation of central memory-like CD8+ T-cells but to a 
significantly lower extent, as compared to rVV40L-infected monocytes. Figures 9A and C 
show a representative experiment and collectively summarize data from eight independent 
assays. Remarkably, 31.4±12.5% (range 14.8-42.9%) of naïve CD8+ T-cells primed with 
rVV40L-infected CD14+ cells acquired a TCM phenotype as compared to 12.1±5.2 % (range 
7.1-20.2%) of central memory-like T cells obtained upon stimulation of naïve CD8+ T cells 
with s40L-activated CD14+ monocytes (P=0.0019) (Fig. 9C). 
 
IL-7Rα has been reported to play a pivotal role in memory cell homeostasis and, as 
indicated in several studies, may be used to identify memory effector precursor CD8+ T-cells 
(MPECs) differentiating towards long-lasting memory cells. In this regard, CXCR3 (CD183) 
expression has also been associated with long-term T cell memory124,130,160. Indeed, it has 
been described that effector CD8+ T cells with enhanced memory potential, longevity and 
proliferative capacity are characterized by the expression, among other surface antigens, of 
IL-7Rα  and  CXCR3  chemokine  receptor.  Therefore,  to  confirm  the  ability  of  rVV40L- 
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infected monocytes to promote the “in vitro” generation of memory CD8+ T-cells, we also 
analyzed the expression  of these markers  in CD8+ cells  allostimulated by  differentially 
activated monocytes. 
 
Confirming the first results, rVV40L-infected monocytes were able to expand 
percentages of CD45RO+/CD62L+/CD127+ CD8+ T cells (17.7±5.8 %, range 12.2-25.1%) 
significantly (P<0.001) higher than all other stimuli. Similar evidence was also obtained for 
CD45RO+/CD62L+/CXCR3+  CD8+  T  cells  (16±9  %,  range  6-32%,  P<0.03),  or  for 
CD45RO+/CD62L+/CD8+ cells expressing both CD127 and CXCR3 (15±9 %, range 1-28%, 
P<0.05). Figures 9B and D report data from one representative experiment and summarize 
data from eight independent experiments. 
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Figure 9. rVV40L infected CD14+ cells promote “in vitro” differentiation of alloreactive naïve CD8+ T cells into central 
memory-like cells. 1x106 sorted peripheral blood derived naïve CD45RO-/CD62L+ CD8+ T-cells from healthy donors were co- 
cultured in RPMI-1640 CM supplemented with 5% HS with 2x105 allogeneic peripheral blood CD14+ monocytes left untreated or 
treated with VV-WT, rVV40L, s40L or VV-WT+s40L (see “materials and methods”). On day 8, CD8+ T-cells were stained with 
fluorochrome labelled anti-CD45RO and anti-CD62L mAbs. Data from a representative experiment are reported in panel A, 
whereas panel C summarizes data from 8 independent experiments. Expression of IL-7Rα (CD127) and CXCR3 (CD183) was 
also evaluated on gated CD45RO+/CD62L+ T cells. Data in panel B refer to one representative experiment whereas panel D 
summarizes the results from eight independent experiments. Data in dot plot quadrants refer to percentages of total CD8+ T cells. 
*: P<0.05, **:P<0.01. 
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3.5 rVV40L-infected CD14+ monocytes promote “in vitro” generation of antigenic 
peptide-specific central memory-like lymphocytes from naïve CD8+ T cells. 
 
 
The data obtained in the allogeneic setting, prompted us to evaluate the ability of 
rVV40L-infected CD14+ cells to shape also CD8-mediated immune responses specific for 
HLA-A0201-restricted antigenic peptides deriving from tumor associated antigen (TAA), 
such as L27MelanA/MART-126-35, or from viral proteins. 
In the TAA-model,  percentages of  antigen specific  CD8+ T-cells  expanded upon 
priming with rVV40L or s40L-activated CD14+ monocytes, as evaluated by multimer staining 
on day 8 (Fig. 4A top), were similar. However, >45% of L27MelanA/Mart-126-35 positive 
CD8+ T-cells primed with rVV40L-infected CD14+ monocytes displayed a central memory- 
like phenotype, whereas APCs treated with s40L recombinant protein promoted the 
differentiation of a significantly lower fraction of naïve CD8+ T-cells into central memory- 
like cells (31.0%) (Fig. 10A). 
 
These data were then further reinforced by evaluating the induction of CD8+ T cell 
specific for a mixture of viral HLA-A0201-restricted immunodominant epitopes derived from 
human cytomegalovirus, vaccinia virus and influenza virus (Vaccinia Virus H3L184–192, 
HCMVpp65495-504  and Influenza A MP58-66). In this setting, multimer staining indicated that 
rVV40L-infected monocytes expanded antigen specific CD8+ T cells, to an extent similar to 
sCD40L activated CD14+ monocytes (Fig. 10B). However, consistent with the TAA-specific 
and allogenic stimulation experiments, a preferential induction of central memory-like CD8+ 
T-cells was also observed upon priming with rVV40L-infected CD14+ cells as compared to 
s40L-stimulated CD14+ monocytes (Fig.10B). 
 
Cumulative results obtained from five independent experiments performed in order to 
evaluate the ability of rVV40L-infected CD14+ monocytes to  promote the induction of 
peptide-specific CD8+ T cells are reported in figure 10C and D. In particular, as reported in 
figure 10C, rVV40L-infected CD14+ monocytes display a significantly higher efficacy in 
promoting the expansion of tetramer positive cells upon naïve CD8+ T cell stimulation. Most 
importantly, rVV40L-infected monocytes were significantly more efficient than all other APC 
under investigation, and, in particular, s40L stimulated monocytes (rVV40L: 35.8±17.9%, 
range 19-62.5%, vs. s40L: 13.5±11.1%, range 3.5-31%, P=0.03) in promoting the generation 
of tetramer positive (CD45RO+/CD62L+) TCM from naïve CD8+ T cells (10D). Furthermore, 
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in line with the results obtained in the allogeneic setting, a significant percentage of these 
peptide-specific CD8+ TCM cells also express IL-7Rα (CD127) (Fig.10D). 
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Remarkably, the acquisition of the phenotypic signature of central memory cells by 
rVV40L-CD14 primed naïve cells does not only reflect the ability of infected monocytes to 
significantly promote the expansion of antigen-specific CD8+ T cells. Indeed, evaluation of 
the Ratio, TCM / Naïve + TEM + Teff on multimer + cells, underlines the unique capacity of 
rVV40L-infected monocytes to modulate not only the magnitude but also, most importantly, 
the quality of CD8-mediated immune responses (Fig. 11). Indeed, among the different APCs 
under investigation, CD40L-expressing recombinant vaccinia virus infected CD14+ 
monocytes, display a superior ability in promoting the differentiation of naïve CD8+ T cells 
into TCM. 
+ 
RFigure 10. rVV40L-infected CD14+ cells promote “in vitro”   generation of   CD8  T cells with a central memory-like phenotype recognizing antigenic peptides from tumor associated or viral antigens. 2x105  magnetically sorted, peripheral 
blood CD14+ cells from HLA-A0201 positive healthy donors, treated as indicated, were incubated for 4 hours with (panel A) 
L27MART-1/MelanA26-35 peptide (1µg per ml) or (panel B) with a mixture of Vaccinia Virus H3L184–192, HCMVpp65495-504 and 
Influenza A MP58-66 (1µg per ml of each) HLA-0201-restricted antigenic peptides. Cells were then washed and used to prime 
1x106 autologous sorted peripheral blood naïve CD45RO-/CD62L+ CD8+ T cells. On day 8, primed CD8+ T-cells were stained 
with (A) L27 Melan-A/MART-126–35 HLA-A0201 multimers. Percentages of total CD8+ T cells are reported in the dot plots. 
Gated, multimer specific CD8+ T cells were then stained with CD45RO/CD62L specific, fluorochrome labelled mAbs. 
Percentages reported within dot plots’ quadrants are referred to total multimer positive cells. Data refer to one representative 
experiment of two performed with similar results. Cultures stimulated with APC pulsed with viral peptides were similarly (as in 
panel A) stained with a mixture of corresponding multimers (panel B) on day eight. Data refer to one representative experiment 
out of three performed with similar results. Panel C summarizes data regarding the expansion of multimer specific CD8+ T cells 
as induced by the differentially treated APC under investigation in the five independent experiments. Percentages of multimer 
specific CD8+ T cells expressing CD45RO/CD62L TCM phenotype and IL-7Rα (CD127) from the five independent experiments 
are reported in panel D. *: P<0.05, **:P<0.01. 
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3.6 Priming of “truly” naïve or restimulation of stem cell-like memory CD8+ T cells. 
 
 
 
Our current understanding of lifespan maintenance of immunological memory is 
compatible with a stem cell-like memory T cells (TSCM) model postulating the existence or a 
rare population of T-lymphocytes capable to self-renew and to differentiate, upon antigen 
recognition, in memory and effector T cells subsets108. Despite considerable efforts, 
phenotypic characterization of TSCM is still elusive. TSCM have been initially identified as a 
distinct subset of CD8+ lymphocytes according to the expression of a panel of surface 
molecules normally detected on naïve precursors including CD45RA, CCR7 (CD197), 
CD62L and CD28 along with high levels of surface antigens such as CD95, CD122 and 
Figure 11. CD40L expressing recombinant vaccinia virus efficiently shape the quality of CD8 mediated immune responses. 
CD8+ T cells from HLA-A0201+ donors were stimulated by autologous APC pulsed with antigenic HLA-A0201-restricted peptides 
following the indicated treatments, as shown in figure 10. In order to better discriminate between quantitative and qualitative CD8+ T 
cell responses induced by rVV40L-infected monocytes the RATIO TCM / Naïve + TEM+ Teff was analyzed as the percentage of 
multimer+ CD8+ T cells with a specific phenotypic profile identified according to the  expression of CD45RO and CD62L surface 
antigens. *: P<0.05, **:P<0.01. The figure reports cumulative data from five independent experiments. 
93 	  
CD183 that, intriguingly are known to be normally expressed by memory and effector CD8+ 
T cells108. 
 
In order to evaluate the percentage of TSCM within sorted CD45RO-CD62L+ naïve 
population used in our experiments, magnetically isolated CD8+ T cells derived from 
peripheral blood of healthy donors were characterized for the expression of specific antigens 
on their cellular surfaces. In particular, identification of antigen-experienced CD8+ T cells 
with stem cell-like qualities has been based on the expression of CD45RA, CCR7 (CD197), 
CD95 and CD62L235 (Fig. 12A) or CD28103 (Fig. 12B). Cumulative results obtained from 
twelve (n:12) independent experiments revealed, in line with other studies, a marked paucity 
of CD8+ lymphocytes with a stem cell-like phenotype in peripheral blood of healthy donors. 
Indeed, based on the expression of CD45RA, CCR7, CD95 and CD62L or CD28, TSCM 
represent 0.67% +/- 0.37% (Range: 1.33% - 0.17%) or 0.57% +/- 0.39% (Range 1.23% - 
0.04%), respectively, of total naïve CD8+ T cells (Fig. 12C). 
 
 
 
 
 
 
 
 
Figure 12. Evaluation of CD8+ T cells with stem cell-like phenotype (TSCM). CD8+ TSCM were identified according to the expression 
of CD45RO, CCR7, CD95 and CD62L (A) or CD28 (B) surface antigens, as shown in representative experiments. Cumulative results 
obtained from the analysis performed on CD8+ T cells isolated from twelve different healthy donors are reported in panel C. 
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This initial phenotypic characterization of memory stem cell-like T cells has been later 
challenged by pre-clinical and clinical studies aiming at specifically targeting this population 
to further define its contribution to immune reconstitution in patients receiving haploidentical 
hematopoietic stem cell transplantation (HSCT). Collectively these studies have demonstrated 
that differentiation of naïve CD8+ lymphocytes in TSCM is also promoted by homeostatic 
cytokines in vitro and in vivo. However, in contrast to pharmacologically instructed TSCM, 
antigen-experienced CD8+ T cells with stem cell-like qualities generated in presence of IL-7 
and IL-15 display a phenotypic profile resembling conventional TCM. Indeed, under these 
culture conditions, TSCM were defined based on the expression on cell surfaces of CCR7, 
CD62L, IL-7Rα, CD95, CD45RA but also CD45RO. In view of these observations, and 
considering the gating strategy that we designed to isolate naïve (CD45RO- CD62L+) CD8+ 
T cells, it is tempting to speculate that the presence of putative TSCM defined as CD45RA+ T 
cells within sorted naïve population may represent a major limitation in our experiments. 
 
Aiming at further confirming the enhanced capacity of rVV40L-infected CD14+ 
monocytes to promote the rapid differentiation of antigen-specific naïve precursors into TCM, 
we performed a set of in vitro experiments in which generation of central memory CD8+ T 
cells was evaluated in healthy donors that had not received vaccinia virus vaccination. 
Therefore, in these donors, vaccinia virus specific CD8+ T cells should be comprised only in 
truly naïve compartment. In line with these considerations, phenotypic characterization of 
CD8+ T cells performed in order to evaluate the possible contamination of TSCM within 
tetramer positive lymphocytes clearly indicated the absence of vaccinia virus specific CD8+ T 
lymphocytes with stem cell-like qualities (CD45RO- CD62L+ CD95+; Fig.13A left panel). 
Nevertheless, also in these not-vaccinated donors the presence of TSCM was comparable with 
the frequency detected in vaccinated donors (Fig.13A middle panel). Cumulative results 
obtained from four independent  donors, indicate, within  vaccinia virus specific  cells an 
irrelevant contamination of naïve T cells also expressing CD95 (0.013% +/- 0.0078%; Range 
0.002%-0.0078%) whereas within total CD8+ T cells, TSCM represented 0.2% +/- 0.2% of 
analyzed cells (Range 0.042%-0.3%) (Fig.13A right panel). Based on this background, we 
evaluated the capacity of differently treated autologous CD14+ monocytes to prime vaccinia 
virus specific CD8+ T cells. Notably, phenotypic characterization performed at day 8, of 
naïve CD8+ T stimulated with CD14+ that were left untreated or alternatively infected with 
VV WT or rVV40L indicate a significant increase in the percentage of vaccinia virus-specific 
CD8+ T cells only upon priming with rVV40L-infected CD14+ monocytes (Fig.13B upper 
panel). Furthermore, phenotypic characterization of tetramer positive CD8+ T cells clearly 
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indicate the preferential differentiation of vaccinia virus specific naïve precursors into TCM 
defined according  to  the  expression of  CD45RO  and  CD62L on  their  cellular  surfaces. 
Indeed, cumulative results from four independent experiments indicate that priming of naïve 
cells with rVV40L-CD14 resulted in the generation of 51.8% +/- 20.2% (Range 71.4%- 
25.5%) of vaccinia virus specific CD8+ T cells with a TCM phenotype. In contrast, only 16.2% 
+/- 11.9% of tetramer positive cells with a central memory phenotype were observed in cell 
cultures primed with VV WT-CD14+ monocytes (Fig.13B bottom panel). 
 
 
 
 
 
 
 
Figure 13. rVV40L-infected CD14+ cells promote “in vitro” differentiation of functionally naïve CD8+ T cells into TCM. (A) 
CD8+ T cells were isolated from HLA-A0201+ healthy donors not vaccinated against small-pox virus were stimulated with APC 
infected with VV WT or rVV40L. On day eight cells were tained with a mixture of Vaccinia Virus HLA-0201-multimers, anti- 
CD45RO mAbsand anti-CD62L mAbs fluorochrome-labeled mAbs. Percentages of multimer positive cells and phenotypes of 
multimer positive cells were then evaluated. A representative experiment and cumulative results from four independent experiments 
are shown. *: P<0.05, **:P<0.01. 
96 	  
Taken together, these data indicate that rVV40L infection of CD14+ monocytes 
resulted in the expansion and acquisition of central memory phenotype of truly naïve CD8+ T 
cells and not as a consequence of the expansion of putative pre-existing antigen specific TSCM. 
 
 
 
 
 
 
 
3.7. Functional  analysis of  central memory-like  CD8+ T  cells induced  by rVV40L- 
infected CD14+ monocytes. 
 
 
CD8+ T-cells generated upon stimulation by rVV40L-infected CD14+ cells were 
characterized by the expression of the typical TCM phenotypic profile. Based on these 
findings, we sought to evaluate also their functional properties. In particular, we addressed the 
proliferative potential, differentiation into effector memory cells and IL-2 production upon T 
cell receptor triggering. 
 
In order to assess the proliferative and differentiation capacity of our rVV40L 
generated TCM, naïve CD8+ T-cells were stimulated with a pool of three HLA-A0201- 
restricted immunodominant viral peptides derived from human cytomegalovirus, vaccinia 
virus and influenza virus (Vaccinia Virus H3L184–192, HCMVpp65495-504  and Influenza A 
MP58-66) using rVV40L-infected CD14+ cells as antigen presenting cells. Cells were then re- 
stimulated on day 10 with peptide-pulsed untreated CD14+ monocytes and characterized for 
phenotypic and functional properties three days later. In this experimental setting, >90% of 
tetramer positive cells showed evidence of CFSE dilution, whereas stimulation by irrelevant 
peptide was completely ineffective. Importantly, in half of the proliferating cells CD62L 
expression appeared to be down-regulated, consistent with the acquisition of a putative 
effector-memory phenotype, while the rest of proliferating tetramer positive cells, retained 
their TCM phenotype (Fig.14A). 
 
A putative limitation of this experimental setting is represented by the inability to 
formally exclude that, within proliferating cell population detected at day three after re- 
stimulation, residual naïve CD8+ T cells eventually unresponsive to primary stimulation. 
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In this regard, we observed a significant lower percentage of peptide-specific CD8+ T 
cells retaining a (CD45RA+/CD62L+) naïve phenotype at day 8 after priming with rVV40L- 
infected CD14+ monocytes as compared to all other culture conditions under investigation 
(Fig14B). 
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Figure 14. rVV40L-CD14 promote “in vitro” generation of functional central memory precursor CD8+ T cells specific for 
human Cytomegalovirus, Vaccinia Virus and Influenza Virus. (A) HLA-A0201+ CD8+ T-cells primed for eight days in the 
presence of rVV40L-treated monocytes pulsed with a mixture of Vaccinia Virus H3L184–192, HCMVpp65495-504 and Influenza A 
MP58-66 peptides (1µg/ml of each) were harvested, CFSE labelled and stimulated for three days in the presence of autologous 
untreated monocytes pulsed with the specific or irrelevant peptides. Cells were then stained with antigen specific HLA-A0201 
multimer, anti-CD45RO and anti-CD62L mAbs. Percentages of cells showing evidence of specific staining or CFSE dilution were 
then analyzed. Data refer to one representative experiment and summarize the results of two independent assays. (B) Percentages of 
multimer positive CD8+ T cells still retaining a naïve phenotype (CD45RO-CD62L+) at day 8 after priming with peptide pulsed 
CD14+treated as indicated or left untreated were analyzed. The panel shows cumulative results from five independent experiments. 
*: P<0.05, **:P<0.01. 
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Nevertheless, to address this issue, we performed additional experiments based on the 
re-stimulation with anti CD3/CD28 of CD8+ T cells sorted according to CD45RO/CD62L 
expression rVV40L-Naïve (CD45RO-CD62L+) and rVV40L-TCM CD8+ T cells generated 
following an initial allostimulation by rVV40L infected monocytes in primary cultures. In this 
setting, <10% rVV40L Naïve CD8+ T cells showed evidence of CFSE dilution contrast as 
compared to >90% of rVV40L-TCM CD8+ T cells (Fig.15A). Interestingly, proliferative 
capacity of rVV40L- TCM CD8+ T cells resulted also in the generation of consistent 
population of CD62L- effector-memory cells was detectable upon secondary stimulation. In 
addition, rVV40L-TCM CD8+ T cells were also able to produce detectable amounts of IL-2 in 
mAb stimulated secondary cultures (Fig. 15B). 
 
 
 
 
 
 
Figure 15. Functional characterization of TCM induced by rVV40L-treated monocytes. CD45RO-/CD62L+ naïve CD8+ T 
cells were stimulated for eight days with allogenic rVV40L-treated monocytes. At day 8, Naïve and TCM CD8+ T cells were then 
sorted based on CD45RO and CD62L expression, CFSE stained and re-stimulated with anti CD3 and anti CD28 mAbs. Following a 
three days culture, cells were harvested, and stained with anti CD45RO and anti CD62L mAbs. CFSE dilution and marker 
expression were then analyzed. Data refer to one representative experiment and summarize the results of two independent assays. 
(B) IL-2 production  by sorted rVV40L induced TCM  following a 3days anti CD3 and anti CD28 mAbs stimulation. Data 
summarize three independent experiments. 
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In conclusion, our data indicate a remarkable efficacy of our CD40L-recombinant 
vaccinia virus to promote the generation of CD8+ T cells with functional characteristics 
of TCM. 
 
 
 
 
3.8 rVV40L infection produces in cytostatic and cytotoxic effects on tumor 
cells. 
 
 
The expression of CD40 receptor has been reported in nearly all B-cell malignancies 
and approximately in 70% of solid tumors. Furthermore, triggering of CD40 expressed on cell 
surfaces of transformed cells has been associated either to pro-survival effects or to inhibition 
of tumor cells proliferation and/or apoptosis of targeted cells. Interestingly, these differential 
effects have been associated to the extent of CD40 receptor expression as well as to the 
specific signal transduction chain integrated by transformed cells184,209. 
 
In order to evaluate the biological responses induced by our replication incompetent 
CD40L-expressing recombinant vaccinia virus (rVV40L), we selected a panel of established 
tumor cell lines. In particular, Na8 melanoma cell line (CD40+), HCT116 (CD40+) and 
Colo205 (CD40-) colorectal cancer cell lines were used in order to evaluate the effects of 
rVV40L infection and s40L treatment. As expected, rVV40L infection resulted in the up- 
regulation of CD40L in a similar fraction of tumor cells regardless of their CD40 receptor 
status. Furthermore, membrane-bound CD40L provided by controlled viral infection resulted, 
in both Na8 and HCT116 cell lines, in a reduction of CD40 receptor expression on their 
cellular surfaces. In sharp contrast, tumor cell lines cultured in presence of soluble CD40L 
recombinant protein display levels of CD40 receptor comparable to untreated tumor cells 
(Fig.16). 
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Figure 16. rVV40L infection of established tumor cell lines. 1x106 cells from Na8 melanoma and HCT116 and Colo205 colorectal cancer 
cell lines were left untreated or infected with VV-WT or rVV40L at MOI 10. Moreover, cells from established tumor cells lines were also 
treated with soluble CD40L recombinant protein alone (s40L) or following VV WT infection (VV WT+s40L). After 24 hours of culture cell 
were harvested and CD40 receptor and CD40L expression on cellular surfaces were evaluated by flow cytometry analysis. Data refer to one 
representative experiment out of five performed with similar results. 
 
 
 
 
 
In line with this observation, suggesting different biological properties of membrane 
bound CD40L as compared to its soluble form, rVV40L infection of Na8 (CD40+) melanoma 
cell line resulted in 30% proliferation inhibition and in a significant increase in the percentage 
of apoptotic cells as compared to untreated tumor cells. In contrast, s40L-stimulation of Na8 
(CD40+) melanoma cell line did not resulted in cytostatic or cytotoxic effects. Remarkably, 
ligation of CD40 receptor expressed on cellular surface of HCT116 (CD40+) did not affect 
their proliferative capacity or their survival. Indeed, similar to Colo205 (CD40-), both 
rVV40L infection and s40L-treatment failed to abrogate in vitro expansion of treated HCT116 
(CD40+) colorectal cancer cell line and did not resulted in an increased percentage of 
apoptotic cells (Figs.17A, B). 
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Figure 17. rVV40L infection of established tumor cell lines resulted in the induction of cytostatic and cytotoxic effects 
 
 
Na8 melanoma cell line, HCT116 and Colo205 colorectal cancer cell lines were left untreated or treated as indicated and cultured for 4 
days. (A) Proliferation of tumor cell lines was assessed by 3H-thymidine incorporation during the last 18h of culture and expressed as % 
of proliferation inhibition as compared to untreated cultures. Data summarize the results obtained in three independent experiments. (B) 
After 4 days of culture, untreated and differently treated tumor cell lines were harvested and percentages of non-viable cells was defined 
as the sum of annexin V+/PI-, annexin V+/PI+ and annexin V-/PI+ cells. A representative experiment (panel B upper dot plots) and 
cumulative results obtained from three independent experiments (lower histograms) are reported. 
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It has been extensively reported that ligation of CD40 receptor by CD40L results in 
the clustering of the receptor that, in turn, induces the recruitment, to its cytoplasmic domain, 
of TNF-receptor associated factors (TRAFs) mediating the activation of different intracellular 
signaling pathways. Six different adapter proteins compose the TRAFs family. TRAF-1 has 
been shown to be regulated at transcription level in response to CD40 receptor initiated 
signals and to play a pivotal role in regulating the activity of the other TRAF proteins 182,236. 
In this scenario, we evaluated whether the absence of cytostatic and cytotoxic effects on 
HCT116 (CD40+) colorectal cancer cell line might be related to an impaired and/or reduced 
intracellular signaling initiated by CD40L-mediated ligation of CD40 receptor expressed on 
their cellular surfaces. Interestingly, we observed a marked up-regulation of TRAF-1 gene 
expression in Na8 (CD40+) melanoma cell line upon rVV40L infection whereas s40L, alone 
or in combination with VV-WT, was significantly less efficient. In sharp contrast, triggering 
of CD40 receptor expressed on cellular surfaces of HCT116 (CD40+) did not result in the up- 
regulation of TRAF-1 gene-expression levels (Fig.18). 
 
 
 
 
 
 
Figure 18. Cytostatic and cytotoxic effects on tumor cells induced by rVV40L infection are associated to the up- 
regulation of TRAF1. Na8 melanoma cell line, HCT116 and Colo205 colorectal cancer cell lines were infected with VV-WT or with 
rVV40L at MOI of 10 or left untreated. Furthermore, tumor cell lines were also treated with soluble CD40L recombinant protein (s40L) 
alone or in combination with VV WT infection (WT+s40L). At day 4, tumor cells from different cultures were harvested and total 
cellular RNA was then extracted, reverse transcribed and TRAF-1 gene expression was analyzed by qRT-PCR, using GAPDH 
expression as reference. Values are reported as mean+/-standard error to the mean (SEM) and summarize the results obtained from three 
independent  experiments. 
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Taken together, these data indicate underline the enhanced efficacy of our replication 
incompetent CD40L-expressing recombinant vaccinia virus as compare to soluble CD40L 
recombinant protein to mediate, upon infection, cytostatic and cytotoxic effects on established 
tumor cell lines. Furthermore, we also reported how abscence of these effects, on CD40 
receptor expressing tumor cells, might be potentially explained as a consequence of an 
impaired intracellular signaling resulting in a defective up-regulation of TRAF-1 adapter 
protein. 
 
 
 
 
3.9 rVV40L-infection promotes tumoricidal activitiy of CD14+ monocytes. 
 
 
The rationale supporting the initial development of cancer immunotherapies strategies 
targeting CD40 receptor was represented by the activation of antigen presenting cells, most 
importantly dendritic cells, in order to promote the generation of effective antitumor T cell 
responses. Furthermore, studies performed in animal models and evidences obtained in 
clinical setting have indicated that tumor regression might also be achieved in a T-cell 
independent manner. In this regard, a pivotal role has been described for myeloid cells of 
monocytes/macrophages lineage. Indeed, CD40-stimulated macrophages have shown to 
efficiently acquire tumoricidal activity based on their capacity to produce reactive nitrogen 
intermediates and effector cytokines including TNF-α 84,209,220. 
 
In order to evaluate the capacity of our CD40L-expressing recombinant vaccinia virus 
to promote tumor regression through the activation of myeloid cells, we performed a set of in 
vitro experiments in which established tumor cell lines expressing CD40 receptor were left 
untreated and infected either with vaccinia virus wild type (VV WT) or rVV40L and then 
cultured in absence or presence of allogeneic CD14+ monocytes isolated from peripheral 
blood of healthy donors. Interestingly, we observed a marked reduction of proliferative 
capacity of H358 (CD40+) non-small-cell lung cancer cell line upon direct infection with 
rVV40L whereas in vitro expansion of HepG2 (CD40+) hepatocellular cell line was not 
affected. Indeed, a similar percentage of proliferating cells were observed upon infection with 
VV WT and rVV40L. Nevertheless, a considerable reduction in proliferative capacity of 
rVV40L  infected  HepG2  (CD40+)  cells  was  observed  upon  three  days  co-culture  with 
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allogeneic CD14+ monocytes (Fig.19A), correlating with the ability of CD40L-expressing 
recombinant vaccinia virus to induce an enhanced TNF-α gene expression (Fig.19B). 
 
 
 
 
 
 
 
 
Collectively these results indicate that replication incompetent CD40L-expressing 
recombinant vaccinia virus might efficiently mediate antiproliferative effects on in vitro 
established tumor cell line either by the triggering of CD40 receptor expressed on their 
cellular surface or by promoting the antitumor activity of CD14+ monocytes. 
Figure 19. rVV40L infection of tumor cells promotes the activation of CD14+ monocytes. 1x106 H358 NSCLC derived cell line and 
HepG2 hepatocellular carcinoma derived cell line were left untreated and infected with VV-WT and rVV40L at MOI 10. After 24 hours 
cells were harvested and cultured in presence of absence of CD14+ monocytes at 1:1 ratio. (A) Proliferation of tumor cell lines was 
evaluated at day 4 by 3H-thymidine incorporation during the last 18h of culture and expressed as % of proliferation as compared to 
cultures that were left untreated whereas induction TNF-α gene expression was evaluated by qRT-PCR. Data are referred to a 
representative experiment out of three performed with similar results. 
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4. DISCUSSION 
 
 
In the last years, therapeutic potential of different cancer immunotherapy strategies has 
been restated by the objective and durable clinical responses observed in treated patients 
enrolled in different trials. In this regard, an increased attention has recently been focused on 
strategies targeting CD40 receptor. Indeed, it has been reported that administration of agonist 
anti-CD40 receptor monoclonal antibodies or CD40L-expressing viral vectors might result in 
vigorous and multifaceted antitumor effects84,209. In particular, it has been shown that ligation 
of CD40 receptor expressed on cellular surface of malignant cells might result in direct 
cytostatic and cytotoxic effects. Furthermore, objective cancer regression might be achieved 
following CD40 receptor induced immune activation. Indeed, signaling via CD40 receptor 
expressed on cellular surfaces of myeloid cells has been shown to result in the acquisition of 
direct antitumor activity and in an enhanced ability, particularly for dendritic cells, to promote 
the generation of tumor-specific CD8+ T cells potentially eliminating, upon recognition, 
target malignant cells. 
 
Antitumor efficacy of CD8+ T cells has traditionally been associated to their enhanced 
production of effector cytokines and cytotoxic molecules initiated by the recognition of 
cognate antigen. In the last decade, this initial interpretation regarding the anticancer efficacy 
of CD8+ T cells has been revised. Indeed, it has been reported that clinical efficacy of CD8+ 
T cells is also affected by their differentiation status. In particular, it is nowadays widely 
accepted how generation and expansion of tumor-reactive CD8+ T cells with phenotypic and 
functional  profiles  of  central  memory  lymphocytes  represent  key  clinical  priorities  for 
successful cancer treatment118,210-212. 
 
An important role in the generation of effective memory CD8+ T-cells is played by the 
conditions of the initial stimulation and CD4+ T-cell help has repeatedly been shown to be of 
essential relevance 237-239. CD8+ T lymphocytes primed in “helpless” conditions might still be 
able to kill targets expressing appropriate antigens and MHC, and to produce a limited array 
of cytokines, but they would fail to respond to specific TCR triggering with proliferation and 
IL-2 production 237. “Helper” functions for CD8+ T-cell activation are basically elicited 
through two main mechanisms. First, stimulation by MHC class II restricted antigenic 
epitopes induces, in CD4+ cells, the paracrine production of high amounts of cytokines, most 
importantly   IL-2,   supporting   CD8+    T-cell   expansion.   Furthermore,   activated   CD4+ 
	  lymphocytes are also able to “license” APCs to optimally present MHC class I restricted 
antigens through CD40 triggering by CD40 ligand (CD154) 240,241. 
 
Clinical application of these concepts suffers from a number of limitations. For 
instance, the use of TAA-derived HLA-class II restricted immunogenic peptides promoting 
CD4+ T cells activation in active specific cancer immunotherapy would imply a strict 
selection of eligible patients based on both HLA-class I and II typing. On the other hand, the 
administration of exogenous cytokines is limited by their inherent toxicity 242,243. In this 
regard, agonistic anti-CD40 therapeutic monoclonal antibodies have been successfully 
utilized, but systemic administration raises concerns due to CD40 expression in platelets and 
endothelial cells and its potential role in auto-immune / inflammatory processes. 
 
Based on this background and further prompted by the clinical experience acquired in 
the last fifteen years227,228,230,244, we have generated a non-replicating recombinant Vaccinia 
Virus encoding human CD40L. We previously demonstrated that infection of CD14+ 
monocytes or DCs, with rVV40L led to their activation as indicated by the up-regulation of 
co-stimulatory ligands and further confirmed by the increased expression of genes encoding 
for pro-inflammatory and effector cytokines 230. In this study we have then carefully analyzed 
the quality of immune responses induced upon naïve CD8+ T-cells stimulation by CD14+ 
monocytes expressing CD40L following rVV40L infection. 
 
Notably, experimental “in vivo” studies suggest that CD40 receptor expression on 
activated CD8+ T-cells, plays a crucial role in promoting their differentiation into functional 
memory cells196,197. However, these models hardly mirror human memory T cell formation 
since we  observed  that  human  resting  or  activated  CD8+ T  cells  do  not  express  CD40 
receptor, although they might exogenously acquire some from adjacent APCs as a 
consequence of intercellular trogocytosis231-233. These observations underlined the critical role 
provided by APCs or more precisely by signals delivered by co-stimulatory ligands and 
soluble factors to CD8+ T cells, in dictating their differentiation toward memory lineage. 
 
In this regard, our data indicate that CD14 infection by rVV40L induces the 
expression of IL-12p40 and IFN-α and –β genes, encoding cytokines of essential relevance 
for T cell memory induction155,156,207. Indeed, these molecules have been shown to activate 
APC and to directly promote the development of memory CD8+ T cells by preventing 
activation induced apoptosis by improving their viability and proliferation potential155,156,207. 
Furthermore, at difference with s40L-stimulated monocytes, rVV40L-activated CD14+  cells 
 
107 
108 	  
do not express IL-10 and IDO genes, thereby suggesting a highly effective capacity of 
activating T cells. In addition, rVV40L infection does not induce a marked up-regulation of 
PD-L1 on non-professional APCs, at difference with CD14+ monocytes treated with VV WT 
or s40L, thus suggesting that these cells are unlikely to induce exhaustion in activated T cells. 
In this respect our data extend previous findings showing that s40L, which is also detectable 
in sera from cancer bearing patients14, may promote PD-1 expression in activated T cells. 
Furthermore, these observations underline the differential biological activity of CD40L in 
surface expressed or soluble form in modulating the activity of APCs and possibly related to 
the ability of the former to efficiently cross-link CD40 receptor184,185. 
In line with this observation, rVV40L-activated CD14+ cells proved highly efficient 
APCs for naïve CD8+ T-cells priming in a variety of experimental settings, including, 
allostimulation, and response to TAA-derived epitopes or viral antigens, although they did not 
appear to differentiate towards professional APCs, since they failed to express CD1a upon 
infection. Most importantly however, they were able to preferentially promote the generation 
of  antigen  specific  cells  with  a  TCM–like  phenotype,  whereas  s40L-activated  CD14+ 
monocytes  appeared  to  promote  the  progression  of  naïve  CD8+   T-cells  towards  more 
terminally differentiated stages (TEM /TEMRA)103. Strikingly, a single “in vitro” stimulation of 
naïve CD8+ T- cells appeared to suffice for effective induction of antigen specific TCM cells. 
 
A variety of factors and multiple mechanisms are known to contribute to memory 
CD8+ T-cell generation. They include antigen specific features, such as nature and 
concentration of the immune-stimulating materials 245 or T cell intrinsic characteristics, such 
as antigen precursor frequency 246. In addition, APCs intrinsic features, including levels of co- 
stimulatory molecules and inhibitory ligands expressed and, most importantly, cytokines 
released by APCs are widely recognized to play a critical role in memory T cell induction. In 
this respect, the increased expression of IL-12 and IFNs-type I detected in rVV40L-infected 
as compared to s40L-tretated monocytes suggest that these cytokines might be of critical 
relevance in promoting the differentiation of antigen-specific naïve precursors into CD8+ T 
cells with phenotypic and functional attributes of central memory lymphocytes. In this regard, 
it has been reported that precursors of long lasting CD8+ T-cells may be identified based on 
their selective expression of surface markers. Detection of a specific phenotypic profile on 
rVV40L primed CD8+ T-cells confirms their activated state, as witnessed by CD45RO and 
CXCR3 expression, their potential ability to localize in secondary lymphoid organs, as 
indicated by CD62L expression, and their responsiveness to homeostatic stimuli, consistent 
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with IL-7Rα (CD127) expression130. Furthermore, besides phenotypic profiles, functional data 
provide striking evidence of the nature and potential clinical relevance of central memory 
CD8+ T-cells elicited upon rVV40L infection. Indeed, these lymphocytes are characterized by 
a high proliferative potential in response to stimulation by non-professional APCs, leading to 
4-5 cell divisions in a large majority of cells. In addition, advanced differentiation towards 
effector T cells was also detectable. In view of these latter observations, it must be underlined 
that despite the “in vitro” nature of this study, phenotypic and, most importantly, functional 
characterization of “8-days” TCM generated upon stimulation of naïve CD8+ lymphocytes 
with rVV40L infected CD14+ monocytes closely resembles features of ex-vivo sampled 
human TCM and and also emerging from a variety of experimental models210-212. Therefore, 
these cells generated through rVV40L infection of CD14+ cells may be considered as “bona 
fide” TCM. In this respect, further investigation are warranted in order to clarify the molecular 
basis and the precise differentiation model underlying the significant expansion of CD8+TCM 
in cell cultures primed with CD40L-expressing recombinant vaccinia virus. 
 
In addition to its remarkable efficacy in the modulation of quality and intensity of 
different signals delivered from APC shaping CD8+ T cell responses, the ability of rVV40L 
to inhibit tumor cells proliferation upon infection or through the activation of myeloid cells of 
monocyte/macrophage lineage was also evaluated. In this regard, preliminary data underline 
the remarkable effectiveness of rVV40L, as compared to s40L-treatment, to promote cell 
death of a panel of established tumor cell lines “in vitro”. Furthermore, CD40L-expression on 
cell surfaces of infected tumor cells was sufficient to provide effective targets for TNF-α 
mediated cytotoxicity elicited, by CD14+ monocytes84,209,220. 
 
Notably, these effects are generated by a replication inactivated CD40L-expressing 
recombinant vaccinia virus, thus suggesting that its “in vivo” administration would be 
associated with minimal potential adverse effects. It is tempting to speculate that similar 
reagents might therefore be of high relevance for vaccination purposes. Indeed, a critical 
limitation of different cancer vaccine formulations to induce objective anti-tumor T cell 
responses is represented by the insufficient delivery, processing and presentation of the 
chosen tumor associated antigen to/by dendritic cells74.On the other hand, in several tumor 
types such as melanomas and lung cancers, it has been reported that majority of tumor- 
infiltrating lymphocytes (TILs) recognize tumor specific neo-antigens arising from non- 
synonymous mutations accumulated in malignant cells during tumor progression27,28. 
Identification of neo-antigens may represent the beginning of a new era for active, antigen- 
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specific cancer immunotherapy strategies. However clinical application of these concepts is 
still limited by the complexity of procedures required for the molecular identification of 
MHC-class I/II restricted tumor antigens arising from non-synonymous mutations. In this 
scenario, thanks to its cytotoxic activity on transformed cells, intra tumoral injection of 
replication incompetent CD40L-expressing recombinant vaccinia virus might favor the 
release on tumor specific antigens promoting the generation of effective and long-lasting 
CD8+ T cell responses through the modulation of antigen presenting capacity of tumor- 
infiltrating myeloid cells84,209,247. 
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